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The NS1 protein is a major virulence factor of influenza virus. Although the protein is encoded by all 
natural influenza viruses, its sequence shows considerable variation suggesting that it interacts 
intimately with the host. Indeed this multifunctional protein has been described to bind a plethora 
of cellular factors.  
The influenza A NS1 protein from A/PR/8/34 was previously shown to enhance translation of a host 
expressed gene. This is likely a consequence of its ability to counter basally expressed host antiviral 
strategies that are activated within the cell upon transfection and transient expression of exogenous 
genes. This work evaluated a panel of NS1 proteins derived from different strains and subtypes of 
influenza, for their capacity to enhance translation. Although it is possible that all natural NS1 
proteins have the capacity for this function, it was found to be often obscured by a dominant 
inhibitory function that was mapped to the C terminus of the protein. Only NS1 proteins that lack 
this second function illustrated translational enhancement without prior mutation. Modification of 
the C terminal domain of NS1 was able to abrogate binding to the CPSF host factor responsible for 
the maturation of host genes transcribed by polymerase II. This then revealed the potential of most 
if not all NS1 proteins to act as translational enhancers. A series of NS1 mutants were engineered to 
test the proposed mechanism of translational enhancement, and this work confirmed that 
enhancement required NS1 to be present in the cytoplasm of the transfected cell, and retain an 
intact dsRNA binding site. 
The intriguing finding that not all natural NS1 proteins bind to the CPSF host factor was investigated 
to ask whether CPSF interaction sometimes carried a cost to viral fitness. The hypothesis was that 
some NS1 proteins adopt this global mechanism for the control of interferon to compensate for high 
levels of PAMP produced by infection more active viral polymerase. The observations deduced from 
this work lead to the suggestion that NS1 participates in the regulation of interferon at the level of 
the polymerase complex by modulating the viral polymerase activity, in addition to its previously 
characterized function to counter the PRR RIG-I, and disruption of CPSF function.  
Combining the approaches established during this body of work, it was established that the 
behaviour of the NS1 protein of the newly emerged swine origin H1N1 2009 pandemic virus were 
unusual. Interestingly this protein was able to strongly enhance translation despite being 
predominantly localized to the nucleus. Importantly a reverse genetic approach demonstrated that 
the levels of interferon induced during infection by the pandemic H1N1 strain could be being under 
represented, and this may explain discrepancies in the literature between different models of 
pathogenicity of the pandemic virus. 
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1.1 The Influenza Virus 
 
In humans the influenza virus typically causes an acute respiratory infection. The etiological agent 
may fall into one of the 3 genera of influenza viruses, members of the Orthomyxoviridae, which are 
known as Influenza A, B and C viruses. Although for the majority of individuals an influenza infection 
may result in a short period of ill health, in vulnerable portions of the population including the 
elderly, the immuno-compromised or asthmatics, infection with influenza can result in medical 
complications including bronchitis and secondary bacterial pneumonia. The majority of influenza 
cases requiring medical intervention result from infection with influenza A and B viruses. 
As a highly contagious disease, influenza contributes significantly to the global disease burden. The 
northern and southern hemispheres have clearly defined “flu seasons” with peak numbers of cases 
occurring at the height of the winter period for that hemisphere. While influenza viruses may vary in 
the degree of severity of symptoms they cause, seasonal influenza strains usually lack the potency to 
cause high mortality in susceptible populations. Typically these strains are closely related to those 
which circulated in previous years, but have acquired mutations in the surface glycoproteins which 
result in antigenic escape. The gradual acquisition of mutations in the influenza virus, as a 
mechanism for escape of the herd immunity is referred to as antigenic drift, and is the reason why 
influenza virus vaccines need to be reformulated annually (Boni 2008; Russell, Jones et al. 2008).  
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In the UK, the annual trivalent vaccine is administered to provide a degree of protection against 
influenza illness to individuals who are deemed most at risk to the consequences of seasonal 
influenza virus infection, or its associated complications. 
The influenza A virus has a genome of approximately 14kb (Hoffmann, Stech et al. 2001), and this is 
subdivided into 8 segments as shown in Table 1. The segmented nature of the virus allows gene 
reassortment, within the confines of gene and host compatibility. Periodically, novel strains of 
influenza may enter the human population from an animal reservoir as a result of this reassortment 
activity (Ma, Kahn et al. 2008). These strains may have a new antigenic profile to which there is little 
pre existing herd immunity, and are able to rapidly spread through a naive human population 
(Yassine, Lee et al. 2010). These rapid changes in antigenic profile as the result of exchange of viral 
genes between influenza viruses of human and animal origin, known as antigenic shift, may produce 
pandemic viruses as occurred in 1957, 1968 and 2009 (Morens and Fauci 2007; Morens, 
Taubenberger et al. 2010).  
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Segment Length in nucleotides of 
A/Pueto Rico/8/34 (A/PR/8/34) 
(Hoffmann, Stech et al. 2001) 
1 PB2 2341 
2 PB1 2341 
3 PA 2233 
4 HA 1778 
5 NP 1565 
6 NA 1413 
7 M 1027 
8 NS 890 
 
Although the influenza A virus genome is typically found as 8 discrete segments, naturally occurring 
viruses lacking the NA segment, therefore deficient for the Neuraminidase surface glycoprotein have 
been isolated (Moules, Ferraris et al. 2010) and it has been possible by reverse genetic engineering 
to create recombinant viruses with 9 (Enami, Sharma et al. 1991; Gao, Lowen et al. 2010)  or 7 
segments (Gao, Brydon et al. 2008). These are significant but special observations, the majority of 
naturally occurring influenza virions contain 8 segments that are packaged using discreet cis acting 
RNA signals (Noda and Kawaoka 2010). 
  
16 | P a g e  
 
1.2 Epidemics and Pandemics 
The entry of a novel influenza virus into a naive population may cause an epidemic or pandemic and 
the latter has occurred at least 15 times within recorded human history, with the first noted incident 
in 1510 (Johnson and Mueller 2002; Morens and Fauci 2007). Typically this occurs as a result of 
genetic reassortment between compatible strains or the direct species transfer of a novel virus from 
the aquatic reservoir as was observed in the 1918 pandemic. This process is known as antigenic shift 
and is a more dramatic change than the drift process. Depending upon the pre-existing immunity 
profiles of the population the novel virus will predominantly affect those members of the population 
which have not seen a virus like this before. For example the emergence of the novel H1N1 virus 
strain in 2009 targeted young adults more than the elderly due to the low rates of protection seen in 
this population. Elderly members of the community had been more likely to have seen viruses 
resembling this strain by prior exposure to related strains (Miller, Hoschler et al. 2010). 
 
The processes of both drift and shift may result in changes to the virus not only in the antigens 
presented to the host, but also in the viral replicative properties, and thus its pathological phenotype 
(Ma, Kahn et al.; Ma, Brenner et al. 2010; Wang, Robb et al.). Understanding the consequences of 
these changes to both virus and host is therefore key information in the fight against this global 
pathogen. As a segmented virus, the exchange of genetic segments between influenza A viruses in 
the reservoir species (aquatic birds) and permissive species such as pigs acting as a “mixing vessel” is 
able to rapidly produce novel gene constellations (Ma, Kahn et al. 2008). Influenza B, which is 
constrained to infection of humans, and seals (Osterhaus, Rimmelzwaan et al. 2000) is limited in its 
capacity for antigenic shift, and therefore does not pose a pandemic threat, although reassortment 
between co circulating influenza B strains (Lindstrom, Hiromoto et al. 1999) implies that this 
mechanism occurs within the human host population. 
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1.3 The coding capacity of the influenza virus genome 
The influenza virus genome encodes its component proteins in the negative sense, meaning the 
mRNA is in the opposite sense to the genomic RNA or vRNA. The proteins encoded by the genome 
are presented in table 2 below. 
The majority of the influenza virus genomic segments contain 1 large open reading frame which can 
be read from a translation start position to a stop codon close to the end of the mRNA to produce a 
single protein. However some RNA segments have the ability to produce additional viral proteins 
(Chen, Calvo et al. 2001; Wise, Foeglein et al. 2009). Furthermore, the mRNA transcripts from two of 
the influenza A virus segments 7 and 8, may be spliced to produce additional products (Lamb and 
Choppin 1983).  
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Table2. Component proteins of the influenza A virus with a brief introduction to their function 
Protein Coding 
Segment 
Extended Name Function 
PB2 1 Polymerase Basic 
Protein 2 
Cap binding protein and component of the 
polymerase complex (Fechter, Mingay et al. 
2003; Fechter and Brownlee 2005) 
PB1 2 Polymerase Basic 
Protein 1 
Protein containing classical RNA dependant RNA 
polymerase (RdRp) Active site for the viral 
polymerase.  
PB1-F2 2 Polymerase Basic 
Protein 1- Frame 2 
Non essential protein factor that may or may 
not be present in a given influenza strain. 
(Chen, Calvo et al. 2001) 
N40 PB1 2 Polymerase Basic 
Protein 1 –Nterminal 
40 
PB1 like protein with a 40 amino acid truncation 
caused from internal initiation within the PB1 
open reading frame (ORF) with an unknown 
function (Wise, Foeglein et al. 2009) 
PA 3 Polymerase Acidic 
Protein 
Endonuclease function for cap snatching 
process (Plotch, Bouloy et al. 1981; Dias, 
Bouvier et al. 2009; Yuan, Bartlam et al. 2009) 
Essential part of the polymerase complex.  
Controversial role in upregulating cellular 
proteases (Perales, Sanz-Ezquerro et al. 2000; 
Naffakh, Massin et al. 2001) 
Role in the assembly of mature virus particles 
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(Regan, Liang et al. 2006) 
NP  Nucleoprotein RNA binding protein which along with PB1, PB2 
and PA form the viral replication complex 
(Portela and Digard 2002). 
HA  Haemaglutinin Virion surface glycoprotein which binds sialic 
acids on the cell surface. Mature HA is cleaved 
into HA0 and HA1 by host proteases, and this is 
important for viral entry and un-coating 
(Steinhauer 1999). 
NA  Neuraminidase Virion surface glycoprotein necessary for viral 
release from the cell surface, via cleavage of 
sialic acids present on the surface (Meindl, 
Bodo et al. 1974; Palese and Schulman 1974; 
Palese, Schulman et al. 1974; Palese, Tobita et 
al. 1974; Palese and Compans 1976). 
M1  Matrix Protein 1 M1 is a structural protein which coats the inside 
of the viral envelope. This protein also coats the 
RNP and functions as part of the export 
apparatus to transport mature viral RNP for 
assembly and budding. 
M2  Matrix Protein 2 This is a membrane bound ion channel, which 
promotes the entry of H+ ions into the virus as 
part of the un-coating process inside acidified 
vesicles (Pinto, Holsinger et al. 1992; Pinto and 
Lamb 2006; Pinto and Lamb 2007). 
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NS1  Non structural 
Protein 1 
This is a non structural protein which functions 
to modulate the host innate responses to viral 
infection (Kochs, Garcia-Sastre et al. 2007; Hale, 
Randall et al. 2008). 
NS2/NEP  Non structural 
Protein 2/Nuclear 
Export Protein 
NEP acts as an export factor binding to the M1 
coated viral RNPs and the host factor CRM-1 
resulting in export of the viral RNPs for 
assembly and budding. (O'Neill, Talon et al. 
1998; Akarsu, Burmeister et al. 2003) 
For influenza A, it was long cited that the genome encoded 10 proteins However, however recent 
studies have proposed a further four encoded viral proteins namely PB1-F2, PB1 N40 and the 
theoretical protein M3 (Jackson and Lamb 2008) with as yet poorly characterised expression or 
functions. 
1.4 The Structure of the Influenza Virus 
 
The structure of the influenza virus is shown in Figure 1. Virus particles are composed of an envelope 
which is derived from the host cell membrane, with an underlying dense concentration of M1 matrix 
protein in a helical configuration (Noda and Kawaoka 2010). The virions of influenza A viruses are 
thought to form both filamentous and spherical particles, with spherical virions being of a size 80-
120nm and more typical of laboratory-adapted influenza strains, and the filamentous forms up to 
microns in length and more typical of low passage history clinical isolates. The virus shape is 
determined by the M1 protein (Bourmakina and Garcia-Sastre 2003; Elleman and Barclay 2004), and 
although specific amino acids in the M1 have been characterised that switch the shape of the virus 
(Burleigh, Calder et al. 2005), the mechanism for this is unclear. The interaction with M1 with other 
components of the virus likely play a role (Noton, Simpson-Holley et al. 2009). Moreover, other viral 
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proteins have been implicated in playing a role in the determination of the morphology of the virus 
particle including the M2 (Grantham, Stewart et al. 2010) and the C terminal “tails” of the surface 
glycoproteins (Chen, Leser et al. 2007). 
The M1 protein within the mature virus particle is highly ordered  (Calder, Wasilewski et al. 2010), 
and it is in close association with the RNP through its ability to bind NP and RNA (Noton, Medcalf et 
al. 2007). Also associated with M1 is the NS2/NEP, which was originally thought to be absent from 
virus particles. NS2/NEP is responsible for the nuclear export of the RNPs prior to assembly (O'Neill, 
Talon et al. 1998; Bui, Wills et al. 2000; Elton, Simpson-Holley et al. 2001; Noton, Medcalf et al. 2007)  
which occurs via a Crm-1 dependant manner (Neumann, Hughes et al. 2000; Watanabe, Takizawa et 
al. 2001) , and has recently been identified as having a role modulating polymerase activity (Robb, 
Smith et al. 2009). 
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Figure 1 Diagram Showing the Structure of the Influenza Virus 
 Virus particles are composed of an envelope which is derived from the host cell membrane, with an 
underlying dense concentration of M1 matrix protein in a helical configuration (Noda and Kawaoka 
2010).  
The virus shown in this diagram is shown spherical in morphology, although influenza is also 
reported to have a filamentous form depending upon its constituent proteins.  
Traversing the host acquired lipid envelope of the virion are the two influenza glycoproteins and on 
the virus surface. These form a tetramer and trimer respectively.  
The envelope encloses the genomic RNA of the virus which is packaged within a structure known as 
the RNP or ribonucleoprotein complex. The RNP is formed from the 3 polymerase subunits PB1, PB2 
and PA, which bind the 5’ and 3’ ends of the genomic RNA, and a large multimer of the 
Nucleoprotein. Within the virion, 7 of the RNPs have been shown by EM to be positioned around the 
edge of the virion, with the 8th RNP in the centre. 
Also associated with M1 is the NS2/NEP, previously thought to be absent from the virion.  
Haemagglutinin (HA) traverses the virus envelope to form spikes and is a trimer. The HA is 
responsible for the binding of the virus to the receptor on the cell surface initiating infection.  
Neuraminidase (NA) protein has a role in the exit of the virus releasing the virus from the cell 
surface. This also traverses the envelope and forms a tetramer on the virus surface.  
The final influenza protein traversing the envelope is the M2 ion channel. This exists as a tetramer in 
the virus envelope (Zebedee, Richardson et al. 1985). 
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Traversing the host acquired lipid envelope of the virion are the two influenza glycoproteins 
Neuraminidase (NA) and Haemagglutinin (HA) which form spikes on the virus surface. These two 
proteins are used to characterise the antigenic subtypes of the virus. There are 16 HA subtypes, and 
9 NA subtypes, and the specific combination of these 2 proteins produces the short name of the viral 
type eg: H1N1, H5N1 (Webby, Webster et al. 2007; Yassine, Lee et al. 2010). The HA is responsible 
for the binding of the virus to the receptor on the cell surface initiating infection, the NA protein has 
a role in the exit of the virus releasing the virus from the cell surface. Another protein traversing the 
envelope is the M2 ion channel. This exists as a tetramer in the virus envelope (Zebedee, Richardson 
et al. 1985). 
The envelope encloses the genomic RNA of the virus which is packaged within a structure known as 
the RNP or ribonucleoprotein complex. The RNP is formed from the 3 polymerase subunits PB1, PB2 
and PA, which bind the 5 and 3 prime ends of the genomic RNA. The RNA is further bound and 
encapsidated by the multimeric NP protein to form the RNP (Lamb and Krug 2001). Within the virion, 
7 of the RNPs have been shown by EM to be positioned around the edge of the virion, with the 8th 
RNP in the centre, in what is referred to as a 7+1 configuration (Noda and Kawaoka 2010). The RNPs 
have multiple interactions between each other along the long axis of the filamentous virus particle.  
A number of proteins produced by the virus are absent from the virus particle (Shaw, Stone et al. 
2008). These include NS1, which is produced in infected cells to modulate host responses to 
infection (Hale, Randall et al. 2008), PB1-F2 which is thought to be a virulence factor and is localised 
to the mitochondria (Chen, Calvo et al. 2001; Chen, Yang et al. 2004), N40-PB1 a recently described 
short form of PB1 (Wise, Foeglein et al. 2009) has yet to be formally excluded from the list of 
proteins present in the virus but is likely absent.  
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1.5 An Overview of the Virus Replication Cycle  
 
The Binding of Influenza A to its Cellular Receptor 
The infection cycle of influenza virus is detailed in Figure 2. The mature virion interacts with a 
receptor on a permissive host cell. The influenza surface protein Haemagglutinin, HA, binds a 
glycoside receptor known as sialic acid present on the cell surface. The surface proteins of cells, such 
as those lining the respiratory tract in mammalian hosts, or the alimentary canal in avian hosts are 
highly glycosylated and most of the glycosides terminate in sialic acid via either a 2-3 or 2-6 linkage. 
It has been shown that the HA proteins of different influenza virus show preference in their affinities 
to one of linkages (Baum and Paulson 1990; Thompson, Barclay et al. 2004; Thompson, Barclay et al. 
2006; van Riel, Munster et al. 2006; Barclay, Jones et al. 2007; van Riel, den Bakker et al. 2010). This 
may constitute one of several host range barriers that prevent the zoonosis of avian influenza into 
humans and other mammals (Ayora-Talavera, Shelton et al. 2009; Shelton, Ayora-Talavera et al. 
2011). 
A further constraint to successful cell binding may be the secretion of mucus. Mucus contains chains 
of the polyvalent sialic acid moiety recognised by HA in the form of mucins, and it has been 
proposed that an additional role of the NA protein is the cleavage of these substrates to facilitate 
access to the cellular receptor (Matrosovich, Matrosovich et al. 2004; Kesimer, Scull et al. 2009).  
 
The Uncoating Process of Influenza A 
Upon binding, the endocytosed virion is transported through a series of endosomal vesicles which 
are acidified (Lamb and Krug 2001). The ion channel M2, which is embedded within the virion 
envelope, allows entry of protons into the virion facilitating the un-coating process. The decrease in 
the pH of the environment within the endosome simultaneously causes a refolding event to occur on 
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the HA protein, which fuses the virus membrane to the vesicle and transfers the genomic RNA 
packaged as RNPs into the cell cytoplasm. 
The vRNPs consisting of the viral genomic RNA or vRNA, bound at the 5’ and 3’ termini to the viral 
RNA polymerase complex and coated in viral nucleoprotein are transported to the nucleus which is 
the site of viral transcription and replication. The influenza A NP contains an NLS which is required 
for the nuclear targeting of the vRNPs (O'Neill and Palese 1995; Cros, Garcia-Sastre et al. 2005) 
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Figure 2 An Overview of the Virus Replication Cycle  
A - A mature virion interacts with a compatible receptor on a host cell. The HA protein determines 
the compatibility of the host receptor to the virus. 
B- The successful binding of HA to the cell surface receptor results in the internalisation of the virus 
into a vesicle. 
C – Vesicle matures and is progressively acidified. Acidification of the vesicle results in the proton 
pump in the M2 protein bound in the virus membrane acidifying the inside of the virus too. 
D – Acidification inside the virus causes the HA fusion peptide to change in confirmation stimulating 
the fusion of the Virus membrane and that of the membrane bound vesicle. Fusion of the two 
membranes and the conformational changes of other proteins within the virus release the genomic 
RNA in the form of RNPs, to the cytoplasm. 
F - RNPs are transferred to the nucleus, and begin to make the 4 species of virus specific RNA. 3 are 
shown in this diagram for simplicity. Viral mRNA is transferred from the nucleus to the cytoplasm for 
the manufacture of new proteins, some of which are needed to make the new virion. Others such as 
NS1 counter the host response to infection. The viral vRNA is transcribed through a complementary 
intermediate cRNA, to make more vRNA.  
G – At late times post infection, new vRNPs are seen to leave the nucleus and are transferred to 
areas at the cell surface where they are assembled into a new virus. New virions are bound to the 
cell surface by the interaction between the cell surface receptors and the HA, and require actions of 
the NA to release them to infect a new cell. Exposure of the HA protein to ubiquitous proteases 
present outside the cell cleaves the HA into a mature HA1 HA2 structure, thus being activated for 
the infection of the next cell.  
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 Replication and transcription of the vRNP in the nucleus. 
The RNP of influenza virus is an important structure which stably encapsidates the vRNA. At the 5’ 
and 3’ end of the viral RNA is a promoter structure which is bound by the 3 subunits of the 
polymerase complex, PB1, PB2 and PA. The promoter structure consists of a highly conserved series 
of nucleotides which interact and are predicted to form a corkscrew structure (Flick and Hobom 
1999). 
Upon reaching the nucleus, the vRNA is transcribed and replicated into mRNA and cRNA 
respectively. It was previously thought that there was a switch between transcription and 
replication, with the viral polymerase having an initial bias for the production of mRNA until a point 
at the infection cycle that sufficient new viral components have been manufactured by the infected 
cell and the virus can synthesise cRNA, the intermediate RNA which is synthesised, and then used as 
a template to manufacture new vRNA. However there is also a hypothesis the viral polymerase has 
no bias, and cRNA production appears initially low until sufficient viral proteins have accumulated to 
protect the cRNA transcripts from host nuclease degradation (Vreede, Jung et al. 2004). Within the 
pool of transcripts there is thought to be some degree of regulation to ensure that some genes are 
accumulated rapidly early on, and other accumulate at later time points in infection (Shapiro, 
Gurney et al. 1987). 
Influenza viruses are unusual amongst those with RNA genomes in that virus replication occurs 
within the nucleus. Localisation to the nucleus allows the viral polymerase to interact with host 
factors such as the host RNA Polymerase II (Engelhardt, Smith et al. 2005; Engelhardt and Fodor 
2006). Pol II is 250 kDa protein that is part of a mega protein complex containing multiple factors 
which produce host mRNAs.  
The C terminal domain, (CTD) of this protein acts as a multi functional scaffold and regulatory 
marker during normal mRNA synthesis, with the different stages of Pol II action being marked by 
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different phosphorylation patterns on the Serine residues within the CTD (Phatnani and Greenleaf 
2006). The RdRp of influenza viruses interact with the Serine5-phosphorylated CTD of Pol II (Chan, 
Vreede et al. 2006), and this interaction provides the polymerase with a ready supply of host 
messenger RNAs. Host mRNAs are required to prime viral mRNA synthesis, to make viral mRNA, the 
virus utilises the endonuclease on the PA protein of the viral RdRp (Dias, Bouvier et al. 2009) to 
cleave 10-13 nucleotides along a host mRNA transcript from the cap structure (Plotch, Tomasz et al. 
1978; Plotch, Bouloy et al. 1979; Krug, Bouloy et al. 1980; Plotch, Bouloy et al. 1981). The stolen cap 
structure and host mRNA component are then utilised as a primer to produce viral mRNA transcripts 
(Bouloy, Plotch et al. 1978; Krug, Bouloy et al. 1980; Robertson, Dickson et al. 1980), which now 
resemble host transcripts at the 5` end, these are protected against the cap snatching process by 
binding of the Polymerase complex to the 5’ end of the growing mRNA template (Shih and Krug 
1996). 
To complete the molecular camouflage, at the 3’ end of viral mRNA transcripts, a poly A tail is 
produced by the viral polymerase complex acting on a polyU signal adjacent to the viral promoter to 
repeatedly add A residues to the end of the transcript (Luo, Luytjes et al. 1991). Localisation in Pol II 
“factories” likely also provides a high abundance of splicing factors which are regulated by the virus 
to ensure production of the 2 viral spliced genes. 
 
Influenza Viral Polymerase activity 
The influenza viral polymerase complex produces the 3 different species of RNA necessary for virus 
replication which includes the viral messenger RNA (mRNA) to produce more viral protein 
components and the viral complementary RNA (cRNA), a full length copy of the genome which is 
replicated to further genomic viral RNA (vRNA). A 4th species of RNA has been recently described as 
part of the replication process, which may exist to modulate the bias of the polymerase from 
transcription to replication (Perez, Varble et al. 2010; Scull and Rice 2010). Although at present 
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insufficient data currently exists as to the precise mechanism of production, they are known to 
represent sequences present within the influenza genome (Umbach, Yen et al. 2010).  
 
Influenza A Viral Assembly and Budding 
The mechanism of viral assembly and budding is a complex process, requiring exit of the mature 
vRNPs from the nucleus, delivery of viral components to the apical sites on the cell surface (Nayak 
and Barman 2002; Nayak, Hui et al. 2004; Nayak, Balogun et al. 2009) and incorporation of the new 
vRNPs into the virus. Although the selective incorporation of the influenza virus RNA into virions has 
been reported (Fujii, Goto et al. 2003), this observation has been controversial (Hutchinson, von 
Kirchbach et al. 2010). The virus buds apically, and this involves the M2 protein (Rossman, Jing et al. 
2010), with the virus particles finally forming by the scission of the envelope, again directed by the 
M2 protein to form a mature virion (Rossman, Jing et al. 2010). Mature virions may remain attached 
to the cell surface via the HA-sialic acid interaction until release via the action of the second surface 
glycoprotein NA. The NA protein cleaves cell surface receptors and releases the virion to then infect 
the next cell. Studies with NA inhibitors have shown that blocking NA action causes virions to 
accumulate bound to cell surface membranes unable to be released (Palese and Compans 1976; 
Garman and Laver 2004), or selects for NA deletions (Nedyalkova, Hayden et al. 2002). 
1.6 The host response to virus infection: RIG-I and Mda5 
The cytoplasmic RNA helicases retinoic acid inducible gene-I (RIG-I) and melanoma differentiation-
associated gene 5 (Mda-5) are two important pattern recognition receptors in mammalian cells, 
which are up regulated in response to interferons α and β (Siren, Imaizumi et al. 2006) and which 
sense and respond to a viral Pathogen-associated Molecular Pattern or PAMP, the molecular product 
recognised by the host cell as being foreign in origin. The expression of viral genes within an infected 
cell may result in the accumulation of both single and double stranded RNAs alien to the cell 
because of their structures or locations, and these are the PAMPS which these two molecules sense. 
32 | P a g e  
 
Both RIG-I, and Mda-5 contain anti viral sensors – the two caspase recruitment domains (CARDs) at 
the N terminus, and a DExD/H box RNA helicase domain within the remainder of the protein 
(Yoneyama, Kikuchi et al. 2005). A schematic of these proteins has been adapted from Yoneyama et 
al. (Figure 3). A further related protein LGP2 has been proposed to act as a negative regulator of 
these two antiviral sensors, as it is lacking the CARD domain and functions by binding viral dsRNA 
limiting the activation of the antiviral helicases (Yoneyama, Kikuchi et al. 2005). However, it has been 
recently shown that this protein may in fact act as a positive regulator of RIG-I and Mda-5 mediated 
antiviral responses in response to the majority of viruses with the notable exception of influenza 
(Satoh, Kato et al. 2010). 
Influenza A viruses do not produce detectable amounts of dsRNA (Weber, Wagner et al. 2006), and 
the activation of RIG-I has been shown to occur in response to single stranded RNAs bearing 5’ 
phosphates (Pichlmair, Schulz et al. 2006). These are found on the viral genomic RNA structures of 
influenza A viruses (Rehwinkel, Tan et al. 2010). 
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Figure 3 Summary of the DExD/H Box RNA Helicases 
The major cytoplasmic pathogen sensors RIG-I and Mda-5, along with a related protein LGP2 are 
shown here. Between all three proteins there is a high degree of homology (Yoneyama, Kikuchi et al. 
2005). RIG-I and Mda-5 both share functionality in recognition of invading pathogen signatures such 
as 5’ triphosphate groups on RNA (RIG-I) or specific highly ordered molecules of RNA dsRNA (Mda-
5)(Pichlmair, Schulz et al. 2009). This is mediated through the helicase domain. The caspase 
recruitment domain (CARD) domain is required for transmission of the signal to downstream 
signalling molecules such as IPS-1 
The protein LGP2 was initially reported as a repressor to Mda-5 and RIG-I, as it has the helicase 
domain, but lacks the CARD domain therefore cannot interact with factors such as IPS-1. However 
this has subsequently been shown to amplify sensed pathogenic signals.  
The IPS-1 target molecule for RIG-I is found on the surface of mitochondria bound via the trans-
membrane region.   








Schematic of RIG-I Family RNA Helicases
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Indeed, the processing of viral transcripts to modify their 5’ end is one mechanism which is 
employed by several RNA viruses to mask their presence and prevent the activation of RIG-I. For 
example the genomic RNA of Hantaan viruses trigger or encode factors which remove the 5’ end tri-
phosphate, and accordingly the purified genomic RNA is a poor interferon stimulant (Habjan, 
Andersson et al. 2008). Experimentally both RIG-I and Mda-5 become activated in response to the 
artificial dsRNA poly I:C (Gantier and Williams 2007) which complicates the difficulties in dissecting 
the cellular responses using this artificial stimuli.  
 Activation of both RIG-I and Mda-5 is achieved by binding of dsRNA, or in the case of RIG-I, ssRNA 
bearing a 5’ triphosphate, to the helicase domain. This then exposes the CARD domain, for 
interaction with IPS-1 which is localised on the outer membrane of the mitochondria (Ohman, 
Rintahaka et al. 2009). For RIG-I the efficiency of this interaction is increased upon the 
ubiquitinylation of the first CARD domain by an E3-ubiquitin Ligase Trim25 (Gack, Shin et al. 2007; 
Gack, Kirchhofer et al. 2008) . The activation of IPS-1 then results in the activation of IRF-3, NFKB and 
IRF7 and the production of interferonβ gene products.  
RIG-I and Mda-5 are involved in influenza A virus induced expression of antiviral cytokines (Siren, 
Imaizumi et al. 2006), but it is primarily the ability of NS1 proteins to modulate RIG-I activation that 
determines the levels of interferonβ induced during infection. Thus transient over expression of 
either RIG-I or Mda-5 only yielded significant IFN signals in response to an influenza A virus lacking 
the NS1 protein (delNS1) in the presence of RIG-I (Opitz, Rejaibi et al. 2007). Furthermore the NS1 
protein of the influenza A virus has been shown to specifically inhibit the function of RIG-I (Guo, 
Chen et al. 2007) and the mechanism for inhibition is either via a direct interaction with RIG-I 
(Pichlmair, Schulz et al. 2006), which in macrophages results in a slower kinetics of accumulation of 
RIG-I at the mitochondria (Ohman, Rintahaka et al. 2009), or via modulation of the TRIM25 protein 
(Gack, Albrecht et al. 2009). This new knowledge about the role of the DExD/HBox helicases also 
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provides the likely explanation for the block in IRF-3 activation which had been measured and 
established previously (Talon, Horvath et al. 2000). 
The activation of IRF-3, as a hallmark for the stimulation of RIG-I can be measured in Influenza A 
viruses which are defective in sequestering TRIM25, but because of alternative mechanisms 
employed by the influenza virus NS1 protein, this does not necessarily lead to the effective 
production of interferon or the antiviral state (Kuo, Zhao et al. 2010). A recent observation 
highlighting the importance of RIG-I in providing an antiviral protection, is that ducks and wild 
waterfowl have RIG-I and are able to propagate influenza while showing little signs of disease, but is 
highly lethal to chickens which lack this protein (Barber, Aldridge et al. 2010). 
The modulation of the RIG-I signalling pathway is not a unique strategy for the down regulation of 
the interferonβ response. The human respiratory syncytial virus is able to bind RIG-I via its non 
structural protein 2 (NS2) with the same effect as the influenza NS1 protein (Ling, Tran et al. 2009), 
and RIG-I is such an important viral RNA sensor that many other RNA viruses have evolved counter 
measures to evade it (Goodbourn, Didcock et al. 2000), and some picornaviridae degrade RIG-I 
(Barral, Sarkar et al. 2009). 
Despite MDA-5 being recognised as being important in the detection of RNA viruses, this has not 
been shown to interact with the influenza virus NS1 protein (Pichlmair, Schulz et al. 2006). This 
implies that while MDA-5 may be activated in influenza virus-infected cells to some degree, RIG-I 
mediated responses are the primary mode of influenza virus detection. Countering the detection of 
the invading pathogen is the influenza virus NS1 protein. 
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1.7 An Introduction to NS1 protein 
 
NS1 protein features 
The NS1 protein of influenza A virus is a variable virulence factor, which is most commonly between 
215-237 amino acids in length depending upon the strain. Within the NS1 proteins there are 
different levels of sequence conservation, but all natural NS1 proteins contain a conserved N 
terminus and a more variable C terminus, referred to as the RNA binding domain and the Effector 
domain respectively. The RNA binding domain extends to amino acid 73, and the effector domain 
comprises the remainder of the protein.  
The related protein of the Influenza B viruses is less variable and longer – up to 284 amino acids but 
it is believed to still be organised into two distinct domains, and be capable of binding dsRNA (Wang 
and Krug 1996) which highlights the importance of this function.  
 
Structure of the RNA binding Domain 
Bacterially expressed NS1 proteins have RNA binding capabilities (Hatada and Fukuda 1992; Hatada, 
Takizawa et al. 1992; Hatada, Saito et al. 1997). In addition NS1 acts as a regulator of the nuclear 
export of spliced RNAs coding for NEP/NS2 and has the ability to bind splicing intermediates as well 
as other RNAs by efficiently binding the poly(A) sequence at the 3’ end of mRNA (Qiu and Krug 
1994). 
Despite comparisons of the sequence of NS1 with those of the existing characterised poly(A) binding 
proteins, the precise RNA binding site was elusive, and it was unclear how an RNA binding site would 
have the flexibility to bind to poly A, a stem bulge in U6 snRNA (Wang and Krug 1998) and dsRNA – 3 
different molecular targets. However, using domain mapping Qian et al discerned the RNA binding 
domain was in the N terminal 73 amino acids of NS1 (Qian, Chien et al. 1995). The structure of the 
RNA binding domain of the NS1 protein of influenza A/Udorn/72 was initially solved by NMR (Chien, 
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Tejero et al. 1997) and X-ray crystallography (Liu, Lynch et al. 1997) in the absence of an RNA ligand. 
The structure presented was of a novel 6 helical domain with RNA binding function. This 
advancement presented information on possible basic amino acid candidates that would be exposed 
to the target RNA molecules. But, additional mutational analysis was required to elucidate the amino 
acids necessary for the RNA binding abilities (Wang, Riedel et al. 1999). 
 
In investigating the RNA binding by the N terminus, insights into the specific requirements for NS1 
dimerisation were also established. The full length NS1 protein forms dimers, an action requiring 
RNA binding (Nemeroff, Qian et al. 1995). Alanine substitution of amino acids D12, R19, D29, R35, 
and R46 in the 73 amino acid N terminal fragment all ablated the ability of the NS1 to form dimers. 
On the other hand, substitutions at amino acids R37, R38, K41and R44 specifically down regulated 
the ability of the NS1 protein to bind a 55bp dsRNA target and the characterised U6 target without 
compromising dimerisation. Therefore, though the dimerisation of the N terminal RNA binding 
domain could be seen as a separate activity to RNA binding, and an inability to form dimers would 
produce a lack of RNA binding, it was shown that disrupting RNA binding would not always abrogate 
dimerisation (Wang, Riedel et al. 1999). 
 
Higher affinity RNA targets of 140bp dsRNA identified peptide mutants containing Alanine residues 
at R37, R38 and K41 with reduced binding to the target. Indeed, the NS1 mutant R38A entirely lacks 
measurable dsRNA binding. Substitution of this arginine for a lysine at the crucial position 38 did not 
ablate the RNA binding, highlighting the requirement of this amino acid being of a basic nature 
(Wang, Riedel et al. 1999). 
Refinements to the NS1 RNA binding model suggest a novel and selective affinity for dsRNA over 
other forms of nucleic acid, including RNA/DNA hybrids, or dsRNA (Chien, Xu et al. 2004; Lin, Lan et 
39 | P a g e  
 
al. 2007). Analysis of the surface charges of the NS1 RNA binding domain revealed conserved 
exposed surface features of the protein required to maintain this function (Yin, Khan et al. 2007), but 
the NS1 protein was not successfully crystallised with RNA until 2008 (Cheng, Wong et al. 2009). The 
crystal structure with the RNA ligand bound revealed that in addition to the previously reported 
residue R38 being important for RNA binding, amino acids R35 and R46 of 2 opposing RNA binding 
domains must have contact with each other, and 2 additional RNA contact residues, T49 and S42 
have some contact with the target. S42 is of particular biological note as it has been implicated in 
having a role in a switch in pathogenicity when converted to a proline (Jiao, Tian et al. 2008), and 
this position acquired a compensatory S to G mutation upon passage of an RNA binding deficient 
virus which removed a degree of attenuation (Donelan, Basler et al. 2003). 
The elucidation of the RNA binding domain of the influenza A NS1 protein was of great use when 
applied to the less well characterised influenza B NS1 protein. The position of basic amino acids in 
the A/Udorn/72 NS1 protein appeared to correspond with the position of basic residues in B/Lee/40 
(Wang, Riedel et al. 1999) which implied that this RNA binding mechanism was conserved between 
influenza A and B NS1 proteins. This observation was supported by the refined crystal structures 
modelling the binding site of RNA on the surface of the NS1 protein binding surface upon 
crystallisation of the Influenza B NS1 protein (Yin, Khan et al. 2007). 
 
 Structure of the Influenza A Effector Domain  
Of the two domains of the influenza A NS1 protein, the C terminal effector domain contains the 
majority of the sequence variation. This domain can be thought of as a protein scaffold to which host 
proteins are recruited to enable the various functions that have been assigned to NS1 to be affected. 
Logistically it is difficult to understand how all the various host factors which can be bound. How is 
this one protein sequence able to conduct such an extensive list of interactions? 
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The crystal structure of the effector domain was obtained with a view to understanding how such a 
plethora of binding partners are sequestered by the virus. Like the N terminus, the C terminal 
effector domain fragment was originally purified as a dimer (Bornholdt and Prasad 2006). The dimer 
was critical in that it suggested that NS1 proteins could be able to bind up to 2 CPSF subunits, 
purportedly on the surface of the protein. Furthermore this crystal structure illustrated the position 
of the NES on the surface of the protein crystal in an accessible location. The amino acid Asp92 was 
localised almost in a cleft which could exist in an open or closed confirmation dictated by the nature 
of residues Ser195 and Thr197. These 2 amino acids have the potential to become phosphorylated 
over the course of an infection. However this discovery did nothing to aid understanding of how this 
amino acid mutation might affect virulence. The authors postulate an increase in the affinity of the 
NS1 for dsRNA is mediated by D92E, and this could account for the mechanism for interferon 
resistance by counteracting the dsRNA activated IFN stimulated genes such as PKR and 5’OAS.  
The full length crystal structure of NS1 from a highly pathogenic H5N1 virus recently published 
showed an N and C terminus recapitulating the 2 structures which had previously been elucidated 
(Bornholdt and Prasad 2008). However, the full length protein was only successfully expressed by 
engineering in the RNA binding mutations at amino acids R38A and K41A so whether the true 
structure is identical is not clear. The inter-domain region was calculated to have a high degree of 
rotational ability and this was proposed to facilitate the ability of the N and C termini to access 
factors without the steric hindrance that would occur if they were too tightly tethered. The flexibility 
of this region meant that it failed to crystallise, suggesting it is capable of forming many different 
confirmations.  
 
Sequence Variation of Influenza Virus NS1 Proteins and Mapping Pathogenesis 
The NS segments, and thus the NS1 proteins of influenza A viruses may be divided into two clear 
groups, which are referred to as the A allele and the B allele. Between the two groups, the sequence 
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homology may be as little as 62%, and the two groups may also be distinguished by their original 
host.  
The A allele consists of segments from viruses of both avian and mammalian hosts, and it has been 
shown that viruses carrying the NS1 of this allele have a explicative advantage in mammalian hosts 
compared to allele B NS1 proteins (Treanor, Snyder et al. 1989). The B Allele is avian in origin and it 
has been shown that the artificial recombination of a B allele into a human virus, and then 
subsequent infection of that virus into a squirrel monkey results in attenuated viral growth 
pathology, and this was one of the first pieces of evidence linking the NS1 protein with pathogenesis 
and virulence. 
Taking this observation further, similar models of artificial recombination events reassorted H7 and 
H5 viruses, and established that the outcome of the recombination events can be host dependant, 
as a similar Allele B virus reassortment event to that reported previously resulted in a virus that had 
higher viral pathology in a murine host (Wang, Suarez et al. 2008; Ma, Brenner et al. 2010; Wang, 
Robb et al. 2010), and the unpredictability of outcome found by these studies was a warning to 
avoid complacency when experimentally combining strains.  
The role of the NS1 protein in pathogenicity is multi-factorial, which is to be expected based on the 
number of reported interactions that the NS1 protein from influenza A has been implicated in. The C 
terminal end of the NS1 protein, (which may or may not be present due to variation in the length of 
the NS1 protein) can contain a sequence which is reported to be a host specific determinant of 
pathology (Soubies, Volmer et al. 2010; Zielecki, Semmler et al. 2010) The last 4 amino acids of an 
NS1 protein from an avian H7N1 virus were ESEV, and were a determinant of severe lung 
inflammation and higher production of type 1 interferon in a murine infection model. Conversely an 
isogenic virus, altered to have the consensus human amino acids RSKV at the terminal end replicated 
with a higher titre than the previous ESEV parental virus in ducks, whereas ducks infected with the 
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wild type virus had exhibited little disease symptoms at all. This demonstrated both the 
unpredictable nature of these gene alterations, and also the host specificity of a relatively subtle 4 
amino acid change for the outcome of infection in the two different host organisms. 
The ESEV PDZ binding motif of the avian influenza A virus such as the one encoded by this avian H7 
virus, recruits Scribble, a factor known to retard apoptosis (Liu, Golebiewski et al. 2010). The control 
of apoptosis could be hypothesised to be a highly successful strategy in maintaining the host 
machinery long enough to fulfil the obligations of an additional round of replication, and ensure that 
the cell the virus is replicating in remains undetected by host immune surveillance.  
It has been shown that phagocytosis aborts viral infection and this is clearly disadvantageous to the 
virus (Hashimoto, Moki et al. 2007). The two pathways p53 and phosphatidylinositol-3-kinase 
signalling pathway (PI3K) act antagonistically with respect to each other with regards to apoptosis 
and cell survival (Zhirnov, Konakova et al. 2002). Infection of cells with influenza results in a rise in 
p53 activity (Turpin, Luke et al. 2005), but the virus holds the cell on the brink of apoptosis by 
modulating the cell survival PI3K signalling pathways until approximately 20 hours post infection 
(Zhirnov and Klenk 2007).  
The modulation of the PI3K pathway is through the binding of the regulatory p85β subunit of PI3K by 
NS1, which activates the phosphatidylinositol-3-kinase signalling pathway (Hale, Jackson et al. 2006). 
If the NS1 gene in an influenza virus is engineered to lose the p85 interaction, the resulting viral 
infections presented a smaller plaque phenotype and grew to a lower titre. The biological relevance 
of this interaction in a natural host has yet to be formally examined and this property is not 
conserved amongst the influenza B viruses (Ehrhardt, Wolff et al. 2007) . 
Within the RNA binding domain of the NS1 protein there is an amino acid at position 42, which is 
implicated in pathogenesis. Conversion of this single amino acid was associated with the conversion 
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of an H5N1 virus from a non pathogenic to highly pathogenic one in a mouse model (Jiao, Tian et al. 
2008).  
Indeed the H5N1 viruses of the 1997 Hong Kong outbreak encoded an NS1 protein which was 
demonstrated to enable the virus to become cytokine resistant (Seo and Webster 2002) and this was 
suggested was a mechanism for a high degree of pathology associated with this particular outbreak 
of influenza viruses (Barclay and Zambon 2004) This virus was able to induce a high degree of 
cytokines during the replication process (Cheung, Poon et al. 2002). The interferon resistance 
phenotype was associated with a novel D92E mutation, which was modelled to increase dsRNA 
binding efficiency (Li and Wang 2007), as does a deletion of amino acids 84-87 in the recent H5N1 
strains. In contrast to the work of Seo et al, these mutations are implicated in virulence, but not 
cytokine resistance by other workers (Lipatov, Andreansky et al. 2005; Li, Jiang et al. 2006). 
 
Cellular localisation of NS1 protein 
Unsurprisingly for a protein with many different functions, the NS1 protein of influenza A viruses has 
been reported to localise to various cellular compartments. The localisation of the NS1 protein of 
A/WSN/33 to the nucleus and nucleolus of MDCK and HeLa cells was demonstrated biochemically by 
nuclear fractionation and gradient centrifugation procedures to divide up the subsequent mixtures 
to isolate the nucleoli (Krug and Soeiro 1975). Mutations retargeting NS1 more efficiently to the 
nucleolus have been described (Hatada, Hasegawa et al. 1990) though the mechanism for this is 
poorly defined.  
The efficient accumulation of NS1 proteins into the nucleus is mediated by up to 2 nuclear 
localisation signals (Greenspan, Palese et al. 1988), one located in the N terminal RNA binding 
region, the second within the last 20 amino acids of the protein. This second nuclear localisation 
signal may be absent depending on the length of the NS1 protein, or the accumulation of amino acid 
mutations in this region of the protein. The efficient nuclear accumulation of NS1 protein is an 
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important factor in determining effective viral growth in Vero cells (Ozaki and Kida 2007). However 
variation has been reported in the localisation of the NS1 protein, both amongst viral strains, and 
infected host cell systems (Volmer, Mazel-Sanchez et al. 2010). For example the A/PR/8/34 virus NS1 
protein was demonstrated by indirect immunofluorescence to be absent from the nucleolus and 
predominantly localised in the nucleoplasm in A549 (human lung carcinoma) cells, localised to the 
cytoplasm and the nucleus but absent from the nucleolus in mouse embryo fibroblasts and finally 
weakly in the cytoplasm, and strongly accumulating in the nucleolus in duck and chicken embryo 
fibroblasts. 
Using E. Coli expressed components of the mammalian host import apparatus, the nuclear and 
nucleolar import signals were determined for the influenza virus strains A/WSN/33 and A/Udorn/72, 
and these were used to establish the localisation determinants (Melen, Kinnunen et al. 2007). These 
include basic amino acids 219, 220, 224, 229, 231 and 232.  
In contrast the determinants of intracellular localisation of the NS1 protein remain poorly defined in 
an avian host cell, even though these are derived from the natural hosts for the virus. The 
localisation of the NS1 protein has been demonstrated to have a degree of temporal regulation 
(Hale, Knebel et al. 2009). Within the sequence of the NS1 protein, there is a nuclear export signal 
(NES) which extends in the region 134-161 (Li, Yamakita et al. 1998), and in A/Udorn/72 comprises 
the sequence 138FDRLETLILL147. The flanking sequences of amino acids were demonstrated as critical 
for the regulation of this NES, with the amino acids at 147, 151 and 152 critical for the regulation. 
Alterations in this region of the protein could destroy the regulation of the NES meaning the protein 
was always in the cytoplasm. Deletion of the C terminal domain of the NS1 protein however, even if 
these deletions maintained the NES and adjacent control sequences, resulted in the nuclear 
retention of the NS1 protein.  
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Taken together, it is likely that the localisation of the NS1 protein is strain, host and temporally 
regulated, likely through post translational modifications of amino acids adjacent to the NES, and 
this, ensures the protein is able to perform both its nuclear and cytoplasmic functions.  
An example of a post translational modification that affects localisation of the NS1 protein is the 
CDK/Erk mediated phosphorylation of the NS1 protein at amino acid 215. Alteration of this amino 
acid from the human; Threonine to Alanine; results in retarded growth of the virus, with the NS1 
protein taking longer to achieve localisation into the typical nuclear puncta than wild type. The 
mutant virus eventually reached the same titre as the wild type virus but the increased length of 
replication cycle suggested a role in the regulation of viral gene synthesis of this gene locus (Hale, 
Knebel et al. 2009).  
The post translational modification of amino acids located near this amino acid with the SUMO 
conjugate, have also been implicated in imparting protein stability to the viral NS1 protein (Xu, Klenk 
et al. 2011). The resistance of this protein to turnover by the host proteome likely increases the 
chances of the NS1 protein to make any one of the diverse interactions that is required of it, and also 
allows a high degree of accumulation of protein over the course of an infection.  
 
The NS1 Protein and splicing 
The NS1 protein of Influenza is expressed linearly from the 8th and smallest segment known as the 
NS segment. Two of the influenza genes undergo splicing; these are the M segment which is spliced 
to produce M1 and M2, and the NS segment which has the ability to generate a second protein 
called NS2 or NEP. It is important for the influenza virus that only a fraction of the NS and M 
segment gene products undergo this splicing, ensuring the correct production of all the gene 
products at a set ratio.  
In order to express NS1 efficiently in mammalian cells outside of the context of the virus, the RNA 
sequence must be modified to remove the splice acceptor sequence from the RNA transcript, as pol 
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II gene product mediated splicing is so efficient as to otherwise result in only small levels of intact 
NS1 mRNA. The splicing of influenza A NS1 virally driven mRNA is independent of the accumulation 
of viral NS1 protein. It is tightly regulated to ensure a discrete proportion of the total mRNA 
transcripts made from the NS segment are spliced (Robb, Jackson et al. 2010). Of the pool of 
transcripts made in a viral infection, only 15% of them will be suitable for the translation of NEP. At 
present there is no clear explanation for how the virus regulates cellular splicing so efficiently, but 
both influenza A and B NS1 proteins are known to associate with the splicing associated factor SC35 
(Fortes, Lamond et al. 1995; Afonina, Stauber et al. 1998; Donelan, Dauber et al. 2004; Schneider, 
Dauber et al. 2009).  
Furthermore the NS1 protein, through the RNA binding site in the N terminus is known to interact 
with important components of the splicing apparatus including the U6 snRNA (Wang and Krug 1998; 
Amorim and Digard 2006). Within the nucleus, RNA binding by NS1 prevents pre-mRNA splicing 
events by binding to U6-U2 and U6-U4. Therefore efficient splicing complexes are unable to form 
(Qiu, Nemeroff et al. 1995). It is likely that this is part of the mechanism for inhibition of pre spliced 
host pre-mRNAs and blocks mRNA nucleo-cytoplasmic transport. The inhibition of splicing is likely to 
be multi-factorial, since the putative splicing factor known as NS1 binding protein, NS1-BP is also 
relocated in virally infected cells (Wolff, O'Neill et al. 1998) and expression of the influenza NS1 
protein has been shown to cause a redistribution of the splicing factors (Fortes, Lamond et al. 1995). 
In addition through its RNA binding site interaction, the NS1 protein disrupts splicing by binding U6 
snRNA (Qiu, Nemeroff et al. 1995) and a specific subset of U6 directly involved in splicing (Wang and 
Krug 1998).  
 
The Effect of NS1 on Mammalian Gene Expression 
Despite the NS1 RNA binding domain sequestering a specific range of splicing factors in the nucleus, 
the predominant block of host pre mRNA splicing exerted by the NS1 protein is through the 
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recruitment of the 30kDa subunit of the host 3’ mRNA maturation complex. This was initially 
identified using Yeast 2 hybrid interaction trap techniques (Nemeroff, Barabino et al. 1998). The 
identification of the interaction provided an explanation for earlier observations that the viral NS1 
protein was difficult to express in mammalian cells, and resulted in the accumulation of host pre 
mRNA in the nucleus which were not transported to the cytoplasm (Fortes, Beloso et al. 1994). 
The process of manufacturing a mature host mRNA, or transcription, is coupled to the termination 
process of that gene which results in the polyadenylation of the 3’ end of the mRNA transcript. The 
host pol II complex passes the poly(A) site encoded by the DNA (AATAAA) which is 10-30 nucleotides 
upstream of the ultimate cleavage site for the mRNA, and copies it faithfully into mRNA (AAUAAA). 
The C terminal domain of pol II, which acts as a molecular scaffold, recruits the factors needed to 
process the mRNA to completion.  
The pol II complex continues making a continuous mRNA transcribing something known as the 
downstream element. The CstF or cleavage stimulation factor assembles on the downstream 
element, and the formation of the cleavage complex proceeds with the recruitment of the CPSF 
complex, which includes the CPSF30 amongst other factors in this mega-complex. The downstream 
element, CstF and CPSF complex are stabilised on the RNA with another 3 factors; Cleavage factor 1 
and 2, which do the job of cleaving the pre mRNA, and PAP, or poly A polymerase. The Cleavage 
factors cleave the mRNA, and the complex on the downstream element dissociates. The PAP then 
adds approximately 10 A residues to the new 3’ end of the mRNA. This stimulates the recruitment of 
PABII, which tethers the CPSF complex and PAP to the RNA until the mRNA polyadenylation process 
is complete (Chen and Krug 2000). 
The NS1 protein of some influenza viruses, typified by the A/Udorn/72 lineage, are capable of 
binding the 30kDa subunit of the CPSF mega complex. With host mRNA maturation aborted, the 
mRNA is recognised as defective and degraded (Kuo, Zhao et al. 2010). The NS1 protein of these 
viruses is able to bind the 30kDa subunit of CPSF, in addition to PABII, which tethers the CPSF 
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complex to the polyA signal on the mRNA. Taken together, this blocks the association of the CstF on 
the downstream element, and this blocks the maturation of host mRNAs. It was hypothesised that 
this retention would increase the pool of host caps available to the influenza polymerase complex. 
However cap snatching has been shown to occur on nascent pol II transcripts, not mature ones in 
transit from the nucleus. This questions the role of NS1 as a component of the host shut off 
phenomenon seen in virus infected cells (Salvatore, Basler et al. 2002). 
The recent crystal structure of the C terminus of NS1 proteins interacting with the F2F3 fragment of 
CPSF has allowed the mapping of a great number of amino acids critical for the binding of these two 
factors (Das, Ma et al. 2008)., Even before this interaction was mapped at high resolution, it had 
been proposed that it would make a good target for rational drug design due to antiviral effects of 
over expressing the F2F3 fragment in tissue culture (Twu, Noah et al. 2006). Targeting the NS1 
protein, due to its essential nature in an interferon competent host, has also been a proposed drug 
target revealed by large scale computational studies (Darapaneni, Prabhaker et al. 2009). 
 
The association of the NS1 protein with nuclear factors such as PABII and CPSF30, explains the 
observation that a proportion of the NS1 proteins in infected cells appear to be present on the poly 
A tails of host mRNAs (Chen, Li et al. 1999), as part of the mechanism to prevent the efficient nuclear 
export of these mRNAs (Satterly, Tsai et al. 2007). The relative affinity of NS1 to polyA regions of 
RNA is less than that of other endogenous host poly A binding proteins. However, by binding 
selectively to the host apparatus which itself binds the RNA with high affinity, this constraint is 
overcome and this explains the RNA independent interaction of NS1 with PABII (Burgui, Aragon et al. 
2003). The demonstration that NS1 protein can directly bind to PABP1 protein nullifies arguments 
about the relative poly A RNA affinity as this interaction will bring the NS1 into close proximity to the 
poly A tail of host RNA, without needing to have a high RNA affinity binding domain. 
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The ability of NS1 proteins to bind CPSF is not universal; some NS1 proteins, such as those of viruses 
from the 1997 Hong Kong H5N1 outbreak lacked this interaction, but subsequently acquired it with 
increasing frequency from 1998 onwards (Twu, Kuo et al. 2007). The interaction of NS1 proteins with 
the 30kDa subunit of CPSF in some strains requires the presence of the viral polymerase complex to 
stabilise the interaction (Kuo and Krug 2009).  
Messenger RNAs made in the nucleus, be they of viral or host origin need to get to the cytoplasm 
which is where the translation apparatus is located. Nuclear export of viral mRNA requires ongoing 
operation of the host RNA pol II apparatus (Amorim, Read et al. 2007). The export of mRNA from the 
nucleus to the cytoplasm usually requires the use of adaptor molecules. The adaptor molecules act 
as an intermediary between the RNA, and the TAP/NXF1/NXT1 complex which then delivers the RNA 
out of the nucleus (Rodriguez, Dargemont et al. 2004) and in the case of normal mammalian host 
genes the number of adapter and intermediate molecules may be numerous. The close association 
of the viral polymerase complex to RNA pol II lends itself to the possibility that the export factors 
which are normally recruited to growing host mRNAs are recruited instead to the growing influenza 
mRNA. Different viral mRNAs are known be differentially sensitive to the interruption of pol II 
activity, and consequently it is thought that the various different mRNAs leave the nucleus via 
different routes (Read and Digard 2010). 
The NS1 protein, in addition to blocking the components of the host mRNA maturation apparatus 
listed earlier, has also been demonstrated forming an inhibitory complex with some of the export 
machinery of the host nuclear pore complex, which both blocks the exit of host transcripts to the 
cytoplasm, it is not clear from this how the viral genes then can be transported to the cytoplasm 
(Satterly, Tsai et al. 2007). 
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A further function of the NS1 RNA binding domain is to block the Protein Kinase R or PKR response 
by the host. PKR is an interferon induced kinase that contributes to antiviral innate immunity. 
Mutations in the N terminus RNA binding domain of NS1 like R38A affect the ability of the virus to 
modulate PKR activation (Hatada, Saito et al. 1999; Talon, Salvatore et al. 2000). Viruses defective in 
this function exhibit poor replication in interferon competent systems (Bergmann, Garcia-Sastre et 
al. 2000). They are unable to control the PKR activation levels (Hatada, Saito et al. 1999). Such 
viruses tend to acquire additional mutations which seem to restore a greater degree of replicative 
ability, for example the additional change in NS1 at S42G (Donelan, Basler et al. 2003) arose upon 
passage of the NS1 R38A mutant and a concomitant increase in replication was observed. 
Interestingly, a mutation observed at the same amino acid position, 42, has also been found to affect 
the virulence of an avian H5N1 virus. A P42S change in the background of a low virulence virus 
increased its virulence (Jiao, Tian et al. 2008). 
The PKR of mammalian cells is a 68kDa protein kinase predominantly found in the cytoplasm, 
although immunofluorescence experiments have also suggested that in some cells PKR is able to 
accumulate in the nucleolus. PKR has a roughly 2 domain structure, an RNA binding domain 
containing 2 RNA binding sites, and a C terminal domain containing kinase activity. 
The RNA binding domain of PKR is thought to act as a regulatory domain to mask the catalytic 
domain and suppress its activity. Upon stimulation by interferon, heparin sulphate or dsRNA, or the 
activator PACT the conformation of this protein changes, with rotation around a hinge region 
exposing the kinase domains. Two PKR proteins may then phosphorylate each other. These hyper-
phosphorylated forms then form a stable dimer which phoshporylates various substrates and then 
translocates to the nucleus where PKR contributes to the up-regulation of antiviral genes. 
The kinase activity of PKR results in the phosphorylation of the translation factor eIF2α. Eukaryotic 
initiation factor 2 (eiF2), is the multi subunit complex which initiates the synthesis of a polypeptide 
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in a eukaryotic cell. A ternary complex forms between the initiation factor eIF2alpha, GTP and the 
initiating tRNA, loaded with the terminal methionine for the synthesis of the de novo peptide, which 
then binds the 40S ribosomal subunit. Taken together this new complex is referred to as the 43S pre-
initiation complex, which sequentially binds mRNA, and then the 60S ribosomal subunit to form the 
80S initiation complex. During this process, the original ternary complex is hydrolysed to GDP. To 
reinitiate translation, this GDP must be exchanged for a new GTP, and this is achieved using the 
guanine nucleotide exchange factor or GEF, also referred to as eIF2B. However, the kinase PKR, 
acting upon serine 51 of the alpha subunit of eIF2 stabilises the GEF-eIF2-GDP complex. The act of 
stabilising the GEF in a complex, coupled with the relatively low levels of expression of GEF within a 
cell, means that small changes in the phosphorylation state of eIF2alpha can quickly deplete the pool 
of GEF within the cell, resulting in the arrest of protein synthesis.  
Upon phosphorylation, eIF2α is unable to initiate translation at the N terminal Met of a protein. Thus 
protein synthesis is down-regulated and this activity contributes to the phenomenon known as host 
protein synthesis shut-off. The PKR of mammalian cells has been shown to interact with the 
influenza virus NS1 protein biochemically (Tan and Katze 1998; Li, Min et al. 2006) although this was 
not reproduced by another laboratory (Falcon, Fortes et al. 1999).  
PKR is such an important antiviral factor that many other viruses have evolved counter measures to 
suppress its actions. In some cases the effects on PKR may not be direct, for example, influenza A 
virus has been shown to up regulate p58IPK, an inhibitor of PKR which controls the unfolded protein 
response in the endoplasmic reticulum (Melville, Tan et al. 1999). When levels of p58IPK are high, 
PKR activation is suppressed which results in the maintenance of high levels of translation and this 
contributes to the relatively low levels of PKR activation observed in the majority of influenza virus 
infections.  
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With the identification of RIG-I as a target for the influenza A virus NS1 protein (Gack, Albrecht et al. 
2009), and the probably source of the majority of the interferon signalling resulting from an 
influenza infection, the role of PKR in sensing and responding the influenza virus has been called into 
question. A recent paper suggested an as yet poorly defined role for PKR in determining the decay 
rate of mRNA (Schulz, Pichlmair et al. 2010), however the authors conceded that their data had not 
yet confirmed a role for this mechanism in an influenza infection.  
 
Enhancement of Translation of Viral mRNAs by NS1 
Global methods for the maintenance of viral mRNA translation in an influenza virus infected cell 
include the enhancement of translation through the repression of PKR (Salvatore, Basler et al. 2002), 
by up-regulating p58IPK a known repressor of PKR activation, and controlling of activation of 2’5’OAS 
(Katze, Detjen et al. 1986; Katze, Tomita et al. 1988; Min and Krug 2006). But these mechanisms do 
not account for the apparently increased efficiency with which influenza transcripts are translated in 
infected cells.  
 
The viral mRNA shares many of the features of host mRNA, for example at the 5’ end there is a cap 
structure, which is scavenged from the host mRNA, there is a poly A tail at the 3’ end, therefore 
there is little to distinguish viral transcripts from those of the host which are no longer being 
efficiently translated in host cells. However, between the 5’ cap structure and the commencement 
of the ORF of the viral protein lays the promoter structure which is copied from the viral gene 
segment. This is 20-50nt UTR is structured, and is vital for the resistance to the host shut off 
processes (Garfinkel and Katze 1992; Garfinkel and Katze 1993; Park and Katze 1995). In contrast to 
the substantial 700nt IRES structures employed by picornaviruses, these leader sequences seemed 
highly inefficient to accomplish the preferential translation of viral mRNA. Using the sequence of the 
5’ UTR of the NP segment as a bait in a three hybrid screen, a protein called GRSF-1 was identified, 
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which has been shown to up regulate the translation of influenza NP and NS1 mRNA, or reporter 
genes flanked by the 5’UTRs of these constructs in transient assays (Park, Wilusz et al. 1999; Kash, 
Cunningham et al. 2002; Kash, Goodman et al. 2006). 
 
In contradiction to the processes described to block protein expression, the influenza virus NS1 
protein is a component of the viral transcription-replication complexes in vivo (Marion, Zurcher et al. 
1997), allowing the NS1 protein access to the vRNA and mRNA of the virus. The effect of this close 
association is to enhance the translation of viral genes (Enami, Sato et al. 1994), by increasing the 
rate of translation initiation (de la Luna, Fortes et al. 1995). The NS1 protein of A/Victoria/3/75 has 
been shown to bind the eIF4GI component of the large cap binding complex in a region naked of 
host factors (Aragon, de la Luna et al. 2000). The recruitment of eIF4GI via amino acids 89 to 113 in 
the NS1, brings the NS1 protein into a region of eIF4G adjacent to another translation factor that 
NS1 has been shown to bind, namely PABP1 (Burgui, Aragon et al. 2003). PABP1, or Poly A Binding 
Protein 1, is a protein which binds the 3’ end of mRNA at the poly A tail, shuttling between the 
nucleus and the cytoplasm (Afonina, Stauber et al. 1998). It is believed to have a role in mRNA 
stabilisation and efficient translation. Mechanistically therefore, it seems that the NS1 protein is 
efficiently loaded to the 5’UTR of viral mRNA transcripts, where it then recruits translation factors 
upon reaching the cytoplasm. The interaction of the NS1 protein with the 5’UTR structure of viral 
mRNAs, coupled with the recruitment of eIF4G and PABP1 are thought to be critical mechanisms for 
the preferential translation of viral messages in an infected cell. The interaction of NS1 with 
hStaufen, a known component of the polysomes associated with cellular translation has also been 
suggested as a mechanism for the increased recruitment of viral transcripts to the translational 
apparatus (Falcon, Fortes et al. 1999). 
 Furthermore, influenza mRNA appears capable of being translated in the presence of high levels of 
phosphorylated eIF2α (Feigenblum and Schneider 1993). Viral mRNA themselves may also be 
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structurally optimised to maximise expression from a given transcript (Ilyinskii, Schmidt et al. 2009) 
which accounts for the continued translation of a greater proportion of these viral genes in the face 
of eIF2α mediated translation arrest (Garfinkel and Katze 1992). 
 
The function of the RNA binding Domain 
The functional significance of the NS1 protein’s ability to bind RNA is difficult to properly assess, the 
NS1 was first shown to selectively bind T7-derived viral negative sense RNA (Hatada, Takizawa et al. 
1992), but not measurably to artificial cRNA transcripts in vitro (Hatada, Saito et al. 1997). The 
binding of dsRNA is known to activate PKR, and NS1 blocked this activation in vitro (Lu, Wambach et 
al. 1995). Further work investigating short model genome RNAs bearing the 5’ and 3’ terminal vRNA 
showed that these constructs activate PKR in vitro and the NS1 protein was able to prevent this 
(Hatada, Saito et al. 1999). Viruses coding for RNA binding deficient NS1 proteins were unable to 
block the activation of PKR in infected cells (Bergmann, Garcia-Sastre et al. 2000). From this, it was 
concluded that a function of the NS1 RNA binding ability was to prevent the activation of PKR. 
Indeed this view was supported by work on the influenza B virus NS1 protein, where RNA binding 
mutants were unable to prevent the activation of PKR (Dauber, Schneider et al. 2006).  
When the RNA binding affinity of NS1 was calculated it was found to be much lower than the affinity 
of other RNA binding proteins present in the cell including PKR (Wang, Riedel et al. 1999; Chien, Xu 
et al. 2004). It was suggested that target in the cell that the NS1 protein is likely able to compete 
with is that of the dsRNA activated 2’5’OAS, which does not bind dsRNA using a conventional dsRBD 
(Hartmann, Justesen et al. 2003), and that the NS1 sequesters dsRNA from this protein preventing its 
activation.  
2’5’OAS is an interferon induced antiviral protein, which is produced as a latent enzyme in the cell 
after interferon stimulation. The latent enzyme is activated by recruiting dsRNA of a length of at 
least 15 nucleotides, and then begins to convert ATP to long 2’5’ linked oligo adenylates from 2mers 
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up to 30mers.These then bind to a second latent protein the endonuclease RNase L, which then 
forms a catalytically active dimer and degrades mRNAs and ribosomal RNAs within the cell, with 
obvious implications for viral replication. RNA Binding and the RNAi Apparatus 
RNA interference or RNAi is host defence mechanism that has been characterised in invertebrates 
including such as drosophila, nematode worms and plants. This mechanism is conserved in all 
animals including mammals. Although the role of components of the RNAi apparatus are often 
overlooked in higher animal cells in favour of other antiviral mechanisms such as the Interferon 
systems, DICER, one of the main constituents of the RNAi aniti-viral mechanism has been implicated 
in protection of mammalian cells against influenza A virus infection (Matskevich and Moelling 2007). 
Over the course of influenza A virus infection, there was a decrease in the levels of DICER in the cells. 
By using Vero cells, which are deficient in interferon, and depleting the cells of DICER, the resulting 
virus yield of a H7N7 virus was boosted suggesting that RNAi does indeed limit influenza replication 
(Matskevich and Moelling 2008). Despite it being an obvious candidate to counter this host 
mediated antiviral strategy, a recent paper proposed that the NS1 protein of A/WSN/33 was unable 
to suppress RNA interference in mammalian cells (Kok and Jin 2006). The influenza virus NS1 protein 
is not alone in being a viral RNA protein which is able to bind RNA, but is unable to interfere with the 
RNAi pathway. Indeed this is also the case for the the vaccinia virus E3 protein (Lantermann, 
Schwantes et al. 2007). 
The RNAi functions of plant cells can be regarded as analogous in function, though clearly not in 
mode of action, to the interferon system of mammalian cells. While in human cells there is only one 
copy of the RNAi system, in plants there are multiple copies of DICER and Dicer-like enzymes. The 
function of these mirror the PRRs of mammalian cells in detecting the PAMP produced by an 
invading pathogen. Since the majority of plant viruses are RNA viruses, it is therefore obvious that in 
the pathogen/host ‘arms race’, multiple copies of RNAi apparatus would be of great use. Over 
expression experiments in plant cells have been developed using a technique known as 
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Agrobacterium infiltration in which disarmed Agrobacterium transfer the DNA sequence coding for 
the gene of interest to the host plant cells, for example leaf explants. However the expression of the 
novel gene is often limited by the RNAI machinery of the cell. The ability of influenza NS1 protein to 
antagonise RNAi activities has been shown experimentally to be very efficient at enhancing gene 
expression in these systems (Bucher, Hemmes et al. 2004; Delgadillo, Saenz et al. 2004; Li, Li et al. 








An investigation into the mechanism behind the NS1 protein’s 
reported enhancement of translation  
The ability to enhance translation of an exogenously expressed gene following mammalian cell 
transfection has been reported of the NS1 protein cloned from the A/PR/8/34 strain of influenza A 
virus (Salvatore, Basler et al. 2002). Based on the variation in gene sequence noted for influenza A 
NS1 proteins from different strains of the virus, the first aim was to establish the effect of a diverse 
panel of NS1 proteins on the expression of a reporter gene in mammalian cells to establish if this 
was a universal feature of NS1 proteins. The documentation of the effects on the reporter gene may 
then allow a rational approach to an investigation of the mechanism(s) by which translation is 
enhanced. 
An Investigation into the Consequences of Diversity in NS1  
The literature suggests that NS1 protein vary in the mechanism by which they counter the innate 
antiviral interferon response. Some viruses lack the ability to control expression of induced host 
genes by inhibition of host mRNA processing and nuclear export. It is not clear why this capacity is 
apparently lost from some naturally occurring influenza viruses. The consequences of this genetic 
diversity will be investigated by pairing the viral NS segments encoding the NS1 proteins that 
encompass the different phenotypes with different viral genetic backbones, and measuring key 
markers of viral fitness such as replication efficiency, RNA production and interferon antagonism to 
qualitatively and quantitatively characterise the effects of differences in NS1 phenotype to biological 
outcome of infection for both virus and host. 
 
An investigation into the NS1 protein of the Pandemic H1N1 Virus 
A/England/195/09 
Since the commencement of this work, a novel pandemic virus, H1N1 2009, has entered the human 
population. Using the experiences gained in Part 1 and 2, an interrogation of the pertinent features 
of the NS1 protein of this new H1N1 virus will be conducted. This may then allow for an account of 
the current biological behaviour of the virus in various hosts and models, as well as predictions as to 
the future course for this virus as it adapts to the human host.  
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Materials and Methods 
Reagents for DNA and RNA Manipulation 
 
6x DNA Loading Buffer - 30% (V/V in dH2O) Glycerol (Sigma), 0.025% (W/V in dH2O) Bromophenol 
Blue (VWR). 
 
TAE Buffer - 40M Tris-Acetate (VWR). 1mM EDTA (VWR), prepared in dH2O and adjusted to pH8 for 
use as a running buffer for DNA gel electrophoresis or to prepare 0.5-2% Agarose gels (W/V - 
Invitrogen). The separation of the DNA was visualised by the addition of 1:10000 dilution of “Gel 
Red” (Molecular Probes) to the agarose gel mix prior to solidification. 
 
Formamide Loading Buffer - 90% (V/V in dH2O) Deionised Formamide (Sigma), 10mM EDTA (Sigma). 
Colouration of the buffer was achieved using small amounts of Xylene Cyanol (Sigma) and 
Bromophenol Blue (Sigma). 
 
Denaturing Urea Gel for Primer Extension Analysis – 6% Acrylamide (from Amresco; Acryl/bis 
Solution 19:1), 7M Urea,  5ml 10X TBE (recipe as described) 0.5 ml 10% (W/V) Ammonium 
Peroxodisulphate (Sigma) 0.05ml TEMED (N, N, N', N'-tetramethylethylenediamine) (Sigma) 
 
10 X TBE 89mM Tris-Base(Sigma) 89mM Boric acid (Sigma) 2mM EDTA(Sigma) adjusted to pH 8. Fresh 
aliquots were diluted 10 times before use as a running buffer for primer extension analysis.  
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Reagents for Protein Evaluation 
 
SDS Running Buffer - 25 mM Tris base(Sigma),  250 mM Glycine (VWR), 0.1% SDS (VWR - W/V in) 
Adjusted to a final pH 8.3 using concentrated HCl (VWR).  
 
SDS Laemmli Sample Loading Buffer - 300 mM Tris base (Sigma), 600 mM Dithiothreitol (Sigma),  2% 
SDS (VWR - W/V in dH2O) 0.1% bromophenol blue (VWR - W/V  in dH2O)  50% glycerol (VWR - W/V in 
dH2O). Adjusted to a final pH 6.8 using concentrated HCl (VWR). 
 
Transfer buffer Recipe- 0.037 % SDS (VWR - W/V in dH2O), 48 mM Tris base (Sigma) 39 mM Glycine 
(VWR), adjusted to pH 8.3 before use. 20% Methanol added just before use (VWR - V/V in final 
solution). 
 
Blocking Solution for Western Blotting – 10% non fat milk powder (Fluka - W/V in PBS),  0.1% Tween 
20 (V/V Sigma). 
 
LacZ Buffer:  60mM Na2HPO4.7H2O (Sigma), 40mM NaH2PO4.H2O (Sigma), 10mM KCl (Sigma), 1mM 
MgSO4 (Sigma).  
 
Phosphate Buffered Saline (PBS) was supplied as a 1X pH 7.4 stock from Invitrogen. The contents of 
this were 8% (W/V) Sodium chloride, 0.2% Potassium chloride 1.15% (W/V), Na2HPO4, 0.2% (W/V) 
Na2HPO4. 
 
10x CN Buffer: 30mM  K3Fe(CN)6 (Sigma), 30mM K4Fe(CN)6 · 3H2O (Sigma), 10mM MgCl2 (Sigma).  
 
X-gal Substrate: (bromo-chloro-indolyl-galactopyranoside - Sigma) - Prepared to 2%(W/V  in 
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Dimethylformamide - Sigma)  for immunohistochemical staining. 
 




Molviol for Microscopy (provided as a recipe for clarity) - 6g glycerol (VWR), 2.4g Molviol 4-8 
Hoescht (Fluka), 6 ml dH2O, 12 ml 0.2M TrisHCl (pH 8). 
 
DAPI - (4',6-diamidino-2-phenylindole - Sigma) was prepared as 1000x stock in DMF(Sigma) and 
stored at -20°C until needed. DAPI was used at 1:1000 with Molviol for microscopy. 
 
Virus Overlay mix (provided as a recipe for clarity)  - 100ml Earle’s minimal essential medium (10 x 
EMEM stock - Invitrogen), 28ml BSA (7.5% Stock –Invitrogen), 1 % glutamine (V/V using 200mM 
stock - Invitrogen),20ml NaHCO3 (7.5% stock - Invitrogen), 10ml  HEPES (1M Stock – Invitrogen), 5ml  
DEAE Dextran (1% filter sterilised Stock made up in dH2O -Sigma), 1% penicillin-streptomycin (V/V 
using 5000 IU/ml - Invitrogen). This mix was dispensed as 17.5ml aliquots. These were  finalised with 
either 8ml 3% Avicel (W/V in dH2O - FMC Polymers) or 2% Number 3 Agarose (W/V in dH2O - Oxoid) 
and 35µl Flu Trypsin (Worthingtons - 1mg/ml stock) per aliquot, which was sufficient overlay for 2 12 
well plates. Aliquots were stored at 4°C until needed. 
Luria Broth (LB): 1% tryptone (W/V - Oxoid),  0.5% yeast extract (W/V - Oxoid), 0.5% NaCl (W/V - 
VWR), 0.1% glucose (W/V - Sigma). This was sterilised by autoclaving before use. 
 
Ampicillin : 100mg/ml stock  of Ampicillin (Sigma) was prepared in dH2O and filter sterilised, typically 
a 1:1000 dilution was used for the generation of plates and liquid culture. Aliquots were stored at -
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20°C until needed. 
 
Virus diluent: 3% BSA (diluted from a 7.5% Stock using PBS – Invitrogen), 0.1% Penicillin 
Streptomycin (V/V using 5000IU/ml - Invitrogen) prepared in advance and stored at 4°C until needed. 
DNA Manipulation Techniques 
 
Mutagenic PCR of pCAGGS NS1 plasmids 
To sub clone from the pCAGGS vector, the primers p85 Rev and 4155 For were used. These flank the 
insertion site of the NS1 coding sequence and allow for the efficient cleavage of the resulting PCR 
product. The manufacturers recommended PCR conditions for Phuzion (Finnzymes) proof reading 
DNA polymerase enzyme were used.  
 
Overlap extension PCR was used to generate the point mutants of NS1 for this work. Briefly 
complimentary primers encoding the mutation were designed and paired with the flanking forward 
and reverse primers in 2 separate reactions. The subsequent PCR product was then resolved from 
the original template on a TAE Agarose gel and the band visualised and excised under low intensity 
ultraviolet light. The DNA in the resulting gel slabs was extracted using a gel extraction kit (Qiagen). A 
1 in 10 dilution of this purified DNA was then used for a second round of PCR, and the success of this 
reaction was confirmed by evaluating 5µl of the PCR on a second TAE Agarose gel.  
 
If this evaluation proved positive, the remainder of the PCR reaction was purified using a PCR 
purification kit (Qiagen). The DNA obtained was treated for approximately 12 hours at room 
temperature with the restriction enzymes Not I and Mlu I in a 20µl reaction assembled as per the 
manufacturer’s instructions (New England Biolabs).  Before ligation, these reactions were heated to 
70°C for 20 minutes to inactivate the restriction enzymes. Ligation of the altered insert was then 
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conducted using Cloneables 2X ligation mix (Novagen/Merck) in accordance with the manufacturers 
instructions. Sequencing of NS1 constructs in the pCAGGS vector used the p85 rev and 4155for 
primers (Sequence included in the table of primers) according to the instructions issued by the 
Imperial College MRC Clinical Sciences Centre Core Genomics Laboratory who provided the 
sequencing service. 
 
Mutagenic PCR of pPOLI NS plasmids 
Overlap extension PCR was also used to engineer sequence alterations into the pPOLI NS plasmids. 
As described 2 rounds of PCR were conducted using the Barclay Laboratory equivalent of the 
universal influenza A primers described by Hoffman et al, altered to be compatible with the pPOLI 
GALAXO vector (Glaxo Smith Kline) and a BsmB1 cloning strategy. The proof reading DNA polymerase 
Phuzion (Finnzymes) was used according to the manufacturer’s instructions.  
 
The PCR product was incorporated into the Topo blunt vector (Invitrogen) using the manufacturer’s 
instructions, and the bacteria spread on pre warmed LB/Agarose plates with appropriate selection. 
The following day 5 colonies were used to inoculate overnight liquid cultures, again under antibiotic 
selection. Using a Qiagen mini prep kit, plasmid DNA was isolated and a 3 hour digest using BsmBI 
was conducted of both the candidate viral segment and the viral pPOLI GALAXO vector, at 55°C in the 
PCR machine in accordance with the instructions of the restriction enzyme manufacturer (New 
England Biolabs). The digested pPOLI Galaxo vector, and PCR inserts released from the Topo vector 
were gel purified as described for the pCAGGS vector, and a ligation was conducted to achieve the 
final products, and the resulting candidates screened by Colony Screening PCR as described. A range 
of positive candidates were subsequently cultivated and the DNA identity confirmed before use in 
the reverse genetics system. 




Ligations of purified Vector backbone and digested PCR insert were done with a volume of 4.75µl to 
0.25 Insert to vector ratio achieving the total volume of 5µl. 5µl Clonables 2X ligation premix 
(Novagen/Merck) was then added and the samples were incubated on the bench for 10-15 minutes 
at room temperature. 3-5 µl of this mix was then transformed into NEB5α cells as according to the 
manufacturer’s instructions (New England Biolabs). 
 
Colony Screening PCR 
Colony screening PCR was used identify positive candidates generated as a result of cloning 
processes from the bacterial colonies growing on an Agar antibiotic selection plate. A master mix for 
a suitable number of experimental candidates and positive and negative tubes were set up using 
GoTaq Green (2X Taq PCR Mix -Promega), primers at 10uM and autoclaved water. PCR volumes of 
between 20 and 40µl were sufficient for this technique and where possible primers annealing on the 
vector adjacent to the NS1 insertion site (for example p85 Rev and 4155 For) were chosen to ensure 
a PCR product in both the positive and negative scenario aiding interpretation. 
 
A pre warmed Agar antibiotic selection plate with a grid of numbers to allow tracking of the 
successful candidates was used. Pipette tips were used to touch a candidate bacterial colony, then 
inoculate the PCR mix, then inoculate the fresh agar plate in the corresponding grid position before 
being discarded.  The PCR was conducted according to the manufacturer’s instructions with a 
modification in that the initial denaturation step was 4 minutes long to facilitate the lysis of the E. 
coli liberating the plasmid template for the reaction. PCR products generated were evaluated on TAE 
Agarose Gels and visualised as described earlier.  
Bacterial Transformation  
2 Different E. coli strains were used. Top10 cells (Invitrogen) were used primarily for production of 
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DNA for sub-cloning from the Topo vector (Invitrogen).  NEB5α cells (New England Biolabs) were high 
efficiency cells used for transforming ligations for a more efficient recovery of colonies. 
An aliquot of chemically competent E. coli was thawed on ice. The DNA solution to be transformed 
was added to the transformation tube and incubated on ice for 30 minutes. The tube was “heat 
shocked” at 42°C for 30 or 45 seconds in accordance with the manufacturer’s instructions and then 
further incubated on ice for 2 minutes. 350µl S.O.C. media was added per tube and the resulting E. 
coli was then incubated at 37°C with shaking an hour. 300µl of the supernatant was spread over pre 
warmed LB/Ampicillin plates which were incubated for 12-18 hours at 37°C.  
 
Ampicillin plates were provided by the Imperial College Section of Virology support staff and made 
up using the standard technique. Briefly 2% (W/V - Oxoid) Number 3 Agarose was added to LB broth 
(see earlier recipe). This was sterilised by autoclaving and the sterile LB/agarose could be stored until 
required at room temperature. To prepare plates, LB/Agarose was melted by heating, and cooled 
until “hand warm” when Ampicillin (stock concentration of 100mg/ml) at a ratio of 1:1000 dilution 
was added and the LB/Agar was well mixed before the plates were poured.  
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RNA Manipulation Techniques 
 
Extraction of Total Cellular RNA from Cells Using the Trizol Method 
Total cellular RNA extraction was conducted using the manufacturer’s instructions. Briefly, 1ml of 
Trizol (Invitrogen) was added per well of cells on a 12 well, or 6 well plate. The cells were incubated 
in the Trizol on the bench at Room temperature for 5-10 minutes, before the liquid was transferred 
to 1.5ml tubes. 200µl chloroform per ml of Trizol used was added to each sample and the samples 
were briefly mixed using a vortex. Tubes were centrifuged at 16000g in a refrigerated centrifuge for 
15 minutes at 4°C. The aqueous upper phase was removed and transferred to 0.5ml isopropanol 
(VWR) per 1ml of Trizol used. The samples were centrifuged using the same conditions as before. 
The resulting pellets were washed with 1ml 70% Ethanol per 1ml Trizol used(V/V freshly made up 
with Ribonuclease free dH2O). The tubes were further centrifuged at 16000g for 5 minutes. The 
ethanol was removed and the tubes given a pulse centrifugation to remove excess ethanol. The 
resulting pellet of RNA was dissolved in Ribonuclease free dH2O. RNA preparations were stored at -
20°C if they were to be used in the short term, or at -80°C for more long term storage. 
 
Extraction of viral RNA from Virus supernatant for RT PCR procedures 
using Trizol LS  
500µl Virus supernatant was removed to a fresh screw cap 2ml tube. To this an equal volume of 
Trizol LS (Invitrogen) was added and the samples were well mixed. 200µl Chloroform was added and 
the tube was briefly mixed using a vortex. . The tubes were centrifuged in a refrigerated bench top 
centrifuge at 16000g for 15 minutes at 4°C, and the resulting upper aqueous phase was removed to a 
fresh 1.5ml tube containing 500µl of isopropanol. The tubes were mixed and then centrifuged at 16 
000g for 15minutes at 4°C. The supernatant was removed and the resulting pellet was gently washed 
with 1ml 70% ethanol (V/V freshly made up with Ribonuclease free dH2O) and centrifuged for 5 
minutes at the previous conditions. The supernatant was removed and the tubes given an additional 
66 | P a g e  
 
pulse spin in the centrifuge to enable the removal of excess ethanol. The tubes were briefly air dried 
and the resulting pellet of RNA was dissolved in Ribonuclease free dH2O.  RNA preparations were 
stored at -20°C if they were to be used in the short term, or at -80°C for more long term storage. 
 
Reverse Transcription from Viral Genes 
To make cDNA of viral genes 5µl of the RNA isolated from viral supernatant as described previously 
was used in reverse transcription with 0.25pmol of the forward BsmB1 cloning primer for the viral 
segment of interest. These were mixed in a 200 µl thin walled PCR tube (Appleton) and this RNA 
primer mix was heated to 99°C for approximately 5 minutes then placed on ice. A 2X premix of 
Superscript II (Invitrogen) was made up as according to the manufacturer’s instructions for a final 
volume of 10µl and pre-incubated at 42°C. After a brief pre incubation of the RNA/Primer mix at 42°C 
alongside the reverse transcription mix, 5µl of this enzyme mix was transferred across to the 
RNA/Primer mix to initiate cDNA synthesis. The RNA/Primer/Enzyme mix was incubated at an hour at 
this temperature to generate cDNA. 
 
A proof reading DNA polymerase was not needed for sequencing therefore Go-Taq Green (Promega) 
was used in reaction conditions described previously to generate the full length PCR product. The 
resulting products was then put through a PCR clean up kit (Qiagen) to remove the primers and 
green pigments facilitating good quality sequencing. 
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Primer Extension Analysis of Gene Expression 
 
Primer Extension analysis was conducted using superscript II under conditions described for Reverse 
transcription with a few modifications. 
Prior to the reaction being conducted, primers were radio labelled using a polynucleotide kinase 
(PNK- Roche), incorporating a phosphate group on the 5’ end of the oligonucleotide from a 
radioactive ATP source (Perkin Elmer). Labelled oligonucleotides were purified from unincorporated 
ATP using a Qiagen nucleotide removal kit (Qiagen).  
To terminate the reaction after an hour, the cDNA synthesis reactions were inactivated by 
heating in an equal volume of Formamide Loading Buffer for 10 minutes at 99°C.  18µl of this 
was then loaded to a 0.38mm thick 7M Urea PAGE, run on an EV400 sequencing gel 
apparatus (Cambridge Design Plastics) with 1X TBE as the running buffer. The apparatus was 
run at 1000V until the bromophenol blue dye was 1 inch from the bottom electrode. The 
gels were dried down on Whatman paper and exposed to Biomax MR film. The signal from 
these samples was boosted using a HE intensifying screen (Kodak) and incubation at -80°C. 
Films were developed using a Fuji developing machine. The radioactive signals were 
captured for quantitation using Kodak phosphor-imager screens. The phosphor-imager 
screen data was measured in a Storm 860 (GE Healthcare), and the data they yielded was 
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List of Kits Used for Nucleic Acid Manipulation 
 
Table of Qiagen Kits Used 
Kit Used Purpose Supplier 
Qiagen Mini Prep Kit Small volume of DNA for cloning 
work or characterisation of a 
small amount of plasmid before 
conducting a maxi prep. 
Typically up to 2ml of overnight 
culture 
Qiagen GmBH. 
Qiagen Maxi Prep Kit Large amounts of DNA from up 
to 250ml of overnight culture 
Qiagen GmBH 
Qiagen Nucleotide Removal Kit Purification of Radio labelled 
Primer after Primer labelling 
Qiagen GmBH 
Qiagen PCR Purification Kit Purification of a PCR product 
without the need to go via a gel 
extraction – typically used for 
low efficiency PCRs. 
Qiagen GmBH 
 
Restriction Enzymes Used 
Enzyme Name Restriction Buffer/Conditions 
Used 
Manufacturer 
Nco I NEB Buffer 4 New England Biolabs 
Not I NEB Buffer 3 New England Biolabs 
Mlu I NEB Buffer 3 New England Biolabs 
Poly Nucleotide Kinase PNK Buffer Roche 
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DNA Polymerases Used 
Enzyme Use Source 
GoTaq Green Taq PCR for sequencing and 
colony screening PCR 
Promega 
Phuzion High fidelity cloning Finnzymes distributed by New 
England Biolabs 
Super Script II Reverse Transcription of RNA to 
single stranded DNA, 
sequencing of Virus preps 
Invitrogen 
 
Plasmids Used for this Study 
(Derivative plasmids are excluded for clarity) 
Plasmid Contents Source 
pβIFN-Luciferase A firefly luciferase reporter 
under the control of the human 
interferon β promoter 
Prof. Steve Goodbourn, St 
Georges, University of London.  
pβgalactosidase A β-galactosidase reporter with 
a rat actin promoter and an 
SV40 T antigen splice and poly 
adenylation signal. 
Prof. Steve Goodbourn, St 
Georges, University of London. 
pPOLI PB2 A/PR/8/34 Human RNA Pol I promoter and 
ribozyme terminator sequence 
flanking vRNA sense sequence 
for Segment 1 from A/PR/8/34 
Alison Whiteley, University of 
Reading/Barclay Laboratory 
Imperial College London 
pPOLI PB1 A/PR/8/34 Human RNA Pol I promoter and 
ribozyme terminator sequence 
flanking vRNA sense sequence 
for Segment 2 from A/PR/8/34 
Alison Whiteley, University of 
Reading/Barclay Laboratory 
Imperial College London 
pPOLI PA A/PR/8/34 Human RNA Pol I promoter and 
ribozyme terminator sequence 
flanking vRNA sense sequence 
for Segment 3 from A/PR/8/34 
Alison Whiteley, University of 
Reading/Barclay Laboratory 
Imperial College London 
pPOLI HA A/PR/8/34 Human RNA Pol I promoter and 
ribozyme terminator sequence 
flanking vRNA sense sequence 
for Segment 4 from A/PR/8/34 
Alison Whiteley, University of 
Reading/Barclay Laboratory 
Imperial College London 
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pPOLI NP A/PR/8/34 Human RNA Pol I promoter and 
ribozyme terminator sequence 
flanking vRNA sense sequence 
for Segment 5 from A/PR/8/34 
Alison Whiteley, University of 
Reading/Barclay Laboratory 
Imperial College London 
pPOLI NA A/PR/8/34 Human RNA Pol I promoter and 
ribozyme terminator sequence 
flanking vRNA sense sequence 
for Segment 6 from A/PR/8/34 
Alison Whiteley, University of 
Reading/Barclay Laboratory 
Imperial College London 
pPOLI M A/PR/8/34 Human RNA Pol I promoter and 
ribozyme terminator sequence 
flanking vRNA sense sequence 
for Segment 7 from A/PR/8/34 
Alison Whiteley, University of 
Reading/Barclay Laboratory 
Imperial College London 
pPOLI NS A/PR/8/34 Human RNA Pol I promoter and 
ribozyme terminator sequence 
flanking vRNA sense sequence 
for Segment 8 from A/PR/8/34 
Alison Whiteley, University of 
Reading/Barclay Laboratory 
Imperial College London 
pPOLI PB2 A/Victoria/3/75 Human RNA Pol I promoter and 
ribozyme terminator sequence 
flanking vRNA sense sequence 
for Segment 1 from 
A/Victoria/3/75 
Dr T Zurcher, GSK (Thompson, 
Barclay et al. 2004) 
pPOLI PB1 A/Victoria/3/75 Human RNA Pol I promoter and 
ribozyme terminator sequence 
flanking vRNA sense sequence 
for Segment 2 from 
A/Victoria/3/75 
Dr T Zurcher GSK (Thompson, 
Barclay et al. 2004) 
pPOLI PA A/Victoria/3/75 Human RNA Pol I promoter and 
ribozyme terminator sequence 
flanking vRNA sense sequence 
for Segment 3 from 
A/Victoria/3/75 
Dr T Zurcher GSK (Thompson, 
Barclay et al. 2004) 
pPOLI HA A/Victoria/3/75 Human RNA Pol I promoter and 
ribozyme terminator sequence 
flanking vRNA sense sequence 
for Segment 4 from 
A/Victoria/3/75 
Dr T Zurcher GSK (Thompson, 
Barclay et al. 2004) 
pPOLI NP A/Victoria/3/75 Human RNA Pol I promoter and 
ribozyme terminator sequence 
flanking vRNA sense sequence 
for Segment 5 from 
A/Victoria/3/75 
Dr T Zurcher GSK (Thompson, 
Barclay et al. 2004) 
pPOLI NA A/Victoria/3/75 Human RNA Pol I promoter and 
ribozyme terminator sequence 
flanking vRNA sense sequence 
for Segment 6 from 
A/Victoria/3/75 
Dr T Zurcher GSK (Thompson, 
Barclay et al. 2004) 
pPOLI M A/Victoria/3/75 Human RNA Pol I promoter and 
ribozyme terminator sequence 
flanking vRNA sense sequence 
for Segment 7 from 
A/Victoria/3/75 
Dr T Zurcher GSK (Thompson, 
Barclay et al. 2004) 
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pPOLI NS A/Victoria/3/75 Human RNA Pol I promoter and 
ribozyme terminator sequence 
flanking vRNA sense sequence 
for Segment 8 from 
A/Victoria/3/75 
Dr T Zurcher GSK (Thompson, 
Barclay et al. 2004) 
pCMV PB2 Expression plasmid for the 
Polymerase Basic 2 Protein of 
A/Victoria/3/75 
Dr T Zurcher GSK (Thompson, 
Barclay et al. 2004) 
pCMV PB1 Expression plasmid for the 
Polymerase Basic 1 Protein of 
A/Victoria/3/75 
Dr T Zurcher GSK (Thompson, 
Barclay et al. 2004) 
pCMV PA Expression plasmid for the 
Polymerase Acid Protein of 
A/Victoria/3/75 
Dr T Zurcher GSK (Thompson, 
Barclay et al. 2004) 
pCMV NP Expression plasmid for the 
Nucleoprotein of 
A/Victoria/3/75 
Dr T Zurcher GSK (Thompson, 
Barclay et al. 2004) 
pPOLI Sc50 NS Human RNA Pol I promoter and 
ribozyme terminator sequence 
flanking vRNA sense sequence 
for Segment 8 from 
A/Scotland/50/03 
Dr Ben Johnson, formerly 
Reading University/HPA. 
pPOLI Eng 612 NS Human RNA Pol I promoter and 
ribozyme terminator sequence 
flanking vRNA sense sequence 
for Segment 8 from 
A/England/612/03 
Dr Ben Johnson, formerly 
Reading University/HPA. 
pPOLI 3-5-8 Luciferase Human RNA Pol I promoter and 
ribozyme terminator sequence 
flanking vRNA sense sequence 
for Luciferase, with segment 8 
non coding regions modified at 
positions 3, 5 and 8(Neumann 
and Hobom 1995; Flick and 
Hobom 1999). 
Dr Dan Brookes, Imperial 
College, London. 
pcDNA eGFP Enhanced Green fluorescent 
Protein under the expression of 
a CMV promoter. 
Barclay Influenza Laboratory, 
Imperial College, London. 
pcDNA 3A Mammalian expression vector 
with a CMV promoter to drive 
protein expression. 
Dr E Fodor, Sir William Dunn 
School of Pathology, Oxford. 
pPOLI PB2 A/England/195/09 Human RNA Pol I promoter and 
ribozyme terminator sequence 
flanking vRNA sense sequence 
for Segment 1 from 
A/England/195/09 
L C S Hartgroves, Barclay 
Influenza Laboratory, Imperial 
College London. 
pPOLI PB1  A/England/195/09 Human RNA Pol I promoter and 
ribozyme terminator sequence 
flanking vRNA sense sequence 
for Segment 2 from 
A/England/195/09 
L C S Hartgroves, Barclay 
Influenza Laboratory, Imperial 
College London. 
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pPOLI PA A/England/195/09 Human RNA Pol I promoter and 
ribozyme terminator sequence 
flanking vRNA sense sequence 
for Segment 3 from 
A/England/195/09 
L C S Hartgroves, Barclay 
Influenza Laboratory, Imperial 
College London. 
pPOLI NP A/England/195/09 Human RNA Pol I promoter and 
ribozyme terminator sequence 
flanking vRNA sense sequence 
for Segment 5 from 
A/England/195/09 
L C S Hartgroves, Barclay 
Influenza Laboratory, Imperial 
College London. 
pPOLI NS A/England/195/09 Human RNA Pol I promoter and 
ribozyme terminator sequence 
flanking vRNA sense sequence 
for Segment 8 from 
A/England/195/09 
L C S Hartgroves, Barclay 
Influenza Laboratory, Imperial 
College London. 
pCAGGS V5 Mammalian expression vector 
with a chicken β actin/Rabbit β  
globin hybrid promoter, 
modified to contain the coding 
sequence for the V5 epitope 
tag, inframe with a Mlu I 
enzyme restriction site.  
Dr Anna Hayman, Reading 
University. 
pCAGGS Newmarket 5/03 V5 pCAGGS V5 plasmid including 
cDNA for A/Newmarket/50/03 
NS1 modified to remove the 
splice acceptor site, for 
mammalian expression. 
Ms Sarah Linton, Reading 
University. 
pCAGGS Sussex/89 V5 pCAGGS V5 plasmid including 
cDNA for A/Sussex/89 NS1 
modified to remove the splice 
acceptor site for mammalian 
expression. 
Ms Sarah Linton, Reading 
University. 
pCAGGS Teal V5 pCAGGS V5 plasmid including 
cDNA for A/Teal/317/97 NS1 
modified to remove the splice 
acceptor site for mammalian 
expression. 
Dr Anna Hayman, Reading 
University. 
pCAGGS Duck/Ukraine V5 pCAGGS V5 plasmid including 
cDNA for A/Duck/Ukraine/63 
NS1 modified to remove the 
splice acceptor site for 
mammalian expression. 
Dr Anna Hayman, Reading 
University. 
pCAGGS PR8 V5 pCAGGS V5 plasmid including 
cDNA for A/PR/8/34 NS1 
modified to remove the splice 
acceptor site for mammalian 
expression. 
Dr Anna Hayman, Reading 
University. 
pCAGGS Victoria V5 pCAGGS V5 plasmid including 
cDNA for A/Victoria/3/75 NS1 
modified to remove the splice 
acceptor site for mammalian 
Dr Anna Hayman, Reading 
University. 
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expression. 
pCAGGS Sydney V5 pCAGGS V5 plasmid including 
cDNA for A/Sydney/97 NS1 
modified to remove the splice 
acceptor site for mammalian 
expression. 
Dr Anna Hayman, Reading 
University. 
pCAGGS Dobson V5 pCAGGS V5 plasmid including 
cDNA for A/Dobson/27 4H NS1 
modified to remove the splice 
acceptor site for mammalian 
expression. 
Dr Anna Hayman, Reading 
University. 
pCAGGS 5092 V5 pCAGGS V5 plasmid including 
cDNA for A/Turkey/50/92 NS1 
modified to remove the splice 
acceptor site for mammalian 
expression. 
Dr Anna Hayman, Reading 
University. 
PR8 REV pCAGGS Plasmid with the open 
reading frame of A/PR/8/34 in 
the reverse configuration for 
use as a control plasmid. 
Prof. Steve Goodbourn, St 
Georges, University of London. 
A list of primers is included in the appendix. 
 
Protein Assay Methods 
 
Western Blotting of Cell Lysates 
To prepare samples for western blot adherent cells were lysed as described for the Luciferase assay. 
To these samples, an equal volume of 2X SDS sample buffer (with 20μl 1M 1,4-Dithioerythritol per 
1ml buffer) was added. The samples were denatured by heating at 100°C for 10 minutes, and then 
5-12µl were loaded to a 0.75mm thick 15% SDS PAGE for evaluation. The gel apparatus was run at 
180V, using the 1X Tris-Glycine running buffer described.  
 
The separated proteins were transferred to Hybond C Nitrocellulose membrane (GE Lifesciences) 
using a Bio-Rad Semi Dry Blotting Apparatus (Bio-Rad) at 15V for 60-80 minutes. The resulting 
membranes were evaluated for successful transfer using Ponceau-S-Red stain (Sigma), then blocked 
for 10 minutes at 4°C using 10ml blocking solution as described earlier. Blocking and antibody 
incubations were done at 4°C in a 50ml Centrifuge tube (Greiner) on a blood roller.  
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The αPK(V5) antibody (ABD Serotec) was used as the primary antibody for the detection of transient 
expression of tagged proteins at 1:1000 in blocking solution, as was the loading control primary 
antibody, raised against proliferating cell nuclear antigen (PCNA, polyclonal rabbit - Santa Cruz). The 
membranes were exposed to the antibody dilution for an hour. These were then washed 3 times 
with PBS supplemented with 0.1% Tween (V/V). Secondary antibodies Goat αmouse and sheep 
αrabbit (containing a horse radish peroxidase conjugate), were diluted 1:1000 and these were 
incubated for a further hour. Membranes were washed 3 times with PBS-Tween solution with 10-20 
minutes incubation between the washing steps to enhance the clarity of the signal.  
 
Enhanced E.C.L. detection reagent (GE Lifesciences) was used according to the manufacturer’s 
instructions and the result was visualised using ECL-Hyperfilm (GE Lifesciences) developed in a Fuji 
developer provided by the Section of Virology, Imperial College. 
Preparation for a Luciferase Assay: 
Cells were gently washed in PBS to avoid detaching. The PBS was then removed using an aspirator. 
500µl freshly made up 1X Cell Culture Lysis reagent (Promega) was used for A549-luc cells, however 
293T cells efficiently lysed using 1X Reporter lysis buffer (Promega). In both cases the cell samples 
were frozen at -20°C and thawed at room temperature to assist the lysis process and the supernatant 
was clarified by centrifugation. To assay for translational enhancement an aliquot of the supernatant 
was diluted 1:10 or 1:100 in PBS. 10µl diluted lysate was then evaluated using the Promega luciferase 
reporter kit (according to the manufacturer’s instructions) and a Turner Instruments TD20/20 set to 
count light units for 5 seconds, or the Berthold Instruments Autolumat, recording 10 seconds of 
luciferase activity again after injection.  For the other luciferase reporter based assays the luciferase 
activity 10µl of undiluted lysate was evaluated using one of these two methods. The values 
generated for this work were entered into a computer using Excel (Office 2007, Microsoft). 
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β-galactosidase Reaction 
OPNG (2-Nitrophenyl b-D-galactopyranoside – Sigma) was dissolved in dH2O at a concentration of 
4mg/ml. LacZ buffer was made up as described. Per sample, 20µl lysate, 80µl LacZ buffer and 20µl of 
OPNG stock were prepared and added to wells on a 96 well plate. The plate was then covered  to 
reduce evaporation and incubated at either room temperature or 37°C until the contents of the wells 
had gone lemon yellow. The wells were then evaluated for their absorbance at 420nm in an Athos 
plate reader and the values entered into Excel (Office 2007, Microsoft). To process an interferon 
luciferase experiment, the raw luciferase value was divided by the raw β-galactosidase reading to 
generate the normalised data. 
Immunohistochemical Staining of Virus Plaques  
To visualise viral plaques the Avicel or agar overlay was removed from the plaque assay and the cell 
monolayer was fixed with 1:1 Methanol:Acetone for 5-10 minutes at room temperature. The fixing 
solution was then removed and the cells were washed 3 times with PBS. A primary mouse α-M 
antibody (ABD Serotec) was diluted 1:300 in PBS with 3% BSA (W/V – Sigma) and 200µl of this was 
added per well of a 12 well plate. The plates were incubated at room temperature on a bench top 
shaker for 1 hour. The primary antibody was then removed from the wells and these were washed 
twice with fresh PBS. 200µl of a 1:400 dilution of secondary Goat-αMouse antibody (with a β-
galactosidase conjugate) in the PBS/BSA solution was then incubated with the wells for a further 
hour. 
 
The secondary antibody solution was then removed and the plates washed with PBS an additional 
twice more. The staining solution contained 0.25ml 2% X-gal (W/V), 1ml 10x CN Buffer (as 
described), and 9.75ml PBS. Equal volumes were added to each well and these were incubated 
overnight at 37°C. Plaques were then counted to calculate viral titres, the resultant blue rings 
indicated the presence of a viral plaque.  
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Table of Antibodies Used in this Work 
Antibody Antigen Source 
Goat α Rabbit HRP Goat antibody against Rabbit 
antigen conjugated to 
Horseradish peroxidase 
ABD Serotec 
Goat α Mouse HRP Goat antibody against mouse 
antigen conjugated to 
Horseradish peroxidase 
ABD Serotec 
Goat α Mouse βGalactosidase Goat antibody against mouse 
antigen conjugated to 
βGalactosidase. 
ABD Serotec 
Donkey α Goat Donkey antibody against Goat 
antigen conjugated to 
horseradish peroxidise. 
ABD Serotec 
Goat αMouse Texas Red Goat antibody against mouse 
antigen conjugated to a texas 
red flourophore for immune 
fluorescence. 
ABD Serotec 
Mouse αMatrix Influenza A Matrix Protein ABD Serotec 
Mouse αV5 Mouse monoclonal antibody 
directed against the V5/PK-tag. 
ABD Serotec 
Rabbit αNS1 Rabbit polyclonal raised against 
the NS1 effector Domain of 
A/PR/8/34 NS1 
Gift from Prof Rick Randall, 
University of St Andrews. 
Goat αVinculin Goat antibody raised against 
Human Vinculin. 
Santa Cruz 
Rabbit αPKR K17  Rabbit antiboday raised against 
Protein Kinase R 
Santa Cruz 
Mouse α PCNA Mouse antibody raised against 




Preparations for Indirect Immuno-fluorescence  
Cover-slips of Vero cells prepared as mentioned later were washed once with PBS. This was replaced 
with fresh dilution of 3.7% microscopy grade Para formaldehyde diluted from a 16% (W/V) master 
stock (Microscopy Services LTD). 0.5ml of this solution was per well and the samples were incubated 
in an enclosed container for 25 minutes at room temperature to fix the cells. 
 
The cells were permeabilised for 10 minutes at room temperature using 0.5% (V/V) Triton N100 
(Sigma) diluted in PBS and subsequently washed for 20 minutes with PBS. A blocking solution 
containing 1% (W/V in PBS- Sigma) Bovine Serum Albumin, and 0.5% Gelatine (W/V in PBS- Sigma) 
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was prepared. 0.5ml of this was added per well and incubated for 10 minutes. The plates were 
subjected to gentle rocking on a Vibrax orbital shaker of no more than 10 RPM. 
 
A 1:1000 dilution of αPK(V5) tag mouse monoclonal antibody was prepared (ABD Serotec) 300µl was 
added per well and the samples were incubated for an hour. The cover slips were given 2 10 minute 
washes in blocking solution.  A 1:1000 secondary αmouse antibody with Texas Red conjugate (Oxford 
Biotechnology) was prepared and 300µl added per well. The samples were incubated for an hour 
enclosed in tinfoil to protect them from light.  
 
Coverslips were given 2 10 minute washes in blocking solution with rocking as described earlier, then 
washed twice in PBS. These were removed from the wells carefully using watchmakers forceps and 
dipped once in dH2O before being inverted and mounted in 25µl Molviol (prepared as described) 
with DAPI (4',6-diamidino-2-phenylindole - Sigma) on thickness 1 slides (VWR). 
 
The slides samples were stored at 4°C until analysis on either a Zeiss Axioplan 2 confocal microscope 
using a Plan Achromat 63x oil immersion lens or a Carl Zeiss Axiovert 40 CFL fluorescence 
microscope. Images were processed using Axiovision release 4.7 (Carl Zeiss GmbH).   




Cells were cultivated in Dulbecco’s Modified Eagles Media, supplemented with 10% foetal calf serum 
(Biosera) and 5ml (5000IU/ml) Pen-Strep (Invitrogen) per 500ml media. Cells were grown at 37°C, in 
a 5% CO2 atmosphere, and were split into new flasks when 90-100% confluent. These were routinely 
split for maintenance at a 1:10 ratio twice weekly using 0.05% trypsin/0.001M EDTA in sterile PBS. 
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Cells were evaluated for the presence of contamination such as mycoplasma by seeding cells to 
coverslips and mounting the cells in Molviol with DAPI (4',6-diamidino-2-phenylindole – Sigma) to 
stain for the DNA of invading micro organisms. Infected cell lines were treated with Plasmocin 
(Invivogen) as per the manufacturer’s instructions.  
 
To prepare long term frozen stocks of cells, a 75cm2 flask of cells was trypsinised and re-suspended in 
3.5ml of normal cell media which was supplemented with tissue culture grade DMSO (10% V/V - 
Sigma). Cells were then placed in a “Mr Frosty” (Nalgene) filled with room temperature Isopropanol 
(VWR) and placed at -80°C overnight. Cells were removed for long term storage in liquid nitrogen 
promptly. To reverse this process, vials of cells were thawed in the incubator at 37°C, and transferred 
to warmed media in a 25cm2 flask. Media was changed 24 hours later and typically cells were split 
1:2 for the first passage after becoming confluent. The expected growth properties of these cells 
were confirmed prior to use in experiments. 
  




Cell Line Name Animal Source Antibiotic Selection Notes 
Vero Cells African Green Monkey Kidney 
Cells 
No selection Acquired for the lab from 
NIBSC 
A549 Human Alveolar lung carcinoma 
cell line. 
No selection From ATCC collection 
A549-Luc Human Alveolar Lung carcinoma 
cell line stably transformed with 




Modified from ATCC 
collection according to 
the processes by Hayman 
et al 
293T Human Embryonic Kidney cell 
line 
No selection From Peter Palese, 
originally from ATCC 
MDCK Madin-Derby Canine Kidney Cells  From ATCC collection 
MDCK-NPro Madin-Derby Canine Kidney Cells 
stabily transformed by Steve 
goodbourn to express NPro from 
BVDV, which removes IRF-3 and 
abrogates the IFN response 
(Hilton, Moganeradj et al. 2006; 
Seago, Hilton et al. 2007). 
 Derivative of a cell line 
from ATCC – kind gift of 
Steve Goodbourn, St 
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Further Details on Cell Lines 
A549 and A549-Luc are both derivative cell lines of a human lung epithelial carcinoma cell line. The 
A549-luc cells are a variant of the A549 cell line which had been transformed to stably express the 
luciferase reporter protein, with expression of this reporter controlled by stimulation of the human β 
interferon promoter.  To maintain the presence of the reporter in this cell line geneticin sulphate 
(Invitrogen) selection at a concentration of 0.5mg/ml was used in the media. 
 
Vero cells or African green monkey kidney cells were used for immuno-fluorescence due to their flat 
morphology. This lends itself well to confocal microscopy with a greater amount of the cell likely to 
be presented in a focal plane, and the cells adhering to coverslips strongly enough to remain 
attached throughout the preparation for microscopy. These cells are reportedly transfectable, and 
when assessed by microscopy this is reported by the manufacturer (Invitrogen) to be up to 80% of 
the cells in a field.  The transfection conditions for this work typically achieved approximately 10% of 
the cells in a given field. 
 
293T cells, or human embryonic kidney cells were used for transient transfection and protein 
expression owing to their ease of transfection. Transfection efficiencies with Lipofectamine 2000 of 
90-100% have been reported of this cell line by the manufacturer Invitrogen, this cell line is poorly 
suited to microscopy due to their poor adherence properties.  
 
MDCK or Madin Derby Canine Kidney cells were used primary for infection studies as these cells are 
resistant to the trypsin used for the cultivation of influenza viruses, and highly permissive to 
influenza virus infection. In the Barclay Laboratory, MDCK cells are the most efficient way to generate 
high titres stocks of virus for research available in the Barclay Laboratory without the use of 
embryonated chicken eggs. 
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MDCK NPro cells are a cell line which has been used in conditions where the subsequent activation 
of the interferon system by the infecting virus would be deleterious to the production of a high titre 
virus stock. Viruses which may be predicted to induce high levels of interferon were cultivated in 
these cells to achieve maximum virus yield (Seago, Hilton et al. 2007). These cells were periodically 
assayed by western blot for the absence of IRF-3 confirming the maintenance of the NPro protein 
activity (data not shown). 
 
Transfection of cell lines 
293T cells were released from 75cm2 tissue culture flasks (Greiner) using the trypsin stock described, 
and the cells were separated from the supernatant by centrifugation at 700 rpm for 5 minutes in a 
desk top refrigerated centrifuge (Eppendorf). The supernatant was discarded, and the cell pellet re-
suspended in DMEM (Invitrogen) supplemented with 10% FCS (Biosera) but lacking antibiotics. 1 
confluent 75cm2 tissue culture flask of cells was used to transfect into 2 6 well plates (Greiner). 8µl 
Lipofectamine 2000 (Invitrogen) was incubated with 80µl Optimem (Invitrogen) for 5 minutes at 
room temperature in each well of the plate to be transfected. 50µl of Optimem was used to transfer 
a premix of 1µg pCAGGS NS1, 0.25µg pCAGGS Luciferase and 2.75 µg pcDNA 3A plasmid, (typically 
diluted to 10µl final volume in sterile water) to this incubated premix. The DNA/Lipofectamine 
2000/Optimem mix was further incubated for 20 minutes, before 1ml of re-suspended cell mix was 
added. The mix was well distributed, and incubated for 48 hours at 37°C before processing for 
protein assays. 
 
Vero cells were transfected as above, but with much lower amounts of DNA: 250ng NS1 plasmid and 
250ng expression plasmid for enhanced-GFP (pcDNA-eGFP). 2µl Lipofectamine 2000 was pre 
incubated with 20µl Optimem for 5 minutes in wells of a 12 well plate (Greiner). As described for 
293T cells, the DNA mixes were transferred using 50µl Optimem to the Lipofectamine 
2000/Optimem mixtures in each well. These were incubated for 20 minutes while 16mm, thickness 1 
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coverslips (VWR) were ethanol sterilised, and placed in the wells of another 12 well plate (Greiner). 
Vero cells cultivated to a confluency of approximately 90% coverage were released from 75cm2 tissue 
culture flasks using trypsin and processed as described for 293T cells. 750µl cell suspension was then 
added to the Lipofectamine/DNA/Optimem mix, and used to transfer the contents of the tube to the 
coverslips at the bottom of the prepared wells. The samples were incubated for 24 hours before 





The influenza viruses used or generated for this work were propagated under Biosafety level 2 
conditions. To grow virus, TPCK trypsin (Worthington) stocks at 1mg/ml in sterile water were diluted 
1:1000 in serum free DMEM supplemented with 1:1000 dilution of penicillin/streptomycin (5000 
IU/ml stock - Invitrogen). Viral stocks to be cultured were diluted 1:10000 and 1ml was added to a 
T25 flask of MDCK cells at 90% confluency. Alternatively, 250µl of the supernatant from a plaque 
picking procedure (as described later) was mixed with 750µl DMEM to generate the 1ml inoculum. 
Virus dilution and cells were incubated for an hour at room temperature, then removed and replaced 
with 5ml viral growth media. This was returned to the incubator and left until cytopathic effect was 
observed up to 4 days later. 
 
The supernatant containing the virus was clarified of cell debris by centrifugation at 2500 rpm for 10 
minutes at 4°C and 0.5ml aliquots of the virus were then stored at -80°C until the virus titre could be 
determined by serial titration on MDCK cells. 
 
Plaque Assay 
2 different conditions were used for plaque assay of influenza virus stocks and each method was 
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specific for the purpose of the titration experiment. If the titration was for the characterisation of 
plaque phenotype, the virus was titrated under a semi solid overlay of 3% Avicel (Matrosovich, 
Matrosovich et al. 2006) with staining using either crystal violet or immunohistochemical techniques 
to visualise plaques. The second method, using 0.8% agar to generate a solid covering was used to 
isolate plaques for plaque purification of reverse genetics viruses, a technique described later. Both 
methods require the use of 35µl of 1mg/ml trypsin (Worthington) per tube of overlay mix to allow 
efficient viral propagation.  
 
Plaque purification 
Virus Diluent was made up as described. A pipette was used to remove the agar plug above the 
visible plaque, and this was placed in 300µl virus diluent for 4 hours. The solution used to inoculate 
flasks of MDCK cells or was frozen at -80°C for future work. 
 
Inoculation of wells for virus titration 
To quantify the amount of virus in a stock by titration, 15µl of virus stock was added to 135µl PBS in a 
sterile v bottomed 96 well plate (Greiner). This was mixed by pipetting up and down, and then 15µl 
was carried over from this well to the well in the next row generating a series of 1:10 dilutions down 
to an appropriate range. A confluent 12 well plate of MDCK cells was washed with PBS. 100µl of virus 
inoculum was then added to the cells. On each plate 1 well was left as an uninfected control, to 
ensure that any loss of cells was entirely due to virus activity and not a failure of a component of the 
overlay mix, an excess of trypsin or bacterial contamination. The virus inoculum was left for an hour 
at room temperature with regular manipulation to distribute the inoculum and avoid the cells drying 
out. Then the inoculum was removed and replaced with 1ml of overlay mix, prepared as described. 
 
Virus infections were left for 2-3 days or until visible plaques develop in the cells under the Oxoid 
overlay. Plaque formation under Avicel requires incubators that are not disturbed to prevent the 
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dispersal of virus from the foci of infection obscuring titration results and so these were processed 
on the 3rd day unless experience with the virus suggested otherwise.  
 
Virus Reverse Genetics Procedure 
Virus reverse genetics experiments were conducted using the co-culture method described in 
Hayman et al. Briefly, 293T cells were transfected on Day 1 in a 12 well plate with 8 pPOLI plasmids 
corresponding to the viral genome, and 4 CMV plasmids encoding the protein for the polymerase 
and nucleoprotein of influenza strain A/Victoria/3/75. 24 hours post transfection the cells were 
removed from the 12 well plates and added to T25 flasks of confluent MDCK cells and allowed 5 
hours to adhere. The attached cells were washed with PBS and the replacement media was serum 
free DMEM with trypsin. Viruses were recovered from this rescue procedure up to 5 days later and 
the NS segments of mutated influenza viruses were sequenced to confirm the presence of only the 
intended mutations in the virus stocks.  Viruses recovered using the reverse genetics method were 
plaque picked as described earlier before characterisation. 
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Chapter 2: The Effect of Exogenous NS1 
on Co-Expressed Reporter Genes 
 
2.1 Introduction 
It was shown some eight years ago that the expression of the NS1 protein from the laboratory strain 
of influenza A virus A/PR/8/34 resulted in enhancement of the expression of a plasmid-driven gene 
in mammalian cells (Salvatore, Basler et al. 2002). Protein levels evaluated either by western blot or 
functional enzyme assay such as that for luciferase were increased in the presence of NS1, with no 
detectable alteration in the mRNA levels coding for the reporter gene. The lack of detectable 
differences in mRNA levels suggested that the NS1 protein mediated a more efficient translation 
from the mRNA inside the transfected cells, rather than affecting transcription. It was proposed that 
the increase in the levels of reporter gene was a consequence of the NS1 protein’s antagonism of 
basally expressed PKR present in the mammalian cells that might be activated during the process of 
transfection, reiterating an observation made over ten years prior to the Salvatore et al. study 
investigating the effects of Adenovirus components (Akusjarvi, Svensson et al. 1987).  
PKR is an antiviral mediator which is constitutively expressed in mammalian cells. Though, as an 
interferon-regulated gene, its levels are also increased after virus infection. PKR is activated after 
binding to dsRNA, active PKR dimerises and autophosphorylates, but this kinase also phosphorylates 
the translation factor eIF2α, which in its phosphorylated state sequesters the guanine nucleotide 
exchange factor (GEF). The GEF is recruited to exchange depleted GDP for GTP on the eIF2 complex. 
The stable complex formed between the eIF2, GDP and GEF is unable to form a new pre-initiation 
complex, and this arrests protein translation. The process of transfection may inadvertently activate 
PKR by the transcription of dsRNAs from plasmid. Indeed other PKR antagonists, such as the VAI RNA 
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of adenovirus which has been shown to block the activation of PKR, have even been marketed as 
agents to increase gene expression in transfected cells as part of the Promega pAdVantage system 
(http://www.promega.com/tbs/tb207/tb207.html retrieved 17/10/10).  
The mechanism by which NS1 affects PKR activity could be either direct via a protein:protein 
interaction with the PKR protein itself, or via one of its many regulators such as PACT (Li, Min et al. 
2006; Li, Peters et al. 2006), or indirectly for example by sequestration of dsRNA which would 
prevent the activation of PKR (Cheng, Wong et al. 2009), or a combination of these. 
Expressed NS1 proteins had been previously shown to block the activation of PKR (Lu, Wambach et 
al. 1995). In addition, the NS1 protein is known to contain a novel RNA binding site (Chien, Tejero et 
al. 1997) that maps to two basic residues, positions R38 and K41 in the N terminal 73 amino acids of 
the protein. Salvatore et al. showed in their 2002 study that this RNA binding property was crucial 
for the NS1 translational enhancement activity, because alanine substitution of these key amino 
acids at R38 and K41 abrogated the ability of the A/PR/8/34 NS1 protein to enhance the expression 
of the reporter gene. It was hypothesised that dsRNA, one of the activating stimuli for PKR, was 
produced during polymerase II transcription from transfected plasmids and that NS1 protein 
sequestered it and reduced PKR activation. It is likely that high levels of NS1 expression would be 
required for this since it was shown previously that the dsRNA binding affinity of NS1 is much less 
than that of PKR (Chien, Xu et al. 2004). A direct interaction between NS1 and PKR to prevent PKR 
activation was not excluded by this work however, and the biological significance of the influenza A 
virus NS1protein’s ability to antagonise PKR has not been completely established.  
The NS1 protein varies considerably in sequence, and this work was aimed at investigating a panel of 
naturally-occurring and artificially-mutated NS1 proteins for their ability to enhance reporter gene 
expression when expressed transiently in mammalian cells. It was hoped that this genetic analysis 
may ‘rank’ NS1 proteins, and allow an assessment of the biotechnological utility of the NS1 protein 
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for enhancing gene expression, as well as revealing more about the mechanism by which this effect 
is achieved.  
2.2 Naturally occurring NS1 proteins can Enhance or inhibit gene 
expression 
The method used to investigate the translational enhancement effects of NS1 is shown in Figure 4A 
and is modified from the method used by Salvatore et al. (2002). The work was conducted using a 
luciferase reporter gene and co-expressing NS1 proteins to which the V5 epitope tag from Simian 
Virus 5 had been engineered on the carboxyl terminus. This allowed a western blot to be run on cell 
lysates to evaluate the expression levels of both the NS1 protein and the luciferase protein in 
addition to a standard firefly luciferase assay as an indicator of reporter gene levels. The amount of 
luciferase expression in the presence of each NS1 protein was then compared to the levels of 
expression when plasmid PR8-REV was co-expressed. This is a control plasmid containing the 
A/PR/8/34 NS1 open reading frame in the reverse orientation, and thus produces no NS1 protein. In 
some experiments an additional control was included that was a plasmid with just a V5 coding 
sequence. 
A panel of NS1 proteins derived from viruses isolated from a variety of species was assembled that 
represented a ‘snapshot’ of the sequence diversity across NS1 proteins. These are listed in Table 1, 
where the reported animal hosts from which the parental virus was isolated are also listed. These 
include human, equine and avian hosts, and the original isolates cover a variety of HA and NA 
subtypes. The NS1 proteins evaluated varied in length between 219 and 237 amino acids. Of the NS 
segments represented here, the NS from A/Turkey/England/50/92 is the only example of a Clade B 
viral NS (Treanor, Snyder et al. 1989). Most had been cloned into the PCAGGS-SV5 expression vector 
by Dr Anna Hayman or Ms Sarah Linton at the start of this project (Hayman, Comely et al. 2007). 
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Cloning involved the removal of the splice acceptor site and the fusion of the ORF with the SV5 
epitope tag; an overview of the cloning process is detailed in Figure 5. 
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Figure 4 Details on the Experimental Set up for an Investigation into NS1 Mediated Translational 
Enhancement 
A - Details of the experimental procedure to investigate the effect on luciferase gene expression 
by NS1 
293T cells were transfected using the suspension method using Lipofectamine 2000 (Invitrogen) with 
1µg of a plasmid coding for NS1-V5 or the control plasmid, 0.25µg of the luciferase reporter plasmid 
and 2.75µg of empty pcDNA 3 plasmid. The cells were then plated out and incubated for 48 hours. 
Subsequently the cells were washed once with phosphate buffered saline and then lysed using 
freshly diluted 1X Cell Culture Lysis Reagent (Promega), and one round of freeze thawing. These 
lysates were briefly clarified by centrifugation in a bench top microfuge and the supernatant was 
assayed for luciferase activity. 
Reading of the samples took place either in a Turner instruments TD20/20, or a Berthold Autolumat, 
and the data was then expressed relative to the control transfection. 
B - Table of the Source of the Panel of NS1 proteins Evaluated 
As shown in this table, the NS1 proteins which have been shortlisted for the initial stages of this 
work vary in length from 219 to 237 amino acids in length. These were also from a variety of viral HN 
subtypes and reflect the diversity found in NS1 proteins across Influenza A viruses.  
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NS1 Source  HN Subtype Virus Host  
Number of amino acids in 
Length
A/Teal/317/97 H6N1 Avian - Teal 230
A/Duck/Ukraine/63 H3N8 Avian - Duck 230
A/PR/8/34 H1N1 Lab Adapted 230
A/Newmarket/5/03 H3N8 Equine 219
A/Sussex/89 H3N8 Equine 230
A/Sydney/97 H3N2 Human 230
A/Victoria/3/75 H3N2 Human 237
A/Chicken/Dobson/27 (4H) H7N7 Avian - Chicken 230
A/Turkey/England/50/92 H5N1 Avian - Turkey 230
Details of the Experimental Procedure to Investigate the 
Effect on Luciferase Gene Expression by NS1.
Table of the Source of the Panel of NS1 Proteins Evaluated
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Figure 5 Coding strategy for the influenza A NS1 and NEP  
The NS segment encodes both NS1 and NEP, with the NEP being spliced out of a transcript produced 
to express NS1, in a +1 reading frame, the translation then reads through the NS1 stop codon to 
produce the 121 amino acid NEP protein. To prevent the production of an NEP fragment, and ensure 
the full length NS1 protein is produced splice site must be removed. A further modification of the 
NS1 sequence was made to engineer in a functional epitope tag into the final construct. This 
required the removal of the NS1 stop codon. The coding strategy employed in the NS segment is 
summarised in part A, with the numbers used taken from Hatada et al 1990. 
Procedure for the Cloning NS1 cDNA into the mammalian expression vector pCAGGS  
I. To make the NS1 construct therefore, 2 rounds of PCR are conducted beginning with a 
cloned pPOLI NS template. The first PCR, produces 2 overlapping fragments, with the 3’ end 
of one fragment, and the 5’ end of the second corresponding to the splice acceptor site at 
approximately 500 nucleotides into the sequence, and nucleotide substitutions built into the 
primers destroy the acceptor site (which has the consensus sequence CAGG), but maintain 
the primary amino acid sequence.  
II. The PCR products from this are then purified and a repeat polymerase chain reaction with 
the previously used flanking primers NS1 Not I For and NS1 Mlu I Rev is conducted, with the 
5’ primer containing a Not I restriction site and the 3’ end primer containing the mutation to 
remove the stop codon and introduce a Mlu I restriction site. Subsequent treatment of the 
PCR product with these two DNA restriction enzymes, and ligation into a similarly treated 
vector finalises the construct for this work.  
III. A modified version of the pCAGGS plasmid had previously been constructed by Dr Anna 
Hayman to contain the V5 epitope tag (GKPIPNPLLGLDST), 3’ and in frame to a Mlu I site 
(coding for the amino acids TR), to produce a cDNA construct that encodes an NS1 with this 
tag at the carboxy terminal end, and this was used for subsequent plasmid constructions. 















NS1 Stop (Mlu I)
NS1 Splice For
NS1 Splice Rev
NS1 For (Not I)
NS1 For (Not I)




NS1 ORF V5 Tag
Coding Strategy for the Influenza A NS1 and NEP
CAGG
Splice Acceptor
93 | P a g e  
 
 The effects of the co-expression of each of this panel of NS1 proteins on luciferase gene expression 
are shown in Figure 6A which is representative of three independent experiments. The data has 
been presented as a percentage of the luciferase activity produced in the absence of NS1 (in 
presence of plasmid PR8 Rev). The effects caused by the NS1 proteins divide into three phenotypes: 
the NS1 proteins from A/Teal/317/97, A/Duck/Ukraine/63 and A/PR/8/34 viruses resulted in an 
enhancement of luciferase expression; the two NS1 proteins derived from equine influenza viruses, 
A/Newmarket/5/03 and A/Sussex/89 had little effect on luciferase expression; the remaining NS1 
proteins, which derived from both human and avian viruses resulted in less luciferase expression 
than in the absence of NS1, and profoundly inhibited both luciferase expression and their own 
accumulation (see table in 4B). There was no correlation between the nature of the original host of 
the virus encoding the respective NS1, and the outcome in this transient assay; for example, 
A/Teal/317/97 and A/Turkey/50/92 enhance and inhibit respectively, despite both being from an 
avian host. 
None of the reporter gene expression levels measured in our hands achieved the twenty-fold 
enhancement effects described by Salvatore et al. The epitope tag utilised in these experiments on 
both the NS1 and the luciferase, but not the earlier work conducted by Salvatore et al, could account 
for the apparently lower level of enhancement measured. The pattern of the data presented here 
resembles that reported by Kochs et al. (2003), who also noted that NS1 expression could either 
enhance or inhibit expression of a co-transfected reporter gene. In their study Kochs et al. used an 
HA epitope tag, on the N terminus of the NS1 protein of A/PR/8/34, and the level of enhancement as 
a consequence of NS1 protein expression was similar to that reported here. Single amino acid 
changes between the various NS1 genes of different A/PR/8/34 strains in these studies could also be 
responsible for the inability to achieve the previously reported enhancement levels, or a difference 
in the basal levels of PKR expression in cultured cells in different laboratories. Finally, variation in the 
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tendency of different expression plasmids to trigger the dsRNA that activates PKR may account for 
quantitative differences in data from different laboratories. 
In Figure 6B the expression of the luciferase reporter gene and of each of the NS1 proteins has been 
compared using western blotting. The V5 epitope on the expressed NS1 proteins allows a 
comparison of the protein expression levels as the antibody target remains constant, something 
which might not be the case for polyclonal αNS1 sera which may favour the detection of the NS1 
proteins more closely related to protein that was used in its production. These results confirm using 
a different technique that the NS1 proteins differentially affect expression of the luciferase protein, 
which was also V5 tagged; thus the western blot data clearly correlate with data from the luciferase 
enzyme assay.  
A host gene PCNA (Proliferating Cell Nuclear Antigen), which is a housekeeping gene of 
approximately 37kDa in size, was used as a loading control and there was no discernable effect of 
NS1 on expression of this gene. In setting up this assay, an alternative host protein Vinculin 
(117kDa), a cell structural protein, was detected with a similar result (data not shown) suggesting 
the translational effects of NS1 modulate the co-expressed reporter gene, but not of either of the 
two constitutive host genes evaluated. The resistance to enhancement could be as a result of low 
levels of turnover of the two proteins chosen as loading controls, or, as these are housekeeping 
genes, that they are under a greater degree of host-specified regulation than the transiently 
transfected genes investigated. 
A further observation from the western blot analysis in Figure 6B was the apparent effects on 
translation of NS1 protein by the NS1 proteins themselves. For the majority of NS1 proteins, it 
appeared that the level of NS1 expression correlated with the effect of NS1 protein on the reporter 
gene. This is unsurprising since both the NS1 and luciferase expression was achieved transiently from 
a polymerase II-driven plasmid. Interestingly, the effect of the NS1 proteins from A/Sussex/89 and 
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A/Newmarket/5/03 equine influenza viruses did not match this trend. Despite inhibiting the 
luciferase expression somewhat, these NS1 proteins accumulated to a surprisingly high level within 
the cell as evaluated by western blotting. This could result from either variation in the NS1 protein 
stability, or the NS1 protein specifically enhancing translation from its own coding mRNA in this 
artificial system. However, as these constructs lack the influenza non-coding regions, it is difficult to 
envisage how these NS1 proteins would be able to specifically up-regulate their own translation. 
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Figure 6 Effect of NS1 Proteins on Translation in 293T Cells 
A Effect on Luciferase Activity From Co-Expression with a Range of NS1 Proteins in 293T Cells 
The panel of NS1 proteins previously listed in the Table 1B were assayed for their effects on 
expression. 1µg of NS1 plasmid, or control plasmid, was transfected alongside 0.25µg luciferase 
reporter plasmid and 2.75µg of pcDNA 3 plasmid as described in Figure 4. After 48 hours the 
transfected cells were carefully washed in phosphate buffered saline, and then lysed in 500µl freshly 
diluted cell Culture Lysis Reagent (Promega). Clarified cell lysates were diluted 1 in 100 in phosphate-
buffered saline and the luciferase activity of 10µl of this dilution was then determined. The data 
generated was then expressed relative to the control transfection PR8-REV as a percentage. 
B Western Blot Analysis of NS1 and Luciferase Proteins Co-Expressed in 293T Cells 
An aliquot of the samples evaluated for luciferase activity was mixed 1:1 with 2 x protein loading 
buffer as detailed in the materials and methods. 5µl was loaded on a 15% SDS PAGE and the gel run 
to ensure an adequate separation of the proteins. The proteins in the SDS PAGE were then 
transferred to hybond C nitrocellulose using the semi dry technique, and probed with mouse 
monoclonal anti-sera raised against the V5 epitope which is present on both the luciferase and NS1 
proteins (ABD Serotec), or mouse monoclonal anti-sera against the proliferating cell nuclear antigen 
as a loading control and example of a host gene. The secondary antibody was a goat anti-mouse with 
a horseradish peroxidase-conjugate (ABD Serotec). The data generated supports the trends in the 
previous figure that the NS1 proteins A/Teal/317/97, A/Duck/Ukraine/63 and A/PR/8/34 are able to 
enhance translation. The NS1 proteins from A/Sydney/97, A/Victoria/3/75, A/Chicken/Dobson/27 
and A/Turkey/England/50/92 inhibit translation of the reporter gene to some degree, and this also 
affects their own expression levels. The remaining NS1 proteins appear to have a negligible effect on 
the luciferase reporter gene, but appear to either enhance their own translation, or have increased 
stability in this over-expression system. 
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A
B Western Blot Analysis of NS1 and Luciferase Proteins Co-Expressed in293T Cells
Effect on Luciferase Activity from Co Expression 
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2.3 Localisation of NS1 proteins 
PKR was proposed to be the interaction target for the A/PR/8/34 NS1 protein which enhanced 
reporter gene expression. PKR has been reported to have a cytoplasmic distribution, with the 
exception of a small amount present in the nucleolus (Garcia, Meurs et al. 2007). The cytoplasmic 
distribution of PKR allows it to respond to dsRNA, or be activated by cofactors including PACT, and to 
access its target the translation factor eIF2a, which is also a cytoplasmic protein. Previous work has 
shown that both during viral infection (Melen, Kinnunen et al. 2007) and when expressed after 
transient transfection (Kochs, Garcia-Sastre et al. 2007) the NS1 protein had a nuclear distribution. 
This was attributed to the action of the importinα on the consensus importinα nuclear localisation 
signal in the N Terminus comprising of amino acids 35-41 (Melen, Kinnunen et al. 2007). However as 
the majority of the cellular PKR is in the cytoplasm, it seemed mechanistically difficult to understand 
how the expressed NS1 proteins which cause enhancement were able to efficiently inactivate PKR if 
they were themselves located in the nucleus.  
To investigate the cellular localisation of NS1 under conditions at which reporter gene enhancement 
could occur, the panel of V5 tagged NS1 proteins were expressed in Vero (African Green Monkey 
kidney) cells and prepared for analysis using indirect immunofluorescence to determine intracellular 
distribution of the NS1 proteins.  
Representative images of the localisation of NS1 proteins are shown in Figure 7. Surprisingly, the 
distribution of the NS1 proteins in Vero cells differed from that reported by others in the literature 
(Greenspan, Palese et al. 1988; Fortes, Beloso et al. 1994; Li, Yamakita et al. 1998; Talon, Horvath et 
al. 2000) but interestingly correlated with the effects on translation established in Figure 6. NS1 
proteins that were shown to enhance reporter gene expression were localised in both the nucleus 
and cytoplasm whereas those that did not enhance, but rather inhibited, reporter gene expression 
were solely in the nucleus.  
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The NS1 protein from A/Newmarket/5/03, despite being grouped with the inhibitors based upon the 
effect on the luciferase gene, exhibited a distribution more characteristic of the enhancing NS1 
proteins (Figure 7 panel C). 
To further investigate the effects of NS1 on translation using confocal analysis, eGFP was co-
expressed with the NS1 proteins in Vero cells. The effect on translation within cells co-transfected 
with plasmids for expression of GFP and NS1 was analysed qualitatively. This was particularly useful 
for NS1 proteins that showed a dual distribution, such as those seen to enhance. Approximately 60% 
of the cells which were transfected show co-expression of the two proteins. The results from this 
assay matched the pattern seen for luciferase. Two examples are shown in Figure 8 in which GFP 
expression in the presence of the enhancer NS1 from the A/Duck/Ukraine/63 located in both 
cytoplasm and nucleus, and the inhibitory NS1 protein from A/Sydney/97 located exclusively in the 
nucleus, are compared. 
While it was possible to discern a difference in eGFP levels between cells expressing A/Sydney/97 
NS1 and the control transfected cells, it was not possible to conclusively demonstrate an enhancing 
effect of A/Duck/Ukraine/63 NS1 by fluorescence microscopy and it is likely that basic microscopic 
analysis is not sensitive enough to detect these differences. 
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Figure 7 Indirect immunofluorescence showing localisation of transient transfected NS1 proteins in 
Vero cells 
Vero cells seeded on coverslips were transfected with 250ng of pCAGGS NS1(V5) and fixed after 24 
hours. The cells were evaluated for NS1 distribution using anti-sera to the V5 epitope and a 
secondary antibody with a Texas Red conjugate and evaluated using fluorescent confocal microscopy 
on Zeiss Axioplan 2 using a Plan Achromat 63X oil immersion lens. Subsequent images were 
manipulated using Axiovision release 4.7 (Carl Zeiss GmbH). An estimated 10% of the cells showed 
successful transfection. In the left-hand box, the Vero cells expressing A/PR/8/34 and 
A/Victoria/3/75 were used as examples of NS1 proteins which enhance or inhibit respectively and 
their localisation is shown alongside their corresponding phase, demonstrating the cellular 
distribution. The A/PR/8/34 NS1 protein appears to be both nuclear and cytoplasmic, in contrast to 
the A/Victoria/3/75 which is very strongly nuclear in localisation in this cell line. 
In the right hand box, the panel lettered A-C shows example images from the two NS1 proteins 
which are able to enhance, A/Teal/317/97 (A) and A/Duck/Ukraine/63 (B), and the NS1 protein 
which seems unable to enhance or inhibit, A/Newmarket/5/03 (C), visualised using the Texas Red 
conjugate. The NS1 proteins from this panel appeared to be distributed in both the nucleus and 
cytoplasm in a manner resembling A/PR/8/34. 
The final panel in the right-hand box lettered D-G includes the NS1 proteins A/Sussex/89 (D), 
A/Sydney/97 (E), A/Turkey/50/92 (F) and A/Chicken/Dobson/27 (G). The localisation of these NS1 
proteins appeared to resemble that of A/Victoria/3/75 and was strongly nuclear in distribution.  
The control transfection PR8-Rev shown in the left-hand box shows little background signal from 
unspecific antibody binding. 
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Figure 8 Assessing effects on translation enhancement using eGFP 
An additional method for qualitatively investigating the effects on reporter gene expression was to 
co-express the green fluorescent protein alongside an NS1 protein of interest. 250ng of pCAGGS NS1 
(v5) was transfected into Vero Cells growing on cover slips with 250ng pcDNA eGFP, and the cells 
were analysed by fluorescent confocal microscopy. Approximately 10% of the cells were transfected 
in any given field, and up to 60% of these cells successfully co-transfected. 
Of the samples co-transfected, clear images were obtained from A/Duck/Ukraine/63 and 
A/Sydney/97, and these samples were qualitatively analysed for effects on expression in comparison 
to the control transfection with PR8-REV. An evaluation by eye supports an inhibition of the 
expression of eGFP by the A/Sydney/97. Though the comparison of PR8-REV and A/Duck/Ukraine/63 
also supports the enhancement effects measured using the luciferase reporter gene work, the 
expression levels varied amongst the transfected cell population and therefore it is impossible 
conclusively distinguish a difference by eye.  
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Figure 9 Effects of NS1 Expression on GFP 
A Western blot analysis of the effect on eGFP from co-expression with NS1 proteins in 293T cells  
1µg of pCAGGS NS1 (V5) or the control sample pCAGGS V5, and 0.5µg of pcDNA eGFP was 
transfected using Lipofectamine 2000 (Invitrogen) into 293T cells and incubated for 24 hours. Cell 
lysate was prepared using freshly diluted 1X cell culture lysis reagent and the samples were prepared 
for SDS Page as described earlier. 5µl was loaded on the gel, and transferred to nitrocellulose. Anti-
sera against Vinculin, eGFP and the V5 epitope tag were used to establish qualitative expression 
levels of these three proteins. The effects on expression appear to approximately correlate with the 
effects seen on the luciferase reporter gene.  
In both cases there was no discernable effect on the host gene Vinculin. Western blot displayed is 
representative of two experiments.  
B Summary of the Effects of Three NS1 Proteins on Co-Expressed Genes  
The Effects of co-expression of either eGFP or Luciferase is summarised for the three NS1 proteins, 
A/PR/8/34 which enhances translation of both of the genes investigated, and A/Sydney/97 and 
A/Victoria/3/75 which inhibit reporter gene expression. 

















































Western Blot Analysis of the Effect on eGFP from Co 
Expression with NS1 Proteins in 293T cells
A
B Summary of the Effects of 3 NS1 Proteins 
on Co-Expressed Genes
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2.4 Mapping the NS1 domain responsible for enhancement or 
inhibition of reporter gene expression 
The NS1 protein has been previously described as containing two functional domains (Hale, Randall 
et al. 2008). To investigate which domain of the NS1 protein determined the effects on reporter 
gene expression, a panel of chimeras were produced between NS1 genes of A/PR/8/34, 
A/Victoria/3/75 and A/Sydney/97. These parental NS1 proteins were chosen because they showed 
distinct phenotypes and differed in NLS (see section below). Figure 9A illustrates the effect of each 
of these NS1 proteins on eGFP protein expression in transfected 293T cells using western blotting. As 
shown previously and summarised in Figure 9B, A/PR/8/34 NS1 enhanced both the production of 
itself and eGFP, whereas A/Victoria/3/75 and A/Sydney/97 NS1 proteins both inhibited the 
production of the reporter gene, with A/Victoria/3/75 NS1 being more inhibitory than that of 
A/Sydney/97 NS1.  
To construct NS1 chimeras we took advantage of a conserved Nco I site in the DNA coding sequence, 
which corresponds to amino acid 78 of all three NS1 proteins. Sub-cloning produced resulting 
constructs which were in frame. A schematic of this cloning procedure is detailed in Figure 10. 
2.5 Localisation of NS1 Chimeras and Effect on the Luciferase Reporter Gene 
The data presented in Figure 7 showed that the wild type NS1 proteins from A/PR/8/34, 
A/Victoria/3/75 and A/Sydney/97 varied in their localisation in Vero cells; A/PR/8/34 localised to the 
nucleus and cytoplasm; while A/Victoria/3/75 and A/Sydney/97 localised strongly to the nucleus.  
Most NS1 proteins have two nuclear localisation signals (Greenspan, Palese et al. 1988), one in the N 
terminus overlapping with the RNA binding site, 34DRLRR38 which is absolutely conserved in all the 
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NS1 proteins investigated and one in the C terminus 216PKQKRK221. The A/PR/8/34 NS1 cloned in this 
study is disrupted in the second NLS by a K221E substitution resulting in 216PKQKRE221. 
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Figure 10 Schematic explaining the construction of the chimeric NS1 proteins from the parental 
A/PR/8/34, A/Victoria/3/75 and A/Sydney/97  
As examples of NS1 proteins which enhance or inhibit the expression of reporter genes, A/PR/8/34, 
A/Victoria/3/75 and A/Sydney/97 were used to map the location of the NS1 protein sequences 
responsible for these effects. The NS1 protein is divided into the RNA Binding Domain and the 
Effector Domain as shown. The RNA binding domain extends to amino acid 73, within the cDNA at 
amino acid 78 there is a conserved restriction site for Nco I site. The original cloning primers for the 
NS1 proteins were used to conduct a round of PCR to generate a full length NS1 protein cDNA, 
followed by enzymatic digestion with the Not I and Mlu I restriction enzymes prepares the NS1 for 
re-ligation into a fresh V5 pCAGGS vector. Digestion of the PCR product with all three enzymes yields 
two major DNA fragments, which can be purified from a TAE 2% agarose gel separately. The purified 
samples can be included in a ligation in various combinations to generate the chimeric constructs 
shown in the lower part of the diagram. 
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The consensus C terminal NLS is present in the A/Sydney/97 NS1. A/Victoria/3/75 NS1 protein has a 
C terminal extension of seven amino acids which may form a strong bipartite NLS, and has been 
shown to target a proportion of the NS1 protein to the nucleolus where it performs an unknown 
function (Melen, Kinnunen et al. 2007) though nucleolar accumulation of A/Victoria/3/75 NS1 was 
not observed in Vero cells in our hands (Figure 7).  
The NS1 protein is also reported to have a nuclear export signal located in the region of 134-147, 
which is regulated by adjacent sequences encompassing the region 134-161 (Li, Yamakita et al. 
1998). An examination of the NS1 sequences aligned in Figure 14 suggests no obvious segregating 
differences between the NS1 proteins at amino acids in the NES regulating region 134-137. Of the 
NS1 proteins A/Teal/317/97, A/Duck/Ukraine/63 and A/PR/8/34, which localise to the cytoplasm, 
there was no obvious variation in the nuclear export signal itself which would account for the 
difference in localisation of these viral NS1 proteins. However, in the region 148-161, there are 
glutamic acid to aspartic acid substitutions in amino acids 152 or 153 present in A/Teal/317/97 and 
A/Duck/Ukraine/63 respectively. The replacement of amino acids located at 148, 152 or 153 for 
alanines in the A/WSN/33 virus was previously shown to block inhibition of the NES of the NS1 
protein, and the NS1 protein was entirely localised to the cytoplasm (Li, Yamakita et al. 1998). There 
were no mutations relating to the regulation of the NES which could account for the predominant 
cytoplasmic localisation of the A/PR/8/34 NS1 protein. A/Victoria/3/75 and A/Sydney/97 NS1 
proteins are both derived from human H3N2 viruses. However their isolation twenty years apart 
means significant genetic divergence, including a series of point mutations and the loss of the C 
terminal extension from the Sydney/97 NS1 protein. These two proteins both inhibit reporter gene 
expression but differ in the nature of their C terminal NLS.  
To investigate the localisation of chimeras between these three different NS1 proteins, the NS1 
proteins were expressed in Vero cells and analysed by indirect immunofluorescence and confocal 
microscopy as described previously. The results of this are shown in Figure 11. To facilitate 
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comparison, data shown in Figure 7 describing localisation of the wild type NS1 proteins is repeated 
here as the left-hand panels of Figure 11. 
Chimeric NS1 proteins in which the C terminus from an ‘inhibitory’ NS1 protein was combined with 
the N terminus of A/PR/8/34 accumulated in the nucleus, and conversely, combining N terminus of 
an inhibitory NS1 protein with the C terminus of A/PR/8/34 NS1 resulted in accumulation of NS1 in 
the cytoplasm. From this experiment it is clear that the localisation of the NS1 protein is dependent 
on a feature residing within the C terminus.  
The effect of these chimeric NS1 proteins on expression of a co-transfected luciferase reporter gene 
was then evaluated as before using the luciferase reporter assay and the data is shown in Figure 
12A. NS1 proteins with the A/PR/8/34 C terminal effector domain enhanced production of the 
luciferase reporter gene. Chimeric NS1 proteins with the C terminal domain from A/Victoria/3/75 
and A/Sydney/97 NS1s, even when combined with A/PR/8/34 RNA binding domains were unable to 
enhance, and instead resulted in lower levels of luciferase activity than in absence of NS1 co-
expression.  
Levels of expression were also evaluated using western blotting as shown in Figure 12B, and the 
trend of these data confirmed that measured using the luciferase assay in Figure 12A. 
The conclusion from these data is that the C terminal portion of the NS1 protein determines the 
phenotype that it will exhibit. The N Terminal domains of the NS1 proteins are functionally 
equivalent in these assays. As established previously, the enhancement effect seems to require a 
cytoplasmic localisation. 
  




Figure 11 Indirect immunofluorescence showing localisation of wild type and chimeric NS1 
proteins in transiently transfected Vero cells 
Vero cells growing on cover slips were transfected with 250ng of pCAGGS NS1 (V5) and fixed after 24 
hours to investigate the localisation of wild type and chimeric NS1 constructs. Approximately 10% of 
the cells were transfected. The cells were evaluated for NS1 distribution using anti-sera to the V5 
epitope and a secondary antibody with a Texas Red conjugate and evaluated using fluorescent 
confocal microscopy. In the left-hand box, the Vero cells expressing wild type A/PR/8/34, 
A/Sydney/97 and A/Victoria/3/75 were used as examples of NS1 proteins which enhance 
(A/PR/8/34) or inhibit (A/Sydney/97 and A/Victoria/3/75) are shown from figure 7, along with a 
phase view to demonstrate the cellular distribution.  
The chimeric constructs A and B, contain the A/PR/8/34 effector domain, and the RNA binding 
domain of A/Sydney/97, and A/Victoria/3/75 respectively. These have a localisation reminiscent of 
A/PR/8/34. 
The chimeric constructs C and D are formed from the A/PR/8/34 or A/Victoria/3/75 RNA binding 
Domains, paired with the A/Sydney/97 effector domain respectively, and exhibit a localisation 
reminiscent of either A/Sydney/97 or A/Victoria/3/75. 
The final chimeric constructs evaluated E and F are formed from either the RNA binding domain of 
A/PR/8/34 or A/Sydney/97, paired with the C terminal effector domain of the A/Victoria/3/75 and 
demonstrate a localisation characteristic of an inhibiting NS1 protein. 
The previously presented PR8-Rev control image was omitted from this figure for clarity. 
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Figure 12 Characterisation of the effect on Protein Expression by the Chimeric NS1 Proteins 
A - Luciferase activity in 293T cells after co-expression with chimeric NS1 proteins 
The Chimeric NS1 proteins, alongside their WT counterparts, were assayed for their effects on 
luciferase expression. 1µg of NS1 plasmid or control plasmid was transfected alongside 0.25µg of 
luciferase reporter plasmid and 2.75µg of pcDNA 3 plasmid as described previously. After 48 hours 
the transfected cells were washed in phosphate buffered saline, and then lysed in 500µl freshly 
diluted 1X cell culture lysis reagent (Promega). Clarified cell lysates were diluted 1 in 100 in 
phosphate buffered saline and the luciferase activity of 10µl of this dilution was then determined. 
The raw data was then expressed relative to the control transfection PR8-REV as a percentage. In 
this experiment, the source of the C terminal effector domain was the determinant of the outcome 
for luciferase expression, as A/PR/8/34 NS1 protein C terminal effector domains were enhancing, 
when expressed in combination with N terminal RNA binding domains from inhibitory NS1 proteins. 
Conversely, the N terminal RNA binding domain of A/PR/8/34 when attached to either of the 
inhibitory NS1 proteins did not confer or override the inhibitory effects of these NS1 proteins. The 
data presented is representative of three experiments.  
 
B - Western blot analysis of luciferase and chimeric NS1 proteins co-expressed in 293T cells 
An aliquot of the samples evaluated for luciferase activity was mixed 1:1 with 2 x Laemmli loading 
buffer as described previously. 5µl was loaded on a 15% SDS PAGE and the gel run to ensure an 
adequate separation of the proteins. The proteins in the SDS PAGE were then transferred to hybond 
C nitrocellulose using the semi-dry technique, and probed with mouse monoclonal anti-sera raised 
against the V5 epitope which is present on both the luciferase and NS1 proteins (ABD Serotec). The 
blots were developed using the enhanced ECL system (GE Healthcare) and images captured on ECL 
hyperfilm (GE Healthcare). After the effect of the chimeric NS1 proteins on luciferase expression had 
been determined, the blot was washed and reprobed for vinculin using goat anti-vinculin (Santa 
Cruz) and then HRP conjugated donkey anti-goat.  
As corresponding to the luciferase data, the effects on the reporter gene expression are 
recapitulated in the western blot data. Furthermore as seen previously, the effects of the NS1 
protein-on-protein expression do not affect the host gene investigated in this experiment. Western 
blot presented is representative of three experiments.  
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2.6 Sequence Analysis of Enhancers and inhibitors 
One of the most extensively characterised interactions that NS1 undergoes via its C terminal effector 
domain is binding to the F2F3 region of CPSF30 host protein. The work of the Krug group established 
a region between amino acids 140-190 in A/Udorn/72 as being crucial for this interaction (Twu, 
Noah et al. 2006). Kochs et al. (2007) suggested that amino acids 103 and 106, outside of this region, 
were also important in determining the ability of the NS1 protein to inhibit the expression of a 
reporter gene, and recently showed that these residues affected the NS1/CPSF interaction (Steidle, 
Martinez-Sobrido et al. 2010).  
We sought to understand whether the lack of a CPSF consensus binding site could explain the 
difference in cell localisation and different effects on reporter gene expression we had observed 
between NS1 proteins. Structural analysis of the CPSF:NS1 interaction using bacterially-expressed 
protein fragments demonstrated a dimer of NS1 effector domains binding a dimer of expressed F2F3 
fragments. The resolution of this structure was sufficient to allow annotation of further contact 
residues outside of the initial range identified and suggested a role for amino acids 103 and 106 in 
stabilising the tetrameric complex without necessitating their localisation within the F2F3/NS1 
binding pocket (Das, Ma et al. 2008).  
The panel of NS1 proteins investigated so far were evaluated using ClustalW, to establish the 
identity of amino acids within the predicted CPSF binding face, and the degree of variation across 
the NS1 proteins. The data is presented in Figure 13.  
As shown by this alignment, the NS1 proteins have a smaller degree of variation at the N terminus 
than the C Terminus. The NS1 proteins all have the conserved NLS overlapping with the RNA binding 
site at amino acids 35-41. Therefore it should be expected that all the NS1 proteins would be 
transported to the nucleus. There is a degree of variation in the C terminal nuclear localisation signal 
(NLS) with A/PR/8/34 and A/Turkey/50/92 NS1s having mutations (E or Y instead of K at the final 
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amino acid, residue 221). A/Newmarket/5/03 NS1 lacks the functional NLS at this point because the 
protein ends before the penultimate amino acid of this protein signal. 
The amino acids identified by the crystal structure as forming the CPSF binding pocket are 
highlighted in purple and include 103, 106, 110, 117, 119, 121, 180, 183, 184 and 187. The table 
shown in Figure 14A also includes the amino acids at these positions for A/Texas/91 investigated by 
Kochs et al. (2007). The implied effect on CPSF binding based on the luciferase reporter gene read 
out is included in this table. 
The A/Victoria/3/75 NS1 protein shows 100% sequence identity to the CPSF binding pocket of 
A/Udorn/72 NS1 modelled in the crystal structure. A/Texas/91 differs at 117 and 119, but was still 
able to bind the F2F3 fragment of CPSF and inhibit gene expression (Kochs, Garcia-Sastre et al. 
2007). 
The remaining NS1 proteins all vary at amino acid 119, which is a methionine not an isoleucine as in 
the canonical CPSF binding structure typified by Victoria/3/75 NS1. However this change clearly does 
not abrogate functional CPSF binding as implied by inhibition of luciferase gene expression in our 
studies.  
Surprisingly, the NS1 protein of A/Duck/Ukraine/63 shares homology in the CPSF binding pocket 
sequence with most of the CPSF binding NS1 proteins, but clearly does not block reporter gene 
expression, and conversely A/Turkey/England/50/92 NS1 has three points of variance but is still able 
to block the luciferase gene expression. These discrepancies might be explained by additional amino 
acid residues in the protein which may disrupt the structure or accessibility of the CPSF binding 
pocket. 
However comparison of the NS1 proteins of A/PR/8/34 and A/Sydney/97 as enhancer versus 
inhibitor, the only difference in the CPSF binding residues was at amino acids 103 and 106. 
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Figure 13 Sequence alignment of panel of NS1 proteins  
The amino acid sequence for the panel of NS1 proteins were processed into FASTA format, and 
processed using the web interface at www.ebi.ac.uk/clustalw to generate a multiple sequence 
alignment. Various features known from the literature were then annotated on this sequence to aid 
in the analysis accounting for the effects on the localisation and co-expressed proteins. 
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A/Teal/317/97 MDSNTVSSFQVDCFLWHVRKRFADQELGDAPFLDRLRRDQKSLRGRGSTLGLDIRTATRE 60 



































A/Sussex/89 LIGGLKWNDNTVRVSETLQRFAWRSSHENGRPSFPPKQKRKMERTIEPEV------- 230 
A/Turkey/50/92 LVGGLEWNDNSIRASENIQRFAWGIHDENGGPPLPPKQKRYMARRVESEV------- 230
A/Chicken/Dobson/27 LIGGLEWNDNTVRVSETLQRFAWRSSNEDRRPPLPPKQKRKMARTIESEV------- 230










Sequence Alignment of  a Panel of  NS1 Proteins
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Figure 14 The potential relevance of CPSF Binding to Protein Enhancement 
 
A - Summary table detailing the conservation of NS1:CPSF interacting amino acids amongst the 
panel of NS1 proteins 
Kochs et al and Das et al proposed a list of amino acids important in the interaction between the 
host mRNA maturation apparatus factor CPSF and influenza A NS1 proteins. Furthermore, the effects 
on a co-expressed gene have been documented either resulting from this work, or in the case of 
A/Texas/91 that of Kochs et al. With the exception of A/Duck/Ukraine/63, and A/Turkey/50/92, this 
summary supports the hypothesis proposed that the nature of amino acids 103 and 106 is an 
important determinant of the levels of reporter gene expression, which is proposed to be via a CPSF 
interaction. 
B The effect on luciferase activity from co-expression with a NS1 Proteins in 293T cells to 
investigate CPSF binding 
Amino acid substitutions at positions 103 and 106 were engineered into A/PR/8/34 and 
A/Victoria/3/75 to exchange the amino acids between these NS1 proteins. These were then 
transfected to evaluate their effects compared to their wild type counterparts on luciferase 
expression. 1µg of NS1 plasmid or control plasmid, was transfected alongside 0.25µg luciferase 
reporter plasmid and 2.75µg of pcDNA 3 plasmid. As described previously, after 48 hours the 
transfected cells were washed in phosphate buffered saline, and then lysed in 500µl freshly diluted 
1X cell culture lysis reagent (Promega). Clarified cell lysates were diluted 1 in 100 in phosphate 
buffered saline and the luciferase activity of 10µl of this dilution was then determined. The raw data 
was then expressed relative to the control transfection PR8-REV as a percentage, which is 
represented by the red line at 100%.  
The F103 M106 amino acid configuration engineered into A/PR/8/34 lowered luciferase activity in 
comparison to wild type to almost A/Victoria/3/75 like levels, the S103 I106 engineered into 
A/Victoria/3/75 however did not make the NS1 enhance in a manner similar to A/PR/8/34.  
The effects on expression were then applied to implied CPSF binding, it is predicted that A/PR/8/34 
has acquired the ability to bind CPSF through this two amino acid substitution, but the reverse 
exchange in A/Victoria/3/75 was insufficient to completely remove this interaction.  
These data are representative of three experiments. 








A/Teal/317/97 L I K I M Q V G G W -
A/Duck/Ukraine/63 F M K I M Q V G G W -
A/PR/8/34 S I K I M Q V G G W -
A/Newmarket/5/03 F M K I M Q V G G W +/-
A/Sussex/89 F M K I M Q V G G W +/-
A/Sydney/97 F M K I M Q V G G W +
A/Victoria/3/75 F M K I I Q V G G W +
A/Turkey/England/50/92 Y M K V M Q I G G W +
A/Chicken/Dobson/27 (4H) F M K I M Q V G G W +
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2.7 Effect of CPSF binding site mutation on NS1 phenotype 
The data describing behaviour of chimeric NS1 proteins in Figure 12 suggested that the N terminal 
RNA binding domain of an inhibitory NS1 protein has the ability to confer the enhancement when 
paired with the effector domain of NS1 A/PR/8/34. If the inhibition phenotype of wild type proteins 
is conferred by CPSF binding in the nucleus, and masks the enhancement phenotype, mutation to 
disrupt the CPSF binding site should result in that NS1 protein being able to enhance reporter gene 
expression. To test this hypothesis, amino acids at 103 and 106 were altered using site-directed 
mutagenesis, exchanging the F103 M106 of A/Victoria/3/75 with the S103 I106 of A/PR/8/34 and 
vice versa. 
The proteins were then expressed in 293T cells to gauge any effects on the translation of the 
luciferase reporter gene (Figure 14B). 
As previously, A/PR/8/34 NS1 showed a reproducible, but not statistically significant increase in the 
level of luciferase activity (p=0.17). All other NS1 proteins investigated in this assay affected the 
luciferase protein expression to a statistically significant degree.  
The acquisition of the putative CPSF binding amino acids F and M, caused a switch to the reporter 
gene inhibition phenotype in A/ PR/8/34 NS1, with the NS1 protein-mediated effects statistically 
different from the parental NS1 (p=0.008), but the mutated A/PR/8/34 NS1 was not as efficient at 
blocking luciferase expression as wild type A/Victoria/3/75 and there remained a statistically 
significant difference in effect between the two (p=0.01).  
A/Victoria/3/75 NS1 with the A/PR/8/34 amino acids at positions 103 and 106 was dampened in its 
inhibitory phenotype but did not completely gain the same phenotype as A/PR/8/34 NS1 (p=0.02). 
Thus, the level of inhibition exerted by the mutant A/Victoria/3/75 NS1 protein was less than, and 
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statistically significantly different to, that for wild type Victoria NS1 (p=0.008) and did not surpass 
the level shown in the absence of NS1.  
The localisation of the mutant NS1 proteins was investigated to establish if the localisation of the 
NS1 proteins had shifted as a consequence of these amino acid mutations. The NS1 proteins were 
transfected into Vero cells and the localisation was investigated using indirect immunofluorescence 
microscopy. The data is presented in Figure 15, and once again the localisation of wild type NS1 
proteins is reproduced here to facilitate comparison.  
The NS1 protein from A/PR/8/34 which has acquired the amino acids from A/Victoria/3/75 (S103F 
I106M) accumulated in the nucleus in a manner very similar to wild type A/Victoria/3/75 NS1. The 
A/Victoria/3/75 NS1 protein which had been mutated to have diminished CPSF binding capabilities 
(F103S M106I) accumulated in both the nucleus and the cytoplasm, in a marked contrast to the 
previous exclusively nuclear pattern exhibited by A/ Victoria/3/75 NS1, and in a manner reminiscent 
of but not identical to A/PR/8/34. 
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Figure 15 Indirect immunofluorescence showing the effect on localisation of exchanges of amino 
acids at 103 and 106 between A/PR/8/34 and A/Victoria/3/75 in Vero cells 
Vero cells growing on cover slips were transfected with 250ng of pCAGGS NS1 (V5) and fixed after 24 
hours to investigate the localisation of wild type and chimeric NS1 constructs. Approximately 10% of 
the cells were transfected. The cells were evaluated for NS1 distribution using anti-sera to the V5 
epitope and a secondary antibody with a Texas Red conjugate and evaluated using fluorescent 
confocal microscopy. In the left-hand box, the Vero cells expressing wild type A/PR/8/34 and 
A/Victoria/3/75 are shown along with their corresponding phase view. 
The right-hand view demonstrates the effect on localisation of the mutations at amino acids 103 and 
106 on the A/PR/8/34 and A/Victoria/3/75 NS1 proteins. 
Images are representative of two independent experiments. 













































































































































































2.8 Mutation of CPSF Binding Pocket Amino Acid 184  
The CPSF binding pocket of A/Udorn/72 includes a cluster of amino acids at residues 180-188 (Das, 
Ma et al. 2008). A different structural analysis of the effector domain of an avian NS1 protein in 
absence of CPSF (Hale, Barclay et al. 2008) suggested that alterations around residue 180, 
particularly at amino acid 187 had the effect of disrupting NS1 dimerisation. NS1 proteins mutated 
around this locus would form dimers only by the activity of the N Terminal RNA binding domain, not 
by the C terminal effector domain.  
The amino acid 184 is of particular interest, because mutation of this amino acid from G to R has 
recently been reported to ablate CPSF binding much more effectively than 103/106 mutation 
(Steidle, Martinez-Sobrido et al. 2010). 
We reasoned that the A/Victoria/3/75 103 106 mutant NS1 protein might still retain some residual 
CPSF binding which was masking its potential to act as an enhancer of reporter gene expression. To 
investigate whether mutation at residue 184 could convert Victoria NS1 into an enhancer protein, 
site-directed mutagenesis converting a G184 to an R was performed. Mutagenesis of A/PR/8/34 NS1 
was included to control for effects caused by potential loss of dimerisation.  
The effect of the G184R mutation in A/Victoria/3/75 NS1 on the expression of luciferase was 
evaluated in 293T cells alongside the effects of changing residues 103/106 (Figure 16). As seen 
previously, A/PR/8/34 NS1 enhanced translation above that of the empty vector translation. The 
addition of the consensus CPSF binding amino acids at 103 and 106 of A/PR/8/34 NS1 protein 
abrogated enhancement, whereas the G184R mutation in A/PR/8/34 NS1 protein had no effect. 
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For the A/Victoria/3/75 NS1 protein, the G184R mutation caused a complete switch in phenotype 
from the previous strong inhibitor to an NS1 protein which enhanced reporter gene expression to a 
degree almost equivalent to A/PR/8/34. 
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Figure 16 The effect on luciferase activity from co-expression with NS1 proteins with mutations 
which may affect CPSF binding in 293T cells  
NS1 Proteins with Amino acid substitutions at positions 103 and 106 or 184, were assayed to 
evaluate their effects compared to their wild type counterparts on luciferase expression. 1µg of NS1 
plasmid or control plasmid, was transfected using Lipofectamine 2000 alongside 0.25µg luciferase 
reporter plasmid and 2.75µg of pcDNA 3 plasmid. As described previously, the results were obtained 
48 hours post transfection, and plotted relative to the empty vector control.  
As shown the A/PR/8/34 NS1 protein becomes an inhibitor upon acquiring the amino acids from 
A/Victoria/3/75 at amino acids 103/106. Acquisition of the G184R mutation in A/PR/8/34 does not 
remove the ability of this protein to enhance translation.  
Conversely, the mutation at 103/106 in A/Victoria/3/75 fails to entirely remove the inhibitory 
properties of this NS1, the mutation at amino acid 184 does, and this protein now enhances to a 
degree equivalent to A/PR/8/34.  
The expression of the NS1 protein was monitored in this experiment using the V5 epitope and this is 
included in the panel below the chart. 
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Figure 17 Indirect immunofluorescence to evaluate the effect of localisation on NS1 proteins which 
may vary in CPSF binding in Vero cells 
Vero cells growing on microscopy cover slips were transfected using Lipofectamine 2000 (Invitrogen) 
with 250ng of pCAGGS NS1 and fixed after 24 hours to investigate the localisation of wild type and 
chimeric NS1 constructs. Approximately 10% of the cells were transfected. The cells were evaluated 
for NS1 distribution using anti-sera to the V5 epitope and a secondary antibody with a Texas Red 
conjugate and evaluated using standard fluorescent microscopy. In blue are the Vero cell nuclei 
stained with DAPI. 
As seen previously, conferring the A/Victoria/3/75 amino acids at 103 and 106 causes a 
redistribution of the A/PR/8/34 NS1 into the nucleus. The G184 mutation does not seem to have a 
discernable effect. Conversely, although the 103/106 mutation in A/Victoria/3/75 does increase the 
prevalence of the NS1 in the cytoplasm, as seen previously this is not have been sufficient to cause 
the A/PR/8/34 phenotype. The G184R mutation in A/Victoria/3/75 causes greater accumulation in 
the cytoplasm. These images are representative of two independent experiments. 















Indirect Immunofluorescence to Evaluate the Effect on 
Localisation for NS1 Proteins Which may Vary in CPSF Binding 
in Vero cells
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2.9 Effect of Localisation on Translation of a Reporter Gene 
The results implied a general correlation between the localisation of the NS1 proteins and their 
effect on the expression of a reporter gene. It seemed that cytoplasmic NS1 was required for the 
enhancement phenotype. Targeting tags can be used to redirect proteins, allowing the evaluation of 
the consequences of protein re-localisation (Kim and Chen 2000). To further investigate whether an 
otherwise enhancing NS1 protein could still function if redirected to the nucleus independent of 
CPSF binding mutations, an artificial localisation tag was introduced to the N terminus of A/PR/8/34 
NS1 protein. The nuclear localisation tag used was the NLS from the SV40 large T antigen which 
directs strong binding to importinα and thus transport into the nucleus. In addition, to test whether 
Victoria NS1 could act as an enhancer if pulled out from its otherwise nuclear localisation, an 
exogenous nuclear export signal derived from the leucine-rich NES of HIV rev protein was fused to 
the N terminus of the NS1 protein. The Rev NES works by interacting with host CRM-1 (Daelemans, 
Afonina et al. 2002). A schematic of these four constructs is included in Figure 18A.  
The NS1 proteins were transiently expressed in Vero cells to confirm the localisation had been 
affected using indirect immunofluorescence microscopy (Figure 18B). The NS1protein from 
A/PR/8/34 was shown to efficiently relocate from the cytoplasm to the nucleus by the addition of 
the NLS. This tag did not alter the localisation of the A/Victoria/3/75 protein which would normally 
be located in the nucleus. 
Unfortunately, the NS1 proteins tagged with the N terminal Rev NES peptide were undetectable by 
IF analysis, and this absence was corroborated by western blot analysis (data not shown). As this 
construct is in frame, and was made to the same design as the NLS tagged NS1, it seems possible 
that the Rev tag may reduce the stability of the protein making it unsuitable for further work.  
The effect on the ability of the N terminally tagged nuclear NS1 protein to alter luciferase expression 
was then evaluated in 293T cells. A/PR/8/34 NS1 enhanced translation however in this experiment  
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Figure 18 An investigation into the Correlation of Localisation and Effect of NS1  
 
A Schematic representation showing the design of N terminally-tagged NS1 proteins to re-direct 
the localisation of NS1 proteins - The NS1 proteins of A/PR/8/34 and A/Victoria/3/75, as examples 
of NS1 proteins that enhance or inhibit reporter gene expression, were recloned using PCR, to have 
an N terminal tag. This tag was either that derived from the SV40 large T antigen NLS, or HIV Rev 
nuclear export signal.  
B Localisation of wild type and N terminally-tagged NS1 proteins in transiently transfected Vero 
cells  
250ng Plasmid encoding the wild type, or N terminally tagged NS1 protein or a control plasmid were 
transfected into Vero cells seeded on coverslips, using Lipofectamine 2000 (Invitrogen). The cells 
were fixed after 24 hours and prepared for confocal microscopy using the methods described 
previously. 
The samples were visualised and this revealed poor expression of the Nuclear Export Signal in the 
Vero cells. 
The NLS successfully relocated the A/PR/8/34 NS1 protein to the nucleus, the localisation of the NS1 
from A/Victoria/3/75 remained unchanged.  










M L Q L P P L E R L T L  








Localisation of Wild Type and N Terminally Tagged 
NS1 Proteins in Transiently Transfected Vero CellsB
A Schematic Representation of the N 
Terminally Tagged NS1 Proteins
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this was not a statistically significant increase in a paired two-tailed t-test (p=0.35). The addition of 
the NLS tag reduced luciferase expression to the same level as when no NS1 was expressed, making 
the behaviour of the NLS-tagged protein significantly different to that of A/PR/8/34 NS1 (p=0.04) 
and to the empty vector control (p=0.08).  
The addition of the NLS to the N terminus of A/PR/8/34 NS1 compromised the protein’s ability to 
enhance translation. It is difficult to eliminate that this is due to the effect of the presence of the tag, 
rather than re-localisation of the NS1 protein. It is noteworthy that Kochs et al. (2007) still saw an 
enhancement effect using an A/PR/8/34 NS1 protein that bore an N terminal HA tag, which is larger 
than the NLS Tag used here. This suggests that the presence of a tag on the N terminus of NS1 might 
not be deleterious per se to protein function.  
The effect of the A/Victoria/3/75 NS1 on the expression of the luciferase reporter gene, which was 
significantly different to the empty vector control (p= 7.6 x 10-5), are not affected by the addition of 
the NLS tag and there was no statistically significant difference between the two A/Victoria/3/75-
derived proteins (p=0.31). This protein would normally be transported to the nucleus and the NLS 
has not significantly compromised the ability of the NS1 protein to interact with the host mRNA 
maturation apparatus, this tag was unlikely to have produced a change in the NS1 effects on the 
reporter gene.   
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Figure 19 Assay of the NLS Tagged NS1 Proteins to Evaluate Effects on Luciferase Gene Expression 
The NLS tagged NS1 proteins, alongside their WT counterparts were assayed for their effects on 
luciferase expression. 1µg of NS1 plasmid or control plasmid, was transfected along side 0.25µg 
luciferase reporter plasmid and 2.75µg of pcDNA 3 plasmid. As described previously, after 48 hours 
the transfected cells were washed, and then lysed in 500µl freshly 1X cell culture lysis reagent 
(Promega). Clarified cell lysates were diluted 1 in 100 in phosphate buffered saline and the luciferase 
activity of 10µl of this dilution was then determined. The raw data was then expressed relative to 
the empty vector control transfection as a percentage. As shown in this experiment, the effect of 
targeting the NS1 protein to the nucleus is sufficient to lose the translational enhancement effects of 
the A/PR/8/34 NS1 protein.  
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Western Blot Analysis Confirming the Expression of NLS 
Tagged NS1 Proteins and their Effect on a Luciferase 
Reporter Gene in 293T Cells
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2.10 Further Approaches to dissecting the mechanism of 
translational enhancement by NS1 
 
Salvatore et al. established that the NS1 protein of A/PR/8/34 enhanced translation of a reporter 
gene in a variety of mammalian cell lines. As the translational enhancement effect was overcome by 
the expression of the dsRNA-activated protein PKR, the conclusion was that the measured effect was 
as a result of NS1 protein deactivating basally-expressed PKR present in the transfected cells. 
The NS1 protein is known to interact with a number of components of the interferon system, 
including two recently-identified proteins TRIM25 and RIG-I, but these interactions were not 
described at the time of the first work conducted on translational enhancement. 
Furthermore, Salvatore et al had focussed solely on the NS1 protein from the A/PR/8/34 laboratory-
adapted strain of influenza, and did not take into account other NS1 proteins which may differ in the 
way they control interferon and bind to different cellular partners. For example A/Victoria/3/75 NS1 
normally inhibits the host mRNA maturation apparatus to suppress innate host responses, but was 
shown to enhance translation after ablation of this function by mutation at amino acid G184 (Figure 
16). 
In the next section of experiments, the proposed mechanism of translational enhancement will be 
tested to ascertain if direct or indirect interaction with PKR can indeed explain the enhancement 
phenotype. Mutations which confer or remove the enhancement activity can then be used to 
investigate the biological consequences of this activity for the virus. 
2.11 Translational Enhancement is Dependent upon RNA Binding 
 
The binding of NS1 proteins to dsRNA has been ablated by mutations of amino acid R38 to alanine 
(Min and Krug 2006), or mutation at both amino acids R38A and K41A (Wang, Riedel et al. 1999) . 
Salvatore et al established that the R38A K41ARNA binding mutant of A/PR/8/34 was no longer able 
to enhance translation of a luciferase reporter gene. The single mutation R38A however was not 
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evaluated, and this single amino acid change is thought to be the most critical amino acid for RNA 
binding. Indeed, the mutation at position 41 has other functions in the NS1 protein, for example 
importinα binding.  
The loss of RNA binding by R38A however does not abrogate the ability of the single amino acid RNA 
binding mutant to bind PKR itself (Min and Krug 2006). Therefore it was hypothesised that the single 
RNA binding mutant might still show translational enhancement if a protein:protein interaction of 
NS1 with PKR is sufficient to prevent PKR activation.  
The importance of the RNA binding ability of NS1 protein has been confirmed in the context of 
whole viruses. Influenza A viruses with NS1 genes that lack RNA binding were found to be 
attenuated in interferon-competent cell culture systems (Lu, Wambach et al. 1995; Hatada, Saito et 
al. 1999). A virus containing an RNA binding defect in the NS1 protein due to R38A K41A mutation 
was attenuated in mice, but subsequently acquired a mutation at amino acid 42 in the NS1 protein 
which caused a recovery of the viral replication fitness (Donelan, Basler et al. 2003). Amino acid 42 
has been shown to be a factor determining virulence (Jiao, Tian et al. 2008) and in the context of the 
R38 K41 mutant, S41G caused a partial reversion of phenotype which lowered the interferon 
induced upon virus infection and increased the yield of virus, but did not restore RNA binding. 
Although the mechanism for this recovery is poorly understood, it may involve an increase in the 
ability to modulate the host interferon response. Therefore if NS1-mediated translational 
enhancement is a consequence of down regulation of an interferon-induced host response, then the 
S41G mutation may cause a restoration of the enhancement effect in the background of the R38A 
K41A mutant.  
 
To test these hypotheses, mutations were engineered in to the A/PR/8/34 NS1 protein by site-
directed mutagenesis and the effects of expressed NS1 protein on luciferase gene expression were 
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tested as before (Figure 20). The enhancement of reporter gene translation was lost from NS1 
proteins containing mutations that disrupted RNA binding. In this experiment, the 1.2 fold 
enhancement activity of A/PR/8/34 over the empty vector was not statistically significant, (p=0.27), 
but the effect of the RNA binding mutants R38A, and R38 K41A on luciferase expression were 
statistically different to that of the parental wild type A/PR/8/34 (p=0.05 and p=0.09 respectively). In 
fact, these mutant NS1 proteins slightly inhibited luciferase expression, and this was statistically 
significant (p=0.05 and p=0.007 respectively). One explanation for this could be a toxic effect of NS1 
protein in this over-expression system, or even simply competition for limiting host factors required 
for translation. The triple mutant was also tested for an ability to enhance the luciferase reporter 
gene in the enhancement assay and was statistically less able to enhance translation than wild type 
A/PR/8/34 NS1 (p=0.004) but was not different from the empty vector control. (p=0.15). These data 
confirm and extend the earlier observations of Salvatore et al. that the translational enhancement 
by NS1 protein requires an intact RNA binding domain.  
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Figure 20 An Investigation into the Role of RNA Binding 
 
A Localisation of transiently expressed RNA binding deficient NS1 proteins in Vero cells  
Vero cells growing on microscopy cover slips were transfected with 250ng of pCAGGS NS1 (V5) and 
fixed after 48 hours to investigate the localisation of wild type and chimeric NS1 constructs. 
Approximately 10% of the cells were transfected. The cells were evaluated for NS1 distribution using 
anti-sera to the V5 epitope and a secondary antibody with a Texas Red conjugate and evaluated 
using confocal microscopy as described earlier. Little significant nuclear accumulation was visualised 
for the RNA-binding mutants in-keeping with the reported disruption of the N terminal NLS. 
B The effect on luciferase activity from co-expression with NS1 proteins with defective RNA 
binding abilities in 293T cells.  
As stated previously, 1µg pCAGGS NS1 Plasmid, 0.25µg Luciferase plasmid and 2.75µg pcDNA 
plasmid were transfected into 293T cells using Lipofectamine 2000 (Invitrogen). These were then 
incubated for 48 hours before being washed once with phosphate buffered saline and assayed for 
their luciferase content. The resulting data was presented relative to the control empty vector 
transfection and is data representative of three separate evaluations. The enhancement activity of 
the A/PR/8/34 NS1 protein was 1.2 fold over the empty vector and was not statistically significant, 
(p=0.27), but the effect of the RNA binding mutants R38A, and R38 K41A on luciferase expression 
were statistically different to that of the parental wild type A/PR/8/34 (p=0.05 and p=0.09 
respectively). These mutant NS1 proteins slightly inhibited luciferase expression, and this was 
statistically significant (p=0.05 and p=0.007 respectively with respect to the empty vector). One 
explanation for this could be a toxic effect of NS1 protein in this over expression system, or even 
simply competition for limiting host factors required for translation. The triple mutant was also 
tested for an ability to enhance the luciferase reporter gene and was statistically less able to 
enhance translation than wild type A/PR/8/34 NS1(p=0.004) but was not different from the empty 
vector control. (p=0.15). These data earlier observations that the translational enhancement by NS1 
protein requires an intact RNA binding domain (Salvatore, Basler et al. 2002). 
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2.12 Cellular localisation of the RNA binding NS1 proteins 
An NS1 protein may contain two NLSs, an N terminal signal which overlaps with the RNA binding 
amino acids, and a C terminal signal (Greenspan, Palese et al. 1988). Whilst mutation of the RNA 
binding amino acids would therefore disrupt one NLS, given the second NLS remained intact, it was 
unclear what effect this would have on the localisation of the protein. 
PKR is predominantly a cytoplasmic protein. If the RNA binding site mutation caused a redistribution 
of the protein to the nucleus, this compromises the ability of the NS1 to counter PKR activation and 
may account for the loss of enhancement activity. The localisation of NS1 with R38A K41A mutation 
was not investigated by Salvatore et al. Conversely the disruption of the NLS caused by the R38A 
K41A mutation may result in even more cytoplasmic retention of NS1. Indeed this was shown to be 
the case by Krug and co-workers, but interestingly not by Pekosz (Newby, Sabin et al. 2007). 
The panel of RNA-binding mutants of A/PR/8/34 NS1 protein were transiently expressed in Vero cells 
and evaluated using indirect immunofluorescence to assess their localisation alongside that of their 
wild type equivalent NS1 proteins. 
The mutated NS1 proteins localised at least as efficiently to the cytoplasm as wild type A/PR/8/34 
NS1. These observations support a mechanism where NS1 proteins that enhance translation bind 
and sequester the dsRNA produced as a consequence of transfection, as opposed to directly 
interacting with PKR to inhibit its kinase activity. 
2.13 PKR binding site of the NS1 Protein of Influenza A 
The NS1 protein of influenza A/Udorn/72 has been shown to interact directly with PKR (Li, Min et al. 
2006), and as a consequence of abrogating this interaction in virus infection the levels of PKR 
activation are increased (Min, Li et al. 2007). The amino acids of NS1 which modulate this interaction 
are located in the region 123-127 and mutation of pairs of amino acids at this locus removed the 
ability of an expressed PKR to co-purify with NS1 protein. The ability of the NS1 protein of A/PR/8/34 
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to modulate PKR behaviour was hypothesised to be the mechanism of translational enhancement. 
To investigate if a direct PKR binding was a requirement for enhancement, the pairs of amino acids 
123 and 124, and 126 and 127 were mutated to alanines in A/PR/8/34. These mutations should 
ablate interaction of NS1 protein with PKR and abrogate enhancement. The inhibitory NS1 protein 
A/Victoria/3/75 was also altered at these amino acids, as this NS1 protein has a primary sequence 
which shares 97% amino acid homology with the A/Udorn/72 NS1 protein for which this PKR:NS1 
interaction was originally described. 
The NS1 proteins were then tested in the luciferase expression enhancement assay (Figure 21). 
Surprisingly, the 123/124 mutation in A/PR/8/34 did not remove the ability of the NS1 protein to 
enhance translation of the luciferase reporter gene. The ability to enhance was however lost from 
the A/PR/8/34 mutant 126/127 (Figure 21A), although the effect was much less apparent when 
luciferase and NS1 proteins expression were analysed by western blot (Figure 21B).  
The same mutations which were engineered into the A/Victoria/3/75 NS1 protein did not prevent 
the ability of these NS1 proteins to inhibit gene expression, indicating that CPSF interaction is likely 
unaffected by these mutations. Since host gene inhibition is a dominant effect of inhibitory NS1 
proteins, it was not possible to assess whether the mutations at 123/124 or 167/127 had affected 
the ability of Victoria/3/75 NS1 to enhance translation. 
Therefore, a further mutation to disrupt CPSF binding, G184R, was included in addition to mutation 
at the PKR binding sites. All of the mutants of Victoria NS1 protein containing the G184R mutation 
continued to enhance translation regardless of their PKR binding sites (Figure 21A). 
Interestingly, by western blot analysis the levels of expression of both the 123/124 and 126/127 
A/Victoria/3/75 NS1 protein were elevated compared with wild type Victoria/3/75 NS1. This was 
particularly apparent for the 123/124 construct. The Victoria NS1 proteins mutated at amino acid184 
were expressed strongly and additionally enhanced translation of the luciferase reporter gene. 
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The localisation of these PKR mutants was investigated in Vero cells. No significant differences were 
found between the A/PR/8/34 constructs (Figure 22 Panels A-C). The A/Victoria/3/75 constructs 
which did not have the G184R mutation showed no differences in localisation compared to wild type 
(D-E) and as seen previously the G184R mutation in the A/Victoria/3/75 background increased the 
proportion of cytoplasmic NS1 observed. This effect was independent of the additional PKR binding 
site mutations (panels G and H).  
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Figure 21 An Investigation into the Importance of PKR to Translational Enhancement 
 
A - The effect on luciferase activity from co-expression with NS1 proteins predicted to vary in their 
PKR interaction abilities in 293T cells 
A panel of NS1 proteins which had been altered in the region of the protein reportedly important for 
PKR interaction were evaluated for their ability to enhance the translation of the luciferase reporter 
gene as described previously.  
Briefly, a pCAGGS NS1 expression plasmid 1µg, 0.25µg of Luciferase expression plasmid and 2.75µg 
pcDNA 3A plasmid were transfected into 293T cells in suspension. These cells were then incubated 
for 48 hours, before being washed and lysed for assay of their luciferase content.  
Data was then expressed relative to the empty plasmid control transfection to determine the degree 
of translational enhancement. The data shown is representative of three separate assays. 
The PKR binding mutation at amino acids 123/124 of A/PR/8/34 does not compromise the ability of 
the NS1 protein to enhance translation of luciferase. By altering an amino acid to that of an amino 
acid which does not allow NS1:CPSF binding to occur, the A/Victoria/3/75 NS1 protein enhances 
translation as shown previously. This mutation, in combination with the PKR mutations, did not 
ablate the ability of the A/Victoria/3/75 NS1 protein to enhance translation.  
B Western Blot Analysis Confirming the Expression of NS1 Proteins and their Effect on a Luciferase 
Reporter Gene in 293T Cells 
10µl of clarified lysates left over from the luciferase evaluation was mixed 1:1 with 2X Laemali 
sample buffer (with 20µl 1M Dtt added per 1ml). The samples were boiled before 5µl was loaded on 
a 15% SDS PAGE and resolved. The gel contents were transferred to nitrocellulose before being 
evaluated using anti-sera for V5 and PCNA as described previously.  
The general trend of the NS1 data is in agreement with the luciferase data, although from these 
loadings it is difficult to discern a difference in the level of luciferase expression established upon 
assay of the A/PR/8/34 126/127 mutant.  
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Figure 22 Localisation of putative PKR binding mutants of NS1 transiently expressed in Vero cells  
To establish if the NS1 proteins were occupying aberrant cellular compartments which could account 
for the lack of enhancement abilities of the A/PR/8/34 126/127 mutant, the PKR mutants were 
evaluated alongside the wild type A/PR/8/34 and A/Victoria/3/75 proteins in a transient transfection 
in Vero cells. As described previously, 250ng of NS1 expressing plasmid was transfected into Vero 
cells seeded on coverslips using Lipofectamine 2000. The samples were incubated for 24 hours 
before being fixed, and permeabilised as described in the materials and methods.  
The subsequent samples were probed with Anti V5 sera, (AbD Serotec) and visualised using an Anti-
Mouse Texas Red Conjugate. DAPI was added to counter-stain nuclei and images were captured 
using Carl Zeiss Axiovert 40 CFL fluorescence microscope and manipulated using Carl Zeiss Axiovision 
4.7. 
In the left-hand panel the localisation of the wild type A/PR/8/34 was captured alongside that of 
A/Victoria/3/75 and the control transfection for the empty vector.  
Panel A shows a field of cells expressing the A/PR/8/34 123/124 mutant NS1 protein, B shows the 
126/127 mutant and C shows the G184R mutation. These do not markedly differ from the 
distribution of the A/PR/8/34 wild type. 
Panels D-F shows the same mutants in the A/Victoria/3/75 background. D and E do not differ in their 
distribution; however F begins to show the elevated levels of protein expression and cytoplasmic 
localisation observed previously for the CPSF binding deficient NS1 proteins. This distribution is 
shared by the two combination mutants with amino acid substitutions at 123/124/184 and 
126/127/184. 
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2.14 Nuclear Localisation and the Antagonism of PKR by Influenza B 
NS1 proteins 
The NS1 protein from influenza B has similarities to the NS1 protein of influenza A. The protein is 
divided up into an N terminal RNA binding domain, and a C terminal effector domain as for the 
influenza A virus protein (Krug, Yuan et al. 2003). In addition, the influenza B NS1 protein blocks 
interferon signalling (Dauber, Heins et al. 2004), however the mechanism for this does not involve 
CPSF binding and inhibition (Yin, Khan et al. 2007). Both the N and C termini of the BNS1 protein 
were able to block interferon signalling (Donelan, Dauber et al. 2004), which suggests an interesting 
duplication of mechanisms, perhaps required to counter the potent activation of PKR induced by the 
influenza B RNP complex (Dauber, Martinez-Sobrido et al. 2009). 
In characterising the modes of action of the influenza B NS1 protein, the amino acids necessary for 
the binding of dsRNA, and for inhibition of PKR activation were established. Mutation of arginine 
residues at amino acids 33 and 38 were shown to minimally alter the ability of the protein to bind 
dsRNA and preserved the NLS of the protein. But when these were engineered into a virus, the 
resulting virus was unable to prevent the activation of PKR (Dauber, Schneider et al. 2006). 
Conversely mutation of amino acids at the three positions 52-54, compromised dsRNA binding to a 
similar degree as the previous 33/38 mutations but also blocked the efficient nuclear targeting of 
the protein by its NLS, without abrogating the ability of the virus to counter PKR activation (Dauber, 
Schneider et al. 2006). Therefore in influenza B NS1 protein, unlike for influenza A NS1, the amino 
acids which determine efficient nuclear import, dsRNA binding/PKR activation were found to be in 
adjacent, but not identical, loci on the protein. This allows the abrogation of nuclear import with the 
maintenance of RNA binding, or the loss of efficient nuclear import, without the loss of RNA binding. 
Work conducted by a MSc student Jason Long to complement this work was conducted using the 
pCAGGS expression system to express B/Beijing/87 NS1 protein sub-cloned from a complete 
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Influenza B reverse genetics system available in our laboratory (Jackson, Cadman et al. 2002). Two 
mutants of this protein were engineered to evaluate the effect of modulating the RNA binding  
abilities by mutation at amino acids 33 and 38, or the PKR activation by mutating the nuclear 
localisation site at amino acids 52, 53 and 54. 
The resulting NS1 proteins were then tested for their ability to enhance translation (Figure 23). The 
data was expressed relative to the level of luciferase expression in the presence of wild type 
B/Beijing/1/87 NS1 protein. 
Figure 23 shows that the mutant 33/38 BNS1 protein that lacked the ability to block the activation of 
PKR was compromised in its own level of translation (Figure 23B) and also resulted in lower levels of 
luciferase gene activity than did wild type BNS1 protein (P=0.01). This decreased level of expression 
was confirmed by western blot analysis on the lysate (Figure 20B).  
In contrast, mutation of amino acids 52-54 of the influenza B NS1protein did not abrogate that 
ability of the BNS1 protein to enhance translation in the transfected cells, in fact luciferase activity 
was even higher than in the presence of the parental wild type protein, although this was not to a 
statistically significant degree (P=0.11). Taken together with the published consequences of these 
NS1 proteins on the PKR activation status induced during virus infection, these data are in support of 
a scenario whereby an NS1 protein, manufactured in the cytoplasm, may act upon cytoplasmic PKR 
prior to targeting to the nucleus. The efficient nuclear localisation of the 33/38 mutant protein and 
the inability to control the activation of PKR during viral infection suggest that this NS1 protein 
mutant is deficient in co-localising with a cytoplasmic factor, and this may result in the elevated 
levels of PKR activation measured by Donelan et al. These prior investigations of intracellular 
localisation measured the expression of BNS1 proteins in the context of cells infected by 
recombinant viruses. Therefore it was important to confirm the localisation of exogenously 
expressed BNS1 protein in the transient expression system.  
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Vero cells were transfected with the influenza B constructs along with the NLS tagged A/PR/8/34 
NS1 protein and the samples were prepared for analysis using indirect immunofluorescence (Figure 
24). 
The NS1 from A/PR/8/34 localised to both the cytoplasm and the nucleus, and was retargeted to the 
nucleus as before by the NLS tag. The wild type B/Beijing/1/87 NS1 localised predominantly to the 
nucleus, although there was some B/Beijing/1/87 NS1 in the cytoplasm. In marked contrast to this, 
there was no 33/38 mutant B/Beijing/1/87 NS1 detectable in the cytoplasm. Although this influenza 
B/Beijing/1/87 NS1 protein was entirely nuclear in distribution, the pattern inside the nucleus did 
not match that of either the wild type or the 52-54 B/Beijing/1/87 NS1 mutant which is in agreement 
with the observations made by Schneider et al, who noted a general nuclear distribution of a virally 
expressed NS1 protein carrying the 33/38 mutations. 
This mutant appeared to be poorly expressed in Vero cell in these experiments, which correlates 
with the observation of lower expression seen upon analysis of the cell lysate by Western Blot 
(Figure 23B). The 52/53/54 mutant was present in the cytoplasm and the nucleus. Levels in the 
cytoplasm were approximately equivalent to wild type and the distribution of the NS1 protein in the 
nucleus was punctuate and formed distinct speckles. 
This differs from that of the published data on 52/53/54 (Schneider, Dauber et al. 2009), which in 
the context of viral expression was deficient in nuclear translocation. It is possible that the 
differences in methods of expression could account for this discrepancy, but other key differences 
include the NS1 protein primary amino acid sequence, and the cell type that this experiment was 
conducted in.   
Influenza B viruses are naturally constrained to human and phocine hosts, and there are species-
specific mechanisms to control interferon controlled by the influenza B virus NS1 (Versteeg, Hale et 
al. 2010), therefore this work has not excluded the possibility that the NS1 protein localisation in the 
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Vero cells may not represent the localisation which might be occurring in the human 293T cells. 
Countering this argument, a recent publication conducting a study on the ISG15 antagonism noted 
that the distribution of influenza B NS1 proteins in the human Hela cell line mirrored those found in 
the African Green Monkey Cos7 cell line (Sridharan, Zhao et al. 2010). 
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Figure 23 Investigating the Enhancement Activities of Influenza B NS1 
 
A - Enhancement activities of an NS1 protein from B/Beijing/1/87 
The NS1 protein from influenza B was evaluated for the ability to enhance translation using the same 
methodology as influenza A. Briefly, NS1 coding plasmids were transfected into 293T cells using 
Lipofectamine 2000, and processed as described previously. The mutant NS1 encoding a defect at 
amino acids 33 and 38 was able to accumulate efficiently in the nucleus, but unable to block the 
activation of PKR in the context of a virus, therefore it was reasoned would be a good control for this 
experiment, in comparison to the wild type protein, and a further protein which is defective at 
nuclear localisation, but still able to block the activation of PKR in the context of a virus. Although no 
translational enhancement was demonstrated relative to the empty vector transfection, these NS1 
proteins delivered effects on the luciferase reporter gene in the pattern predicted for the 
experiment, with the NS1 unable to block PKR activation exhibiting a reduced level of luciferase 
expression, compared to the mutant at amino acids 52-54 which is able to enhance translation 
relative to the wild type NS1 protein. Both of these effects on translation were statistically significant 
compared to that of the wild type NS1 protein as shown on the figure.  
 
B - Western blot analysis confirming the expression of NS1 proteins and their effect on a luciferase 
reporter gene in 293T cells  
The clarified lysates from 293T cells which had been evaluated for luciferase expression was 
evaluated using western blotting for the expression of NS1 protein and Luciferase Protein. As 
described previously 5µl of the lysates which had been mixed 10µl to 10µl with 2X protein loading 
buffer stock (with 1M DTT) was separated on a 15% SDS PAGE and transferred to hybond C 
nitrocellulose, and evaluated with V5 anti sera as described previously.  
The resulting evaluation confirmed the previously documented enhancement and inhibitory 
activities on the luciferase reporter gene of A/PR/8/34 and A/Victoria/3/75. The effects of the 
influenza B NS1 proteins on translation are recapitulated by this probe for the V5 epitope.  
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Figure 24 Localisation of influenza B NS1 proteins in transiently transfected Vero cells  
The localisation of the mutated influenza B NS1 proteins was compared to that of the WT 
B/Beijing/1/87 and A/PR/8/34 viral NS1 protein using transient transfection in Vero cells. As 
established previously, 250ng pCAGGS NS1 or empty vector plasmid was transfected into Vero cells 
growing on cover slips using Lipofectamine 2000. After 24 hours the cells were fixed and 
permeablised, and evaluated using the V5 anti-sera. The predominant distribution of the NS1 
protein from influenza B regardless of the amino acid mutations appeared to be in a manner 
reminiscent of the NLS tagged A/PR/8/34 NS1 protein.  
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2.15 Discussion 
The ability of NS1 proteins to enhance translation was identified by Salvatore et al. (2001) and this 
phenotype was noted by Kochs et al. and Hayman et al. (2007) to be strain-specific. Only the NS1 
protein derived from the A/PR/8/34 laboratory-adapted virus had been documented to possess this 
phenotype. The work described in this chapter has identified two other naturally-occurring influenza 
A virus NS1 proteins, plus the influenza B NS1 analogue, as well as a variety of chimeric proteins and 
some NS1 proteins with point mutations which are capable of enhancing translation of an 
exogenous reporter gene.  
In contrast, some NS1 proteins, typified by A/Udorn/72, have extensive interactions with the host 
mRNA processing apparatus, resulting in a block in protein expression (Nemeroff, Barabino et al. 
1998; Chen, Li et al. 1999; Noah, Twu et al. 2003). Therefore had Salvatore et al. performed their 
experiments with a A/Udorn/72-like NS1 protein, the result would have been an inhibitory rather 
than an enhancing effect on the reporter gene, and this has also been modelled in the co-
transfection assay described in this chapter. 
The NS1 protein of influenza A has two domains linked by a flexible region. Each of the two regions 
have been crystallised separately and their structures solved (Liu, Lynch et al. 1997; Bornholdt and 
Prasad 2006; Yin, Khan et al. 2007; Das, Ma et al. 2008; Hale, Barclay et al. 2008; Cheng, Wong et al. 
2009) but it is not at present clear how or whether the two halves interact with each other. The 
recently published full length crystal structure lacks resolution in the flexible hinge region and was 
expressed as an RNA binding mutant to ensure solubility (Bornholdt and Prasad 2008). The studies 
with chimeric NS1 proteins presented here, and also those described by Kochs et al, established that 
the N terminal RNA binding domain and C terminal effector domains from two different NS1proteins 
can be combined. This finding is compatible with the idea that the NS1 protein is comprised of two 
independently acting domains, as the crystal structures suggest. The results presented here map the 
effector C terminal domain from the parental NS1 protein being dominant in determining the 
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outcome of reporter gene enhancement or inhibition. NS1 proteins which inhibit the production of 
the eGFP or luciferase reporter gene likely do this by binding CPSF, since mutations that abrogate 
the inhibition are the same as those shown by Das et al. (2008) and by Kochs et al. to disrupt CPSF 
binding. We did not test CPSF binding directly in this work however, and therefore cannot exclude 
the participation of other components of the host 3’ mRNA maturation apparatus in these effects. 
The enhancement mechanism explored in this work, and by the earlier work of Salvatore et al, 
differs from mechanisms of enhancement of viral gene mRNA translation which have been reported. 
Several groups have shown that the 5’ UTR sequences of influenza virus gene segments allow the 
NS1 protein to recruit translation factors to viral mRNAs to enhance their translation over that of 
host mRNAs (Katze and Krug 1990; Garfinkel and Katze 1992; Garfinkel and Katze 1993; Enami, Sato 
et al. 1994; de la Luna, Fortes et al. 1995; Park and Katze 1995; Marion, Aragon et al. 1997; Park, 
Wilusz et al. 1999; Aragon, de la Luna et al. 2000; Kash, Cunningham et al. 2002; Dauber, Martinez-
Sobrido et al. 2009). Importantly the reporter genes used in the work presented in this thesis do not 
contain influenza gene non-coding sequence and would be processed exactly as host genes rather 
than as viral mRNAs. It is more likely that the translational increases measured here are a 
consequence of the reduction of the levels of the phosphorylation of eIF2α stimulated as a 
consequence of the transfection process (Akusjarvi, Svensson et al. 1987). 
Data presented here suggests that enhancement of translation requires the NS1 protein to 
accumulate in the cytoplasm. In retargeting the enhancing NS1 protein A/PR/8/34 to the nucleus, 
the ability to enhance was lost. Moreover, mutation at residue 184 in A/Victoria/3/75 NS1 protein 
which is known to destroy binding to the F2F3 fragment of CPSF (Steidle, Martinez-Sobrido et al. 
2010) ablated its inhibitory effect on luciferase gene expression, simultaneously relocated the 
protein to the cytoplasm, and resulted in translational enhancement.  
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Work was conducted with expression constructs of influenza B NS1, to ascertain if this NS1 protein 
would have a similar effect to the NS1 of influenza A, as this protein was also known to bind dsRNA 
and antagonise the actions of PKR (Dauber, Schneider et al. 2006). This NS1 protein was not as 
effective at enhancing translation in the experimental system used as the influenza A analogue. This 
might be because it tends to accumulate more actively in the nucleus than the NS1 protein of 
A/PR/8/34, even after mutation of the well-characterised nuclear import signals. The studies 
performed with influenza B NS1 were nonetheless useful in understanding translational 
enhancement, in that they provided the observation that an NS1 protein that was able to bind 
dsRNA, but was unable to block the activation of PKR and was entirely absent from the cytoplasm, 
was unable to maintain the translation of a reporter gene to a level equivalent to that of a wild type 
B/Beijing/1/87 NS1 protein (p=0.01). This emphasised the importance of cytoplasmic localisation of 
NS1 protein for this phenotype coupled with an ability to counter PKR activation.  The accumulation 
of the enhancing NS1 proteins in the cytoplasm likely affords them access to the factors which 
otherwise restrict the amount of reporter gene which is produced, which is hypothesised to be PKR 
or factors that control PKR activity. 
The influenza A NS1 proteins expressed in Vero cells differed in their cellular localisation, despite 
them all containing the intact NLS sequence in the RNA binding domain. Variation in NS1 localisation 
has been reported as being cell type dependent, at least in the context of a viral infection (Volmer, 
Mazel-Sanchez et al. 2010). Generally in the literature, NS1 proteins expressed from plasmids or as a 
result of a virus infection are reported to accumulate strongly to areas within the nucleus 
(Greenspan, Palese et al. 1988; Kochs, Garcia-Sastre et al. 2007; Melen, Kinnunen et al. 2007). 
However A/PR/8/34 has been reported in having a greater degree of translocation to the cytoplasm 
(Hayman, Comely et al. 2007) which is in support of the observed variation in NS1 localisation 
measured here. 
161 | P a g e  
 
Li et al, (1998) suggested that the ability of NS1 proteins to localise to the cytoplasm is frequently 
overlooked, as acetone used as a fixative for virus infected cells extracts the majority of the NS1 
protein present in the infected cell cytoplasm. The current model for the regulation of the NES is not 
supported by this data. Although two of the NS1 proteins which were investigated for this work 
localised to the cytoplasm, perhaps due to the adjacent regulatory signal being compromised by 
single amino acid substitutions, this mechanism could not account for the accumulation of 
A/PR/8/34, and A/PR/8/34 effector domain chimeras localising in this cellular compartment. This 
data supports the hypothesis that the localisation of the NS1 protein may be influenza strain and 
host specific (Volmer, Mazel-Sanchez et al. 2010). The regulatory domains were initially defined 
using the protein primary amino acid sequence, as at the time the crystal structure of the effector 
domain had not been completed. Therefore revisiting the work to evaluate the integral NES with 
respect to amino acids localised adjacent to this sequence in three-dimensional space may explain 
these experimental discrepancies. 
Surprisingly, although the mechanism of translational enhancement by the A/PR/8/34 NS1 protein 
was supposed to involve PKR, the use of mutations designed to ablate a PKR:NS1 interaction failed 
to prevent the ability of the NS1 protein to enhance translation. Although interactions between NS1 
and PKR have been shown by various biochemical methods (Tan and Katze 1998; Li, Min et al. 2006; 
Min, Li et al. 2007) and the NS1 protein undoubtedly has a role in counteracting PKR-mediated 
inhibition of replication (Bergmann, Garcia-Sastre et al. 2000), the direct interaction of NS1 with PKR 
has been controversial (Falcon, Fortes et al. 1999). The loss of NS1:PKR binding by the engineered 
mutations at positions 123- 127 of NS1could not be confirmed in this work (data not shown). A 
future study evaluating the relative contribution of PKR, and PKR regulatory factors to the 
translational enhancement effect of NS1 would be beneficial to the interpretation of this work. 
A difficulty in evaluating the expression of the NS1 proteins for this work has been associated with 
the expression of NS1 proteins which inhibit the expression of both a reporter gene and themselves 
162 | P a g e  
 
due to their mode of action. Densitometric analysis could not be performed on western blots, as for 
the most part to enable the visualisation of inhibitory NS1 proteins, the film was significantly over-
exposed for the enhancing NS1 proteins.  
Developments in the measurement of protein expression mean that fluorometric analysis using the 
Odyssey system (Licor Biosciences) could be adopted to quantitatively evaluate the expression 
effects presented here by western blot with a greater degree of accuracy. In this work, western 
blotting confirmed that the NS1 proteins were affecting their own expression, in addition to that of 
the luciferase reporter suggesting a global mechanism, such as an interaction with CPSF, or PKR. An 
optimised evaluation of this expression system, would enable a loading control, the NS1 protein and 
the luciferase gene expression to be evaluated from one blot, and may generate a greater level of 
accuracy than for densitometric analysis, which would likely be out of the linear range for the 
enhancers of protein expression, and at the lower end of accuracy for the NS1 proteins which inhibit 
protein production in the transfected cells.  
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Chapter 3: Accounting for the Non 
Universal Nature of CPSF Binding 
Amongst Influenza NS1 proteins 
 
3.1 Introduction 
Krug et al. have shown that the NS1 protein of the A/Udorn/72 influenza virus interacts with CPSF 
and other components of the host mRNA apparatus resulting in a block in mRNA maturation and 
nuclear export. In the previous chapter the expression of a subset of NS1 proteins resulted in an 
inhibition of the expression of a reporter gene, and CPSF binding is a likely mechanism for this since 
mutations that are reported to disrupt the NS1-CPSF interaction (Kochs, Garcia-Sastre et al. 2007; 
Das, Ma et al. 2008) also abrogated the inhibitory effect. Not all wild type NS1 proteins showed the 
inhibitory phenotype, and from this it can be concluded that CPSF binding is not entirely conserved. 
Some NS1 proteins such as that of the mouse adapted A/PR/8/34 strain are hypothesized to bind 
CPSF only weakly, but the interaction can be stabilised by participation of other viral components, 
namely the polymerase subunits (Kuo and Krug 2009). Of the NS1 proteins analysed here at least 
three naturally occurring NS1s A/Teal/317/97, A/Duck/Ukraine/63 and A/PR/8/34 were deficient in 
this inhibitory activity. Furthermore it is worth noting that the influenza B virus NS1 lacks this 
inhibitory phenotype and does not bind CPSF (Wang and Krug 1996), suggesting that other 
mechanisms can be sufficient to overcome the host antiviral response to influenza virus generated 
PAMP. In other words the functional CPSF binding by influenza virus is not absolutely essential.  
In this chapter the first aim was to establish the correlation between inhibition of the reporter gene 
expression and inhibition of an induced interferon response. Then we considered whether there was 
a consequence to viruses that did not possess the CPSF binding phenotype, in order to account for 
why this varies between strains. 
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3.2 The Ability of the Influenza NS1 Protein to Control Interferon 
Induction  
Previously the ability of NS1 to counter an interferon response has been compared by over-
expression of the protein in A549 cells with a reporter construct in which the human interferonβ 
promoter is upstream of the luciferase protein (Hayman, Comely et al. 2006; Hayman, Comely et al. 
2007). After 24 hours, these cells were stimulated with either the artificial dsRNA Poly I:C, Sendai 
Virus or Newcastle Disease Virus (NDV) which all induce a robust interferonβ response in 
mammalian cells. Lysates prepared from cells under these conditions when assayed for luciferase 
activity provided a simple methodology for the evaluation of NS1 protein function in blocking the 
interferon response, with significant levels of luciferase protein being produced only where there 
was no block to interferon production. 
An additional reporter plasmid encoding β-galactosidase was also included, providing a gene for the 
luciferase levels to be compared to. Normalising values in this way minimises the impacts of 
variation in transfection efficiency and operational variation such as cell number.  However as the 
data from the previous chapter suggests, a more critical role for the β-galactosidase in this work is 
mitigating the effects of translational enhancement or inhibition which might lead to an erroneous 
conclusion about the abilities of NS1 proteins to perform their functions in countering the interferon 
pathway.   
For this work the control plasmid V5 was used as a baseline to indicate the degree of interferon 
induction by the stimulus. This plasmid lacks the NS1 open reading frame, but contains the coding 
sequence for the V5 epitope tag that each NS1 protein has on their C terminus and is referred to as 
the Empty Vector. The NS1 proteins were tested to establish if they were able to control the 
induction of luciferase protein driven by the interferonβ promoter differently from this control 
transfection.  
165 | P a g e  
 
This assay was modified by the exchange of A549 cells for 293T cells in the transfection. As 
summarised in Figure 25A after 24 hours the cells were treated with Poly I:C or NDV.  
Using this method the NS1 proteins shown in Chapter 2 to cause reporter gene enhancement rather 
than inhibition and thus proposed to be deficient at CPSF binding were compared to A/Victoria/3/75 
NS1 for their ability to block the luciferase production. This luciferase was produced in response to 
the activation of the plasmid encoded interferonβ promoter when the transfected cell was 
stimulated by poly I:C. It was hypothesised that these NS1 proteins may be deficient in controlling 
interferon, and this would correlate with an inability to block gene expression. However Figure 25B 
shows that the wild type NS1 proteins thought to be lacking in CPSF binding were able to control 
interferon induction as well as the A/Victoria/3/75 NS1 able to bind CPSF. Interestingly, 
A/Duck/Ukraine/63 NS1 appeared somewhat less able to control the interferon gene expression. 
Despite the amino acid sequence coding for the consensus CPSF binding amino acids at 103 and 106 
(as demonstrated in the sequence analysis in the previous chapter), this NS1 protein was still 
functional at blocking the interferon stimulation to a statistically significant degree (p=0.009). These 
data confirm that the assay is working in 293T cells, and that this system can be used to model the 
intervention of NS1 in interferonβ signalling. 
To investigate the effect of the normalisation procedure on the interferon luciferase values to those 
generated by the β-galactosidase to exclude that this altered the experimental outcome, the raw 
data for the luciferase measurements were evaluated in figure 25C. When interpreted in this 
manner, the data remains statistically distinct from that of the empty plasmid transfection. The 
levels of luciferase expression for the stimulated A/Victoria/3/75 NS1 in the un-normalised data set 
are considerably lower and of a similar level to the unstimulated empty vector samples suggesting a 
robust control of gene expression by A/Victoria/3/75 NS1 supporting data in the previous chapter.  
Normalising this data to β-galactosidase appears to correct for this, and as a consequence there is an 
elevated luciferase signal in figure 25 B.  
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Figure 25 Experiment Work to Evaluate the Ability of NS1 Proteins to Block Interferon Induction 
A - Overview of Experimental Procedure to Evaluate the Ability of NS1 Proteins to Block Interferon 
Induction 
293T cells were transfected in suspension using Lipofectamine 2000 (Invitrogen) with 250ng each of 
the reporter plasmids encoding β-galactosidase and the interferonβ luciferase plasmid (Hayman, 
Comely et al. 2007), alongside 200ng pCAGGS NS1 expression plasmid per well of a 12 well plate 
(Cellstar, Greiner). 
 24 hours post transfection, wells were either infected with NDV diluted in serum free media, or 
mock treated for an hour, then the media was replaced with 2% foetal calf serum DMEM for a 
further 20 hours. To stimulate with poly I:C, a stock of poly I:C (1mg/ml Sigma) was diluted in serum 
free media 1 in 50, and transfected into 293T cells using Lipofectamine 2000. The resulting samples 
were then harvested as for the NDV and mock samples. To harvest the assay, the cells were washed 
once with ice cold phosphate buffered saline, and lysed and assayed for both luciferase and 
βgalactosidase. The luciferase readings were normalised using the β-galactosidase to control for 
variance in transfection efficiency, cell number and the effects of NS1 proteins on protein expression 
between the samples. Each data point represents the average of 3 identically treated samples, and 
the error bars are the standard deviation of each group.  
 
B - Normalised Interferonβ Luciferase Reporter Activity in Transfected 293T Cells after stimulation 
with Poly I:C 
Transiently transfected samples were assayed for the ability of the NS1 proteins to block the 
stimulation of a poly I:C mediated stimulus. The panel of NS1 proteins included the 3 NS1 proteins 
which had been established as capable of enhancing translation, and the NS1 protein which 
represented the most efficient block of protein translation. The p values shown on the graph 
indicate that the NS1 proteins were all capable of blocking the poly I:C mediated stimulus in 293T 
cells. This data is representative of at least 3 independent experiments. 
 
C- Interferonβ Luciferase Reporter Activity in Transfected 293T Cells after stimulation with Poly I:C 
The un-normalised luciferase activity values corresponding to the data presented for Part B, is 
displayed here to demonstrate the effect that the normalisation to β-galactosidase has upon the 
experimental results. The p values shown on the graph are those relative to the stimulated empty 
vector control and indicate that the NS1 proteins were all capable of blocking the poly I:C mediated 
stimulus in 293T cells. As before this data is representative of at least 3 independent experiments. 
 
D – Activity of the β-galactosidase Reporter Measured by the Absorbance at 420 nm  
Levels of β-galactosidase activity were evaluated by measuring the absorbance of an aliquot of 
lysates at 420 nm after incubation with a substrate. The conversion of the colourless artificial β-
galactosidase substrate OPNG  to produce a coloured product of the varied according to the levels of 
reporter protein expression. (See Materials and Methods). The data shown here is that measured for 
the experiments presented in Parts A-C which is representative of at least 3 independent 
experiments. The error bars represent the standard deviation.  
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The difference in luciferase activity between the A/Teal/317/97 and A/Duck/Ukraine/63 is decreased 
in the absence of normalisation, but despite the subtle differences in values between Figures B and C 
these differences do not substantially alter the conclusions drawn from this experiment about the 
abilities of the NS1 protein to control interferonβ.  
In figure 25D the effect of A/Victoria/3/75 on the expression of β-galactosidase supports the data 
seen in the previous chapter in which this NS1 protein inhibits protein expression strongly, and the 
levels of enzymatic activity are markedly reduced for this sample. The enhancement effects caused 
by the NS1 protein expression relative to the empty vector control however are not as clear cut or 
consistent as was measured in previous work.  
For all NS1 samples there is a marked difference in β-galactosidase activity between the stimulated 
and unstimulated cell samples. This difference is likely to be as a result of a difference in cell 
numbers between the stimulated and unstimulated samples. The lower values of absorbance 
measured in the stimulated samples reflect a loss of cells in the sample pool due to the treatment 
with the poly I:C dsRNA analogue, which results in a proportion of the cells present entering 
apoptosis. Due to the experimental design it is not possible from these data to discern if it is 
variation in cell number, or effects on translation that is the specific cause of the decrease in β-
galactosidase activity measured, this could be achieved using protein quantitation methodologies in 
future work.  
Next the effect of mutations in the CPSF binding site of NS1 on its ability to control interferon 
induction by either poly I:C or NDV was evaluated. The results of the reporter gene assay in the 
previous chapter suggested that the inhibitory effects on gene expression which were implied to be 
a CPSF binding ability, could be conferred to A/PR/8/34. These could not be removed entirely from 
A/Victoria/3/75 by the converse 2 amino acid substitution at residues 103 and 106. The exchange of 
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the conserved amino acid at position 184 in A/Victoria/3/75 entirely ablated this block on reporter 
gene expression.  
Therefore beginning with the experiment to investigate the effects of the double mutants at amino 
acids 103/106, as seen previously both wild type A/PR/8/34 and A/Victoria/3/75 NS1 proteins were 
able to block the interferonβ promoter induction by either NDV (figure 26A) or poly I:C (Figure 26B) 
stimulation to a statistically significant degree.  
 
The exchange of amino acids at the 103/106 locus of A/Victoria/3/75 NS1 with those of A/PR/8/34 
which lowered but did not entirely remove the restrictions on reporter gene expression in the 
previous chapter, did not abrogate the control of NDV or Poly I:C stimulated interferon reporter 
activity, and the differences between the stimulated NS1 samples and the stimulated control 
samples remain statistically significant. The difference between wild type A/Victoria/3/75 NS and 
that altered at amino acids 103/106 was not significant in the either the case of NDV stimulation 
(p=0.19) or poly I:C mediated stimulation (p=0.11). 
The converse substitution at residues 103/106 in a A/PR/8/34 NS1 protein did not increase its ability 
to control NDV stimulation over wild type, although poly I:C stimulation was more efficiently 
controlled by the CPSF positive A/PR/8/34 NS1 protein (Figure 26B) and there is a statistically 
significant difference between the wild type and the altered protein in this experimental system 
(p=0.01).   
 As established for figure 25 the apparent ability to block the stimulation of the interferonβ 
promoter was not an artefact of the normalisation of the luciferase activity to that of the 
βgalactosidase. As the matched panels C and E demonstrate, although the values may differ, the 
pattern remains equivalent to that of the normalised data. 
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The β-galactosidase data shown in figure 26 D and F  was generated for use as a mechanism to 
compensate for the effects of enhancement of translation (such as A/PR/8/34), or NS1 proteins 
which block protein expression (such as A/Victoria/3/75). As seen previously in Figure 25D these 
show differences across the NS1 samples tested with the gain in CPSF binding by the A/PR/8/34 
resulting in a decrease in the levels of β-galactosidase activity, and the abrogation of CPSF binding by 
A/Victoria/3/75 resulting in an increase in the levels of this enzymatic activity relative to the wild 
type.  
A further difference which was also seen previously is the decrease in β-galactosidase activity 
between the stimulated and unstimulated groups. This measured difference between the samples is 
greatest in figure 26D which represents the data derived from the NDV challenge experiment. As the 
β-galactosidase activity corresponds to a measure of cell number this decrease likely represents the 
result of increased levels of cell death as a consequence of NDV replication inside the transfected 
293T cells. As the virus is able to replicate through multiple rounds, this amplifies the stimulation 
and in comparison to the “one shot” stimulation caused by the transfection with poly I:C results in 
fewer cells remaining to be harvested in the NDV stimulated samples compared to the unstimulated 
than for the dsRNA analogue treated cells. 
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Figure 26 Investigating the Ability of NS1 Proteins Mutated at Amino Acids 103/106 to Block 
Stimulation of the Interferonβ Promoter 
 
 A - Normalised Interferonβ Luciferase Reporter Activity in Transiently Transfected 293T Cells after 
stimulation with NDV 
NS1 proteins were expressed alongside the interferonβ luciferase reporter construct and that for the 
constitutive expression of β-galactosidase (using the method described in Figure 25A). The ability of 
NS1 proteins engineered, to have increased or decreased ability to counter the expression of a 
reporter gene, likely through a CPSF mediated mechanism was evaluated. 
The NS1 protein for A/PR/8/34 NS1 does not gain an advantage in blocking an NDV mediated 
stimulus upon gaining CPSF binding abilities. Conversely the A/Victoria/3/75 NS1 protein which likely 
binds this factor efficiently does not seem to lose the ability to control interferon stimulation via 
NDV. There was no statistically significant difference in the ability to counter the interferon 
stimulation modelled in this system upon the predicted acquisition of CPSF binding. The P value 
represents the statistical significance of the stimulated samples compared with the stimulated 
sample of the control empty vector transfection, and these were all significant. This data is 
representative of at least 3 independent experiments. 
 
B Normalised Interferonβ Luciferase Reporter Activity in Transiently Transfected 293T Cells after 
stimulation with Poly I:C  
As for Part A, the panel of NS1 proteins engineered to vary in their ability to interact with the host 3’ 
mRNA maturation apparatus were expressed alongside the interferonβ luciferase reporter construct, 
and that for the constitutive expression of β-galactosidase (using the method described in Figure 
25A). As before, all 4 NS1 proteins tested are able to block interferon signalling to a statistically 
significant degree as shown by the p value on the graph.  
The 103/106 mutant of the A/PR/8/34 NS1 protein exhibits a statistically significant enhancement to 
its ability to block poly I:C triggered interferon signalling. (p=0.01) However there was no statistically 
significant alteration in the ability of the mutated A/Victoria/3/75 NS1 protein to control the 
interferon signalling compared to the wild type protein. (p=0.11) This data is representative of at 
least 3 independent experiments. 
(Panels C and D show the un-normalised Data from A, and the β-galactosidase activity used to 
adjust the Data.) 
(Panels E and F show the un-normalised Data from B, and the β-galactosidase activity used to 
adjust the Data.) 
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The glycine at position 184 in the NS1 protein is absolutely conserved. Mutation to arginine has been 
shown to disable CPSF binding (Das, Ma et al. 2008; Steidle, Martinez-Sobrido et al. 2010) and it was 
demonstrated in a previous chapter that this reversed the inhibitory effects of A/Victoria/3/75 NS1 
on reporter gene expression. There was no measureable effect of this mutation in the context of the 
A/PR/8/34 NS1 protein, which is not thought to bind CPSF efficiently. NS1 proteins harbouring the 
G184R mutation were tested for their abilities to block interferon induction by NDV. As shown in 
figure 27A, the A/PR/8/34 G184R mutant retained the ability to block the NDV stimulus, whilst the 
A/Victoria/3/75 G184R mutant was much less able to block the interferon signalling than the wild 
type A/Victoria/3/75 NS1 protein. These two NS1 proteins were able to control the interferon 
signalling to a degree significantly better than the control transfection (p=0.003 and p=0.002 
respectively), but also to a degree statistically different to that of their parental NS1 proteins 
(p=0.005 and p=0.008 respectively).  
In the previous chapter, it was demonstrated using confocal microscopy that different NS1 proteins 
localised to different compartments of the cell. Although the wild type A/PR/8/34 NS1 protein was 
largely cytoplasmic, the addition of a nuclear localisation tag on the N terminus resulted in its 
accumulation in the nucleus and destroyed its ability to enhance translation. To investigate the 
effect of redirecting the PR8 NS1 protein to the nucleus on its ability to block IFN induction, the NS1 
proteins were transiently expressed in the interferon blocking assay, and cells were stimulated with 
NDV (figure 27B). The NLS tagged A/PR/8/34 was much less efficient at controlling the interferon 
response than the wild type NS1 protein, and there is no statistically significant difference between 
this transfection and the empty vector transfection with regards the interferon derived signal. 
This is likely due to the inability of the NLS tagged NS1 protein to interact with CPSF, or other nuclear 
factors efficiently, therefore direction into the nucleus results limits the interaction with cytoplasmic 
factors such as PKR, RIG-I and TRIM25 which are located in the cytoplasm, and therefore the tagged 
NS1 protein is limited in its ability to control the interferon induced by the NDV. 
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The primary role of dsRNA binding of NS1 has been reported to be the control of interferon by 
controlling the activation of the 2’5’ OAS pathway (Min and Krug 2006). RNA binding mutants of NS1 
are also unable to functionally inhibit TRIM25 mediated RIG-I signalling (Gack, Albrecht et al. 2009). 
As NS1 proteins with poor localisation to the nucleus due to mutations in their NLS, (which overlaps 
the RNA binding site) these NS1 proteins should be highly deficient at controlling interferon 
stimulation from NDV. 
The results of a transient expression of the RNA binding NS1 proteins in 293T cells is shown in figure 
28. Surprisingly the NS1 proteins despite containing the published RNA binding mutations are 
competent at blocking the NDV stimulus in these cells to a statistically significant degree with the p 
values of the stimulated NS1 transfection calculated relative to the stimulated empty plasmid 
transfection and shown on the figure. The NS1 proteins however did block interferon stimulation 
with less efficiency than the wild type, and the differences between the wild type NS1 protein and 
the R38A mutant, R38A K41A and the R38A K41A S42G mutant all varied in their abilities to block 
interferon with a statistically significant degree (p=0.01, p=0.002 and p=0.004 respectively). 
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Figure 27 NS1 Proteins from A/PR/8/34 and A/Victoria/3/75 Seem able to Block Interferon 
Signalling by accumulation In the Cytoplasm 
 
A Normalised Interferonβ Luciferase Reporter Activity in Transiently Transfected 293T Cells after 
stimulation with NDV 
NS1 proteins were expressed alongside the interferonβ luciferase reporter construct and that for the 
constitutive expression of β-galactosidase (using the method described in Figure 25A). This panel 
represented the NS1 proteins which had been altered to vary in their CPSF binding ability using a 
G184R mutation, which previously resulted in the flip of an inhibitory NS1 protein to an Enhancer. 
This NS1 protein represented the NS1 protein most likely to be deficient in the ability to counter the 
interferon response to NDV challenge.  
As shown in this figure, the CPSF alteration in both the A/PR/8/34 and A/Victoria/3/75 NS1 did not 
result in a loss of ability to control interferon relative to the control transfection. (p values on the 
chart). However the G184R NS1 proteins did show a statistically significant behaviour in their ability 
to control interferon relative to the parental NS1 protein p=0.005 and p=0.008 for A/PR/8/34 and 
A/Victoria/3/75 NS1respectively. This data is representative of at least 3 independent experiments.  
 
B Normalised Interferonβ Luciferase Reporter Activity in Transiently Transfected 293T Cells after 
stimulation with NDV 
 
The targeting of an NS1 protein which is normally able to accumulate in the cytoplasm to the 
nucleus using an SV40 NLS tag was found to ablate the ability of an NS1 protein to enhance 
translation. This NS1 protein was also thought unable to bind to the host 3’mRNA apparatus, as 
localisation to the nucleus did not result in the NS1 reducing luciferase activity to the levels 
measured of A/Victoria/3/75 transfections. The ability of this NS1 protein to block interferon 
signalling was evaluated in this assay, hypothesising that the nuclear localisation would be away 
from the usual panel of cytoplasmic PRRs that the NS1 would interact with. NS1 proteins were 
expressed alongside the interferonβ luciferase reporter construct and that for the constitutive 
expression of β-galactosidase (using the method described in Figure 25A). The p value displayed 
represents a comparison of the stimulated experimental transfection and that of the stimulated 
control empty vector transfection. There was no statistical significance to this comparison meaning 
that the NLS tagged NS1 protein is no longer able to block the interferon signalling measured in this 
assay. This data is representative of at least 3 independent experiments.  
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Figure 28 Normalised Interferonβ Luciferase Reporter Activity in Transiently Transfected 293T Cells 
after stimulation with NDV 
It was hypothesised that RNA produced by the replication of NDV, or stimulation of the RIG-I 
pathway may be the cause of the interferon signal. The published RNA binding mutants of NS1 are 
not thought able to counter the stimulation of this pathway, the ability of the RNA binding mutants 
of A/PR/8/34 were evaluated for their ability to block interferon signalling in this reporter assay. NS1 
proteins were expressed alongside the interferonβ luciferase reporter construct and that for the 
constitutive expression of β-galactosidase (using the method described in Figure 25A). The resulting 
luciferase values were compared to those of the control transfection and a p value generated. The 
reduction compared to the empty plasmid control was found to be statistically significant meaning 
that these NS1 proteins are still able to block the NDV stimulus. However the interferon blocking is 
achieved with a statistically significant retardation compared to the wild type A/PR/8/34 NS1 protein 
(R38A mutant p=0.01, R38A K41A p=0.002 and the R38A K41A S42G mutant p=0.004). This data is 
representative of at least 3 independent experiments.  
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An explanation of this effect could be, that the NS1 protein is being over expressed to such a degree 
that this is able to quench the stimulus the NDV is creating within the cell. A second explanation is 
that there is an additional mechanism for controlling interferon induction within the NS1 protein of 
influenza A, in a manner reminiscent of the 2 different domains for controlling interferon that exist 
in the influenza B NS1 protein (Donelan, Dauber et al. 2004). A final interpretation of this data is that 
the over expression of the NS1 protein in this manner, and stimulation with artificial stimuli does not 
model the interferon blocking mechanisms that would occur in a normal influenza virus infection.  
Data in support of the deleterious nature of an RNA binding defect, is the highly attenuated nature 
of viruses encoding RNA binding deficient NS1 proteins which have been published to induce high 
levels of interferon and present replication deficiencies in mice (Donelan, Basler et al. 2003; Steidle, 
Martinez-Sobrido et al. 2010).  
As mentioned previously, viruses containing the double mutation at R38 K41 to ablate RNA binding 
abilities, have also been shown to be defective in binding to importin α via the interaction of amino 
acid of the NLS at amino acid at K41 (Melen, Kinnunen et al. 2007), and the only amino acid in this 
region that has been shown to be required only for RNA binding is R38 (Li, Min et al. 2006; Min and 
Krug 2006). A biologically relevant reiteration of this data was recently conducted in the work of 
Steidle et al, (2010), in which the effects of various combinations of CPSF mutations and RNA binding 
mutations were evaluated in the mouse adapted A/PR/8/34 virus to investigate the importance of 
RNA binding, versus CPSF binding; reasoning that the whole animal model would represent a more 
stringent evaluation of their conditions than the testing in tissue culture conducted to compliment it. 
It is interesting to note that the A/PR/8/34 which has single amino acid change to ablate RNA 
binding engineered into its NS1 in the context of a virus resulted in considerable levels of interferon 
production upon virus infection. The replication kinetics in MDCK cells of this and similar viruses was 
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unaffected. Furthermore, the additions of CPSF binding amino acids were not sufficient to return the 
virus to a low interferon inducing phenotype and compensate for the RNA binding lesion. 
 A further point of variance between this data and similar work of Donelan et al using the RNA 
binding mutants R38A K41A, and R38 K41A S42G Upon assay of an equivalent interferonβ promoter 
these authors demonstrate a clear deficiency in action as a result of these gene alterations. The data 
presented by Donelan et al was conducted using a Sendai virus stimulus, and perhaps subtly 
different reporter genes, furthermore the data presented lacked statistical interpretation making 
comparison between the three bodies of work difficult. It is likely that the A/PR/8/34 virus NS1 
proteins may have also some variation between the 3 experimental systems reviewed. 
The differences between the data generated for this work, and the work of Steidle et al and Donelan 
et al, highlight the requirement for a more rigorous dissection of the impact of an RNA binding 
deficiency in the transiently expressed protein system. The NS1 proteins with RNA binding defects 
are able to block interferon signalling in the context of one viral stimulus (NDV), but not the native 
virus back ground, or that produced by Sendai virus and it is important for future work on interferon 
stimulation in the Barclay Laboratory to understand why. 
 The explanation for these discrepancies could lay in the interaction with the NS1 with the 
introduced viral components, or differing panels of virally induced host genes, and in the absence of 
an understanding of how this occurs, the only conclusion is that NS1 blocks NDV stimulated PAMP.  
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3.3 The Effect of Mutating the NS1 CPSF Binding site in the Context of 
an Influenza Virus infection 
To investigate the importance of CPSF binding on the ability of NS1 to control interferon induction in 
the context of actual influenza virus infection, recombinant viruses were generated using the reverse 
genetics technique that contained exchange or mutation of RNA segment 8. The viruses were 
constructed and titrated as described in the Materials and Methods and equal multiplicities (MOI =3) 
of each recombinant virus were used to infect the A549 (human lung carcinoma) cell line stably 
transformed with the human beta interferon promoter upstream of the luciferase reporter gene 
(Hayman, Comely et al. 2006). After 16-20 hours infection lysates were prepared and these were 
assayed for the luciferase activity. This procedure is summarised in Figure 29. 
The genetic backbones for the recombinant viruses were either A/PR/8/34 or A/Victoria/3/75. First, 
segment 8 exchanges between these two viruses were generated and tested for interferon 
induction. The results are shown in figure 29B. Both A/PR/8/34 and A/Victoria/3/75 wild type viruses 
induced low but detectable levels of luciferase activity. Exchanging the A/PR/8/34 segment 8 for that 
of A/Victoria/3/75, resulted in a reduction in the interferon levels induced. Conversely replacement 
of the NS segment of A/Victoria/3/75 with that of A/PR/8/34 resulted in an approximately 4 fold 
increase in the levels of interferon induction. This supports data suggesting that influenza viruses 
such as A/Victoria/3/75 use CPSF binding abilities of their NS1 proteins to control the interferon 
produced as a consequence of infection of a host cell (Noah, Twu et al. 2003; Das, Ma et al. 2008).  
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Figure 29 Introduction to the A549-Interferonβ Luciferase Reporter Cell Line 
 
A Overview of Experimental Procedure  
In a variation of the previous assay, a reporter cell line carrying a stably transformed reporter 
plasmid was used to model the interferon induced upon viral infection of A549 (human lung 
carcinoma) cell line. Cells were plated out 24 hours before use, and monitored for growth density 
before infection. The cells were washed with PBS to remove traces of serum which would lower 
infection efficiency, and then virus was added to an MOI of 3. After an hour the virus inoculum was 
removed and replaced with 2% FCS DMEM and the samples were incubated for a further 20 hours. 
This was typically done in 12 well plates, the plates were washed and the cells lysed using freshly 
made Passive Lysis buffer (Promega).  
B Interferonβ Induction by Influenza Viruses Using A549-Luc Reporter Cells  
Recombinant viruses encoding whole NS segment swaps were evaluated for the level of interferon 
induced in A549-luciferase reporter cells. The p values above each data point represent the 
statistical significance relative to the mock infection, and reveal that there was no statistical 
significance to the increase in luciferase in the A/PR/8/34 (with A/Victoria/3/75 NS) virus infection. 
There was statistical significance to the increase in luciferase expression of the A/Victoria/3/75 ( PR8 
NS) p = 0.009, which represents an inability of this virus to control interferon as efficiently as the 
parental virus.  
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To assess whether this increased level of interferon production affected growth kinetics, the 
influenza virus recombinants A/Victoria/3/75 and A/Victoria/3/75 with A/PR/8/34 NS were 
compared in a multi cycle growth curve. MDCK (Madin Derby Canine Kidney) cells which are highly 
permissive to influenza infection but also interferon competent cells, were inoculated with a low 
multiplicity of infection (0.01) and samples were taken approximately every 12 hours were titrated 
on fresh MDCK cells as described in the Materials and Methods. 
Despite the observation that the A/Victoria/3/75 virus carrying the A/PR/8/34 NS segment induced a 
raised level of interferon in the A549 reporter cell line , the growth kinetics of this virus in interferon 
competent cells was unaffected with respect to the wild type virus and this is shown in Figure 30 
The most appropriate cell culture system available for influenza virus is arguably the differentiated 
human airway epithelium culture (HAE). HAE cells contain multiple layers of differentiated cells 
grown on a gas permeable membrane suspended in a nutrient culture. The population of cells 
contains a mixture thought to be representative of the human respiratory tract, including ciliated 
and non ciliated cells, and the ability to secrete mucous. These cultures have been used to measure 
interferon responses induced by several human respiratory viruses (Scull, Gillim-Ross et al. 2009; 
Schaap-Nutt, D'Angelo et al. 2010) 
HAE cells were infected at a low MOI of 0.01 and samples of virus released from the apical surface 
were harvested every 24 hours. This experiment was conducted by Dr Holly Shelton at UNC (Chapel 
Hill) as part of an ongoing collaboration with Dr Ray Pickles. Upon return to the UK these time points 
were evaluated by titration on MDCK cells as described previously and the data presented in figure 
31. There was no difference in the growth kinetics of the two viruses in HAE cells. 
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Figure 30 Multicycle Growth Kinetics for 2 Recombinant Viruses in MDCK Cells  
The wild type recombinant A/Victoria/3/75 virus was compared to that of the recombinant virus 
encoding the NS segment from A/PR/8/34. This second virus induced the highest level of interferon 
of the panel assayed in Figure 29B, therefore was thought the most likely to demonstrate a growth 
difference due to the interferon induced in replication. 
The two viruses were inoculated at an MOI of 0.01 and samples were taken at 12 hour intervals. 
These were titrated on MDCK cells and evaluated for titre using crystal violet staining to visualise 
plaques in the cell monolayer. 
A statistically significant difference in titre was measured at early times post infection, suggesting 
that the virus encoding the A/PR/8/34 NS grew with a faster growth kinetics. This difference is not 
represented later on in the infection and the two viruses are indistinguishable by growth titre.  
This data represents at least 3 independent experiments 
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Figure 31 Multicycle Growth Kinetics for 2 Recombinant Viruses in HAE Cells  
The wild type recombinant A/Victoria/3/75 virus was compared to that of the recombinant virus 
encoding the NS segment from A/PR/8/34. This second virus induced the highest level of interferon 
of the panel assayed in Figure 27B, therefore was thought the most likely to demonstrate a growth 
difference due to the interferon induced in replication. This was not the case in an evaluation done 
on MDCK cells, but it was considered a possibility that this was as a result of the highly permissive 
nature of this cell line, which does not represent the best choice model for viral growth substrates. 
The two viruses were inoculated at an MOI of 0.01 on well differentiated human airway epithelia by 
Dr Holly Shelton while at the laboratory of Prof Ray Pickles, UNC (Chapel Hill). Samples were taken at 
24 hour intervals. These were titrated on MDCK cells and evaluated for titre using crystal violet 
staining to visualise plaques in the cell monolayer. 
There was no statistically significant difference between the growths of these viruses in the HAE 
system.  
  


















Multicycle Growth Kinetics for 2 Recombinant 
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3.4 The Effect of Mutations in the CPSF binding sites of NS1 on 
Interferonβ Induction by recombinant Influenza A Viruses 
 
To investigate the effect of mutations at amino acids 103 and 106 in the A/PR/8/34 or 
A/Victoria/3/75 NS1 proteins on the control of interferon induction by the influenza virus, 
recombinant viruses were recovered using plasmids mutated appropriately in both the A/PR/8/34 
and A/Victoria/3/75 genetic backgrounds. All the reverse genetics viruses were recovered containing 
the A/PR/8/34 HA and NA segments, which would ensure equal binding and entry efficiencies 
between the viruses. 
Each of the recombinant viruses was assayed at an MOI of 3 on the A549 reporter cell line to 
establish the levels of interferon they induced. The effects of these substitutions are shown in figure 
32.  
As established in previous assays the wild type A/PR/8/34 and A/Victoria/3/75 viruses were both 
competent at controlling interferon induction, and levels of luciferase produced were only slightly 
raised above but statistically distinct from the Mock treated samples (p=0.02 and 0.07 respectively). 
These two viruses could also be separated based on the levels of interferon signal that they induced 
(p=0.01).  
As shown in Figure 32, exchanging the A/PR/8/34 wild type NS segment with a wild type 
A/Victoria/3/75 NS segment slightly enhanced the virus’ ability to control interferon response but 
this was not to a statistically significant degree with respect to the wild type induction levels (p=0.5). 
Conversely the introduction of the A/PR/8/34 NS gene segment to the A/Victoria/3/75 virus 
compromised interferon control and this increase was statistically significant (p=0.02). 
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In the A/PR/8/34 genetic background, mutation at the CPSF binding site of either the A/PR/8/34 NS1 
gene itself or of the heterologous A/Victoria/3/75 NS gene increased the interferon induction. In the 
case of the engineered A/Victoria/3/75 NS1 this resulted in a statistically significant increase in 
luciferase signal (p=0.07) supporting the role of CPSF binding for the control of interferon as a mode 
of action for this viral NS1 protein. However the reciprocal mutation designed to confer CPSF binding 
to the A/PR/8/NS1 protein did not alter the levels of luciferase expression significantly with respect 
to the wild type induction levels (p=0.36), and this mutant was statistically indistinguishable from the 
either the wild type A/Victoria/3/75, or CPSF mutant of A/Victoria/3/75 in the level of luciferase 
induced with p values of 0.36 and 0.44.  
The levels of interferon driven by the stimulation of the interferon beta promoter by viruses with the 
A/Victoria/3/75 internal genes seemed greater affected by mutations at the CPSF site. The 
recombinant A/Victoria/3/75 virus with A/Victoria/3/75 NS1 lacking the consensus CPSF binding 
amino acids at 103 and 106 showed an elevated level of interferon induction, similar to that seen by 
a virus in which the entire segment was exchanged for a wild type A/PR/8/34 NS. The levels of 
interferon driven luciferase were statistically significant for the A/Victoria/3/75 virus encoding the 
A/PR/8/34 NS, and the recombinant containing the A/Victoria/3/75 CPSF 103/106 mutant (p= 0.017 
and 0.013 respectively), and the levels of interferon induced were statistically indistinguishable 
(p=0.73). 
Moreover, the levels of interferon induced could be brought under control upon mutation of the 
A/PR/8/34 NS1 to S103F I106M to facilitate CPSF binding, with the levels of luciferase activity now 
indistinguishable from that of the levels induced by infection with the wild type A/Victoria/3/75 virus 
with a p value of 0.46.  
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Figure 32. Interferon Induction of Recombinant influenza Viruses Evaluated Using A549-Luciferase 
Reporter Cell Line  
The panel of recombinant viruses for evaluation was expanded to include viruses encoding 
mutations at amino acids 103/106 in NS1. These were recovered with HA and NA of A/PR/8/34 to 
equalise binding and entry. Groupings of internal genes for the sake of this work were referred to as 
wild type despite this surface protein exchange. To aid analysis the viral samples have been colour 
coded. If they encode an NS1 known to strongly block reporter gene expression (Previous Chapter) 
they are red, if they weakly alter gene expression, or enhance they are coloured green 
The levels of interferon were measured for these viruses using A549-Luciferase cell line. Virus 
infections at an MOI of 3 were applied to the reporter cell line for 20 hours prior to harvesting, and 
assay for luciferase content. There was a statistically significant difference between the A/PR/8/34 
and A/Victoria/3/75 wild type viruses p=0.01, therefore all the viruses were compared to the wild 
type virus that they shared a polymerase complex with and this is the p value at the top of each data 
point. A/PR/8/34 Vic SI (p=0.44) has a statistically significant increase over the wild type A/PR/8/34 
which supports an abrogation of the ability to block interferon in the context of a genuine influenza 
challenge. However there was no statistically significant difference between the interferon signal 
levels generated by this virus the A/PR/8/34 (PR8 NS FM), between A/PR/8/34 (PR8 NS FM) and 
A/PR/8/34 (Vic NS) suggesting that overall the differences between the A/PR/8/34 are small. 
In the A/Victoria/3/75 virus group, A/Victoria/3/75 (PR8 NS) where p=0.02 and A/Victoria/3/75 (Vic 
NS SI) with a p value is 0.01 differed significantly from the parental virus. In contrast to the 
A/PR/8/34 data this supports an abrogation of the interferon control response in these viruses. P 
values of the luciferase signals for all infections relative to the mock samples were all significant. 
(data not shown)  
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3.5 Investigating the Mechanism behind Increased Levels of 
Interferon in Recombinant influenza Viruses that lack CPSF 
binding in their NS1 proteins. 
The data presented here established a model by which the levels of interferon induced in during the 
infection of a A549 reporter cell line could be modulated through the putative addition or removal of 
a CPSF interaction to the viral NS1 protein. Thus we speculated that the inherent polymerase activity 
might differ between the A/Victoria/3/75 virus and the A/PR/8/34 virus and that A/PR/8/34 virus 
would lack CPSF binding because it was not ‘required’ to control the rather modest levels of PAMP 
produced by this virus. (Das, Ma et al. 2008) The influenza viral polymerase produces the viral PAMP, 
which is recognised by the host cell as foreign, and it is the role of the NS1 protein to interact with 
either the PAMP, thereby limiting its availability to trigger PRRs, or with components of the antiviral 
apparatus preventing or limiting an effective response to this viral stimulus. It might be expected, 
that where variation in viral polymerase activity occurs, viral polymerases which are highly active will 
be paired with NS1 proteins which are able to conduct a global suppression of host antiviral gene 
products via a mechanism like CPSF. A less active polymerase complex would be able to rely on a 
single mechanism to control induced antiviral responses.  
 To measure the influenza virus polymerase activity in the context of infection by each of the 
recombinant viruses, an assay in which the viral polymerase drove expression and replication of a 
modified viral like mini genome was used. 
The influenza reporter construct contained the NS gene segment non-coding regions into which 
mutations in the promoter at nucleotides 3, 5 and 8 were introduced. These mutations increase the 
amplification of the viral like RNA (Neumann and Hobom 1995; Flick, Neumann et al. 1996; Flick and 
Hobom 1999) and are essential because mini genomes with wild type promoters are not amplified 
and expressed when driven by virus infection in our hands. 
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293T cells were transfected with the 3-5-8 promoter Luciferase construct, and then infected 24 
hours later at an MOI of 3 with each of the recombinant influenza viruses Figure 33. 
In contrast to what was expected, the activity of the A/PR/8/34 polymerase in this assay appears to 
be greater than the polymerase activity of the A/Victoria/3/75 and this difference is statistically 
significant p=0.017. 
Within the two groups of viruses, the A/PR/8/34 viruses which acquired the A/Victoria/3/75 NS 
segment, with either the wild type sequence, or that predicted to abrogate CPSF binding had a lower 
polymerase activity than the wild type A/PR/8/34 in this assay, and these decreases were statistically 
significant (p= 0.006 and 0.003 respectively). Abrogation of the proposed CPSF interaction in the 
A/PR/8/34 virus encoding the A/Victoria/3/75, through the 103/106 mutant did restore some 
polymerase activity in this assay, but this was not a statistically significant increase over the isogenic 
wild type segment in the A/PR/8/34 virus background. 
The addition of the CPSF binding function to the A/PR/8/34 NS1 protein in the background of the 
A/PR/8/34 virus did not affect the polymerase activity significantly as measured by this assay 
(p=0.67) and the levels of polymerase activity were therefore indistinguishable from that of the 
parental virus. 
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Figure 33 Evaluation of Influenza Viral Polymerase Activity Using a Transiently Transfected Viral 
Genome Like Reporter in 293T Cells 
293T cells were transfected for 24 hours with a reporter construct which generates a viral genome 
like RNA coding for a luciferase reporter gene flanked by the influenza NS segment non coding 
region, altered at nucleotides 3,5 and 8 in the promoter. Subsequent protein expression was then 
driven by viral infection at an MOI of 3 for 20 hours. The wild type A/PR/8/34 and A/Victoria/3/75 
panels of recombinant viruses were then evaluated. As luciferase expression was driven by the 
actions of the viral polymerase in the infection, this assay is a measure of the polymerase activity 
encoded by these viruses, and the variation in luciferase activity was then evaluated for its statistical 
significance. 
Significant variation was established between the polymerase activity of A/Victoria/3/75 and 
A/PR/8/34 wild type viruses (p=0.017). Within the A/PR/8/34 group of viruses, A/Victoria/3/75 
derived segments lowered the A/PR/8/34 polymerase activity as measured by this assay to a 
statistically significant degree (p values of 0.006 and 0.003). Conferring CPSF binding abilities to the 
A/PR/8/34 NS segment was not sufficient to induce this reduction however. 
Conversely in the A/Victoria/3/75 grouping, the A/PR/8/34 segment has the effect of increasing the 
polymerase activity in this assay (p=0.002). Reduction of CPSF binding efficiency in the 
A/Victoria/3/75 (Vic NS SI) is not sufficient to increase this level to that of A/PR/8/34, but the 
increase is significantly above that of A/Victoria/3/75 (p=0.03). There is no statistically significant 
difference between the luciferase activity generated by these two viruses with a p value of 0.6.  
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The most striking result was the high levels of mini genome amplification and expression driven by 
the virus with A/PR/8/34 NS gene segment in the A/Victoria/3/75 background. The signal from this 
virus infection was 4 times that from the wild type A/Victoria/3/75 isogenic control (p=0.017). It is 
possible that this increased polymerase activity, either contributes to or is entirely responsible for 
the increase in the amount of interferon stimulation measured in the A549 reporter gene assay 
(Figure 32). 
The transference of CPSF binding abilities to the A/PR/8/34 NS1 protein, in the context of an 
A/Victoria/3/75 virus, lowered the elevated polymerase activity measured by this assay, and 
although these levels were still significantly above the wild type virus (p= 0.007) these were also 
significantly different from the isogenic virus lacking the mutations at 103/106 in the A/PR/8/34 NS1 
protein (p = 0.003). The reduction in polymerase activity of this construct relative to the wild type 
isogenic control compares mirrors the reduction in luciferase signal and thus interferon induction 
which occurs in the A549-luciferase cell, and is in support of this assay being a measure of the 
amount of PAMP generated within the cell by the viral polymerase. 
3.6 Is there a Viral Cost to CPSF Binding? 
Surprisingly in previous experiments the growth kinetics of the A/PR/8/34 NS recombinant with the 
A/Victoria/3/75 virus, had a limited effect on the viral kinetics despite inducing the elevated levels of 
interferon modelled in a reporter cell line. Segment reassortment experiments have also established 
that these exchanges also affect the polymerase activity; which in some cases correlated with the 
modelled levels of interferon induced by these viruses. Therefore a further experiment was 
conducted to investigate if the measured alterations in polymerase activity had a consequence on 
the growth of the panel of recombinant viruses.  
The virus growth yield from an inoculation at a multiplicity of infection of 0.01 was investigated in 
the permissive MDCK cell line. After 24 hours, the supernatant containing released virus was 
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evaluated by titration on MDCK cells as described in the Materials and Methods, to quantify the 
yield which is displayed on a logarithmic scale in figure 34 in plaque forming units per ml (log 
PFU/Ml). 
Pairing A/PR/8/34 virus components with a wild type A/Victoria/3/75 NS segment results in a 
reduction of the viral yield by approximately 2 logs. This decrease was statistically significant 
(p=0.0003) and correlates with the decrease in polymerase activity measured in the transient 
reporter system and the slight decrease in interferon induction that was modelled in the reporter 
cell line. The isogenic version of this virus, which encoded a A/Victoria/3/75 NS1, engineered to be 
deficient in the CPSF binding abilities of the NS1 protein grew to a higher titre than the A/PR/8/34 
virus encoding the wild type A/Victoria/3/75 NS segment, and this increase was also statistically 
significant over the virus containing the wild type NS1 protein(p=0.01), but this increase of 
approximately 1 log in titre did not translate to a full recovery, therefore the yield of the A/PR/8/34 
virus with A/Victoria/3/75 encoding NS1 F103S M106I was still statistically distinct in yield from that 
of the wild type A/PR/8/34 virus (p=0.0004). This recovery in viral titre correlates with an increase in 
interferon production but does not correlate with an increase in the observed polymerase activity in 
this reporter assay.  
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Figure 34 Yield of Virus Obtained after 24 Hours from an Initial infection of MDCK Cells at an MOI 
of 0.01  
MDCK cells were infected with the viral recombinants at an MOI of 0.01, and then viral supernatants 
were harvested 24 hours later. The viral titre achieved was assayed by titration on further MDCK 
cells as described in the Materials and Methods. These have been plotted as a Log PFU/ml for each 
virus. All viral titres achieved were found to be both statistically distinct from the relative wild type 
virus, and the isogenic viruses within each virus group. This data generated does not correlate with 
either the reporter cell line or the polymerase assay data generated in the previous two figures.  
The two viruses which can not be distinguished on the basis of viral yield using a t test are 
A/Victoria/3/75 PR8 NS and A/Victoria/3/75 Vic NS SI.  
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The putative acquisition of CPSF binding engineered into the NS1 protein of an A/PR/8/34 NS 
segment, expressed in a A/PR/8/34 virus, surprisingly produced a virus yield that was intermediate 
between A/Victoria/3/75 and A/PR/8/34, and statistically different from both (p= 0.0006 and 
p=0.025 respectively), and this also correlates with the previously modelled polymerase activity and 
levels of interferon beta induced. The virus yield from this infection was also significantly different 
from that of the A/PR/8/34 virus encoding the A/Victoria/3/75 encoding an NS1 protein with the 
A/PR/8/34 amino acids at this locus (p=0.07). 
The A/PR/8/34 NS segment in the A/Victoria/3/75 virus shows a statistically significant decrease in 
virus yield at this time point. This virus has been shown in previous experiments to reach the same 
titre as wild type A/Victoria/3/75 viruses over the course of a growth analysis in both Human Airway 
Epithelial cells and previously in MDCK cells. However the yield at 24 hours was reproducibly 
reduced, therefore despite being a virus that was more active in the polymerase reporter assay, this 
virus appeared reduced in virion output in this experiment. 
The A/Victoria/3/75 virus encoding the A/PR/8/34 NS which had been altered in the NS1 gene to 
encode a protein proposed to bind CPSF, which exhibited reduced polymerase activity relative to the 
isogenic control which lacked this mutation had grew to the lowest titre, and this decrease was 
statistically significant compared to the wild type p =0.0003. 
 
Surprisingly, comparing the final titres achieved of the A/Victoria/3/75 virus to the A/Victoria/3/75 
virus encoding the mutated A/Victoria/3/75 segment with the F103S I106M mutation, demonstrated 
a statistically significant difference in viral yield after 24 hours. Taken together this suggests a 
scenario whereby this altered segment is having differing effects in different viral backbones, and in 
the context of one virus is able to alter yields, but unable in another. Such a scenario would be 
compatible with the idea that the NS1 protein interaction with CPSF, has not been ablated, and the 
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cognate polymerase complex is stabilising the CPSF interaction, thereby ameliorating the effect of 
the mutation. 
Viruses encoding the mutated NS segment from A/PR/8/34, behave in a statistically significantly 
different manner regardless of the backbone they are compared to 
In both cases the effect of exchanging the NS segment, for a segment encoding an NS1 protein which 
is able to block CPSF activities causes a reduction in the maximum titre achieved but the effects of 
NEP/NS1 cannot be excluded. 
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3.7 RNA analysis of the Panel of Recombinant Influenza Viruses 
 
These viruses had all been formulated with identical surface glycoproteins to facilitate equivalent 
entry efficiencies. These therefore shared a common sequence which could be used as an RNA 
target to establish the levels of expression of the three types of RNA expressed within a cell during 
an influenza virus infection.  
 
The virally driven reporter assay predominantly provides information about the levels of mRNA 
production within a cell which is a process known as transcription. The RdRp of influenza also has 
the job of directing replication and the effects of the segment reassortment may also affect this 
function. The alteration of replication kinetics may be responsible for the low viral yield of the 
A/Victoria/3/75 virus encoding the A/PR/8/34 NS with the S103F I106M mutation in the NS1 protein. 
 
Furthermore, the observation that the A/Victoria/3/75 virus encoding the A/PR/8/34 NS segment 
has enhanced reporter gene production was unexpected, this assay presented an opportunity 
investigate if this increase in polymerase activity could be mapped to a genuine viral segment 
transcript in the course of an infection. 
 
To evaluate the effects of the NS reassortments on the 2 other species of viral RNA present in an 
infected cell, 293T cells were infected with the panel of recombinant viruses at an MOI of 3, for an 
equivalent amount of time as for the virally driven promoter assay. The total cellular RNA was then 
isolated and evaluated for the relative abundance of the three RNA species using primer extension 
analysis, and an example of the resulting gel is presented in figure 35.  
 
The 5S RNA marker which was included in this assay demonstrates that equivalent cells were 
harvested for their RNA at the end of the first part of the experiment. This gel confirms the 
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observation that the A/PR/8/34 WT virus and the A/Victoria/3/75 WT have similar activity levels, 
with the A/PR/8/34 virus encoding a polymerase that is slightly more active which has been 
modelled in the luciferase reporter assay, although the distinction in that assay is more than is 
reflected by this gel image. 
 
Conversely to what was measured in the luciferase reporter assay however, the levels of polymerase 
activity appear elevated in this analysis for the viral reassortments which have occurred between the 
A/PR/8/34 and the A/Victoria/3/75 NS segment, with the greatest increase in RNA production 
measured in this assay for the A/PR/8/34 virus encoding the A/Victoria/3/75 NS with the mutations 
at amino acids 103 and 106.  
 
Analysis of all three species of RNA produced by the virus and probed by this assay was conducted 
using phosphoimage plates and a phosphoimage plate reader (Storm 860 GE Healthcare). The 
captured images were quantitated using ImageQuant version 5, and the data was processed using 
Excel as previously. The data was expressed relative to the signal generated by A/PR/8/34, and the 
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Figure 35 Primer Extension Analysis for Transcripts Derived from the HA Segment of A/PR/8/34 
and A/Victoria/3/75 Recombinant Viruses in Infected 293T Cells  
12 well plates were set up and infected at an MOI of 3, to mimic the conditions used for a the viral 
reporter luciferase reporter assay. After 20 hours the samples were harvested with Trizol reagent 
(Invitrogen) and RNA isolated. The RNA was then analysed by Primer extension analysis using HA 
specific primers, and the products were resolved on a 7M Urea, 6% PAGE run at 1000W for 2 hours 
using 1X TBE as the buffer. The subsequent autorad was an overnight exposure to Kodak MR film, at 
-80oC with an intensifying screen (Kodak).  
Gel demonstrates an increased level of polymerase activity for the A/PR/8/34 virus encoding the 
CPSF deficient NS1 protein. Other elevated levels of activity correspond to that of the A/PR/8/34 
with Vic NS, and these do not correlate with the results of the reporter assay. Furthermore, the 
A/Victoria/3/75 wild type, exhibits a higher activity than that of the A/PR/8/34 NS recombinant, 
which contradicts the interferon and the polymerase driven reporter data. 
The result displayed is representative of 3 gels, and 3 individual batches of RNA. 
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Figure 36 Primer Extension Evaluation of the m and cRNA Levels Inside 293T Cells Infected at an MOI 
of 3 for 20 Hours of a Panel Viral Recombinants 
The Raw data collected from the phosphoimage analysis was expressed as a percentage relative to 
the signal generated by A/PR/8/34. The resulting signals were analysed for statistical significance 
and only the A/PR/8/34 viruses with Vic and Vic SI were statistically significant.. The p value relative 
to A/PR/8/34 is shown. 
A -Quantitation of the Relative Levels of cRNA Expression derived from Primer Extension Analysis 
of HA Transcripts 
Primer extension analysis was conducted on RNA extracted from 293T cells, infected at an MOI of 3 
for 20 hours to mirror the conditions used for the polymerase driven expression system. The data 
from 3 separate RNA panels was evaluated relative to that generated by the A/PR/8/34 infection for 
the cRNA levels. There was no significant difference in cRNA levels between the A/PR/8/34 wild type 
and almost all of the viruses analysed in these assays. Statistically significant increases exist for the 
A/PR/8/34 Vic NS and A/PR/8/34 Vic NS SI viruses. 
 
B - Quantitation of the Relative Levels of mRNA Expression derived from Primer Extension Analysis 
of HA Transcripts  
Primer extension analysis was conducted on RNA extracted from 293T cells, infected at an MOI of 3 
for 20 hours to mirror the conditions used for the polymerase driven expression system. The data 
from 3 separate RNA panels was evaluated relative to that generated by the A/PR/8/34 infection for 
the mRNA levels. 
A statistically significant increase was seen for A/PR/8/34 Vic NS and A/PR/8/34 Vic NS SI viruses as 
for the cRNA.  
The A/Victoria/3/75 PR8 NS showed a statistically significant decrease which is entirely opposite to 
what was observed in the polymerase assay using the 3-5-8 luciferase reporter.   
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Figure 37 Evaluation of the Relative Value of the vRNA Signals from Primer Extension Analysis 
Conducted on the HA Segment of a Panel of Viral Recombinants 
The raw data collected from the phosphoimage analysis was expressed as a percentage relative to 
the signal generated by A/PR/8/34 for the vRNA. The resulting signals were analysed for statistical 
significance and showed statistically significant increases in the levels of vRNA for A/PR/8/34 (Vic NS) 
A/PR/8/34 (Vic NS SI) A/Victoria/3/75 (PR8 NS) and A/Victoria/3/75 (PR8 NS FM) infections.  
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The results of quantitation (shown in figures 36 and 37) allow values to be placed on the increases or 
decreases observed in the autorad. The most consistent statistical differences were observed for the 
A/PR/8/34 based virus encoding a Vic NS or a Vic NS SI, which were the ones which gave the 
strongest bands on the gel exposure, and this is a surprising result as these were viruses 
unremarkable in their interferon induction, polymerase assay yield, or yield of infectious virus after 
24 hours. 
Infact, the virus with the greatest signal in the polymerase reporter assay is the virus which shows a 
statistically significant decrease in mRNA signal by primer extension analysis, and the virus which 
drove a similar level of protein production in this assay, the A/Victoria/3/75 Vic SI, was also down in 
mRNA production, though not to a statistically significant degree.  
A similar inconsistency exists when comparison is made between the vRNA signal of the 
A/Victoria/3/75 PR8 NS FM and the virus yield assay, where this was one of the lowest virus yields 
achieved, but ranks second for the level of vRNA produced at nearly double that of A/PR/8/34.  
The true nature of these differences and discrepancies is difficult to piece together from these 
separate figures so has been assembled into a table (Figure 38) 
To make comparisons easier the viruses have been expressed as 2 groups, with A/PR/8/34 values 
being set to 1, and A/Victoria/3/75 values also set to 1, and the viruses formed from these parental 
viruses compared to them.  
  




Figure 38 Summary Table Highlighting the Biological Outcomes for 4 Separate Assays of Biological 
Activity  
The salient points of data were summarised for the 4 different assays used to quantitative the effect 
of CPSF mutations on the growth characteristics of the resultant recombinant viruses.  
The viruses were grouped into 2 groups based on the source of their internal genes, and the data 
points which correspond to a decrease in a given property are coloured pink. On occasions where 
data points are equal or greater than they have been left clear. In all cases the exchange of the NS 
segment in the parental A/PR/8/34 virus reduced viral yield at the point at which the viruses were 
harvested and lowered the polymerase activity levels as measured in the 3-5-8 reporter assay. The 
same viruses generated equal or greater than levels of HA transcript as evaluated by Primer 
Extension analysis. The reductions in polymerase activity for the A/PR/8/34 group in general 
correlate with a decrease in interferon levels. 
For A/Victoria/3/75 based viruses the increase in polymerase activity modelled by virus encoding the 
A/PR/8/34 segment 8 is not consistent with the Primer Extension Analysis.  
Consequently the relationship between these 4 assays has yet to be properly established.  
 
 




Summary Table Highlighting the Biological Outcomes 
for 4 Separate Assays of Biological Activity
Titre in MDCK 






Assay cRNA mRNA vRNA
A/PR/8/34 WT 1.78E+07 1.00 1.00 1.00 1.00 1.00
A/PR/8/34 (Vic NS) 7.83E+04 0.31 0.71 1.83 2.36 1.27
A/PR/8/34 (Vic NS SI) 5.83E+05 0.40 0.75 5.72 4.52 3.35
A/PR/8/34 (PR8 NS FM) 1.50E+06 0.98 1.06 1.02 1.24 0.95
A/Victoria/3/75 WT 3.13E+05 1.00 1.00 1.00 1.00 1.00
A/Victoria/3/75 (PR8 NS) 2.65E+04 8.69 2.40 0.95 0.76 1.44
A/Victoria/3/75 (Vic NS SI) 3.73E+04 3.27 2.46 1.04 1.04 0.84
A/Victoria/3/75 (PR8 NS FM) 3.65E+03 2.90 1.32 1.30 1.46 1.73




3.8 Conclusion  
The interaction of NS1 protein of A/Udorn/72, an NS1 protein up to 97% identical to 
A/Victoria/3/75, with components of the host mRNA 3’ mRNA maturation apparatus has been 
extensively studied. The importance of this interaction to the virus has been proposed as the 
structural mechanism for the control of host interferon (Das, Ma et al. 2008). 
This then raised the question which was the starting point for this chapter, why don’t all influenza 
viruses encode this CPSF binding property into their NS1 protein? Indeed, it was demonstrated by 
this work that the result of the artificial reassortment of an NS segment coding for an NS1 protein 
which blocks reporter gene expression does result in a lowering of interferon induction, and the 
reverse scenario results in a logical increase of interferon induction (Figure 29). However, the levels 
by which interferon stimulation increase, do not translate into a deficiency in viral growth 
phenotype as assayed in both MDCK cells and the more stringent HAE cultures (Figures 30 and 31). 
Indeed, in the case of the A/PR/8/34 virus the converse appears to be the case, and acquisition of a 
CPSF binding NS1 protein retarded viral growth in a 24 hour viral yield assay (Figure 34) which was a 
highly unexpected finding if the CPSF binding property is advantageous. 
The relative lack of attenuation resulting from loss of CPSF binding by NS1 is in agreement with data 
which suggested that although NS1 proteins do have differences in their abilities to control 
interferon, they were still able to control interferon driven by artificial stimuli when expressed 
transiently from plasmids. However, neither of the two different challenges utilized entirely 
recapitulates the environment inside an influenza virus infected cell. Newcastle Disease Virus 
replicates in the cytoplasm of infected cells and notoriously triggers large amounts of interferon 
production in mammalian cells because it lacks an antagonist of this response (Park, Garcia-Sastre et 
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al. 2003). In contrast, influenza virus replicates in the nucleus and therefore the viral PAMP may not 
contact the cytoplasmic pathogen pattern receptors until much later in infection.  
Furthermore, the synthetic product poly I:C contains a nucleotide inosine which is thought to be at 
low concentration in the cell, and is unlikely to be present in long nucleotide strands binding to 
cytosine. It has not been proven that influenza viruses produce dsRNA in the course of their 
replication so the validity of this stimulus could be also be questioned (Weber, Wagner et al. 2006). 
Therefore the ability of influenza NS1 to block a poly I:C pathway does not necessarily reflect a 
property of the viral NS1 that is biologically relevant, and this data has to be analysed with caution. 
To investigate the consequences of CPSF binding by NS1 protein that do not usually possess this 
function, an attempt was made here to correlate interferon induction, viral polymerase activity on 
an artificial promoter based on the NS gene segment and the bona fide viral RNA transcripts for the 
HA segment accumulating in infected cells, following infection by recombinant viruses. However 
although this data showed patterns that indicated that the CPSF binding phenotype mattered, 
discrepancies were apparent. For example the A/Victoria/3/75 recombinant virus with the PR8 NS 
segment had enhanced luciferase signal for the reporter gene assay, which provided an explanation 
for the increase in luciferase signal measured in the A549 reporter cell line. However by primer 
extension analysis this virus showed a lower level of HA transcripts at 20 hours post infection 
implying a lower polymerase activity and this did not correlate with the growth outcomes measured 
in this work. 
Conversely the elevated levels of interferon induced by the A/PR/8/34 virus encoding the 103/106 
mutant of A/Victoria/3/75, translated to a lower polymerase activity on the artificial promoter, a 
lower than wild type yield of virus in the 24 hour growth experiment, but surprisingly an enhanced 
accumulation or production of HA mRNA transcripts as analysed by primer extension.  
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This work may support the notion that the exchanging NS segment resulted in differing effects, 
depending upon the choice of viral gene assayed. Indeed the only assay for the whole virus is the 
growth yield at 24 hours assay, which is a comparatively blunt, but biologically relevant read out. In 
future work utilizing other measures and whole animal models might help to elucidate the effects of 
the NS1 protein on the biology of the virus.  
Taken together, this data supports the notion that altering a virus’ ability to bind CPSF does alter the 
phenotype of the virus. Based on growth of virus at 24 hours this suggests that viruses such as 
A/PR/8/34 and A/Victoria/3/75 have evolved to work efficiently with their native NS, and exchanges 
of segment can be problematic for the virus and have undesirable outcomes in terms of interferon 
induction, and growth yield. It is likely that such mixing events that occur during reassortment or 
host species jumps result in rapid evolution of NS1 to accommodate the new host as well as the new 
polymerase constellation  
 
An interpretation of this work is that taken together these findings point to a dysregulation effect, as 
a consequence of pairing potentially incompatible replication and interferon moderating 
components together in a single virus. The surprising effects measured here are reminiscent of those 
measured by Ma et al, (2010) who observed that H7N7 reassortment viruses in which NS gene 
segments were exchanged resulted in unpredictable alterations in viral phenotypes. 
Finally, a difficult in interpreting the reverse genetics data is that one of the proteins coded for by 
the made by the NS segment is able to act to modify the activity of the polymerase complex (Bullido, 
Gomez-Puertas et al. 2001; Robb, Smith et al. 2009). At this time this is assumed to be the NS1 
protein as a 2 amino acid substitution in the A/PR/8/34 NS1 protein was sufficient to both reduce 
the interferon and down regulate the polymerase activity, but we have not excluded that the 
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different NS segments, and the effects of alterations at 103/106 result in different levels of NEP 
being made, and these contribute to these effects. 
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Chapter 4: An Investigation into the 





In 2009 a new variant influenza virus entered the human population from a swine reservoir, which 
was a novel strain containing a gene constellation which had not previously become successfully 
established in the human population. The virus contains gene segments derived from the classical 
swine H1N1 virus lineage, which had persisted in the swine population since at least 1930. In the 
mid-1990s this virus had reassorted with an avian virus and acquired an avian PA and PB2. A 
subsequent reassortment event led to acquisition of HA, NA and PB1 gene segments from a human 
virus to produce the first swine triple reassortant virus. Viruses with the TRIG constellation of genes 
seem very successful in their swine hosts and have also sporadically infected humans since around 
1998. Typically these cases were isolated infections and confined to individuals with recent or 
frequent close contact with agricultural environs. Further reassortment events, likely occurring in 
late 2008, brought a TRIG-like virus with the H1 from the North American swine population, 
alongside an N1 NA and M genes from the Eurasian lineage of swine influenza viruses. This virus 
became capable of sustained human-to-human spread, and constituted the 2009 pandemic H1N1 
virus (Arias, Escalera-Zamudio et al. 2009; Brockwell-Staats, Webster et al. 2009), which caused the 
first pandemic for forty years (Fraser, Donnelly et al. 2009).  
In most animal models, H1N1 2009 infections produced a high degree of pathology (Itoh, Shinya et 
al. 2009) intermediate between that of the circulating seasonal H1N1 viruses and the highly 
pathogenic H5N1 viruses (van den Brand, Stittelaar et al. 2010).  
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These observations are consistent with an analysis of the pulmonary pathology upon autopsy in fatal 
cases of H1N1 infection (Gill, Sheng et al. 2010). However out of millions of people infected 
worldwide, there are only around 20,000 confirmed fatalities and most infections resulted in mild 
illness, or were even subclinical. In vitro, infection of human macrophages and dendritic cells with 
the new variant 2009 virus did not induce a significant level of secreted cytokines (Osterlund, 
Pirhonen et al. 2010), in contrast to the situation seen for the highly pathogenic avian influenza 
H5N1 (Cheung, Poon et al. 2002). The NS1 protein is a major virulence factor for influenza viruses 
(Jackson, Hossain et al.; Ma, Brenner et al. 2010), so the emergence of a novel virus presented an 
opportunity to investigate the contribution that the NS1 protein made to the viral phenotype.  
The NS cDNA for the new pandemic H1N1 strain was cloned, to allow the comparison of this protein 
to those previously dissected in this thesis. The prototypical strain of the pandemic H1N1 chosen for 
this work was A/England/195/09. This strain was isolated from a 22-year-old male traveller, who 
upon return from a trip to Houston Texas on the 27 April 2009 to London Heathrow Airport 
presented with an acute respiratory infection. The reported symptoms for this patient included 
fever, sneezing, cough, vomiting, shortness of breath, chills, sore throat, fatigue, muscle aches, 
rhinorrhoea, loss of appetite, headache and dry cough. The patient did not present with diarrhoea or 
conjunctivitis, and the clinical signs associated with his infection are representative of the majority of 
mild influenza cases reported at the height of the first and second waves of the pandemic. A reverse 
genetics system to allow the recovery of A/England/195/09 from cDNA was then established in the 
Barclay influenza lab at Imperial College. The in vitro growth properties of reverse genetics Eng195 
virus were equivalent to those of the original low passage clinical isolate stock obtained from the 
Health Protection Agency (Ruth Elderfield, unpublished data not shown).  
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4.2 Sequence Analysis of the NS1 protein  
 
The NS1 protein sequence of A/England/195/09 was aligned using the online version of Clustal 
2.0.12 accessed at http://www.ebi.ac.uk/clustalw to the protein sequences of A/PR/8/34 and 
A/Victoria/3/75 which are examples of a laboratory-adapted influenza strain and a well-
characterised human isolate respectively. The NS1 protein of A/England/195/09 was eleven amino 
acids shorter than the PR/8/34 NS1 reference sequence which has the typical NS1 length of 230 
residues (Figure 39).  
Variation in the length of NS1 proteins is known to occur, for example NS1 of a recent equine strain, 
A/Newmarket/5/03 is 219 amino acids, and the NS1 of an older avian strain A/Duck/Czech/56 was 
previously noted to be short (Hayman, Comely et al. 2007). The shorter length of NS1 of 
A/England/195/09 was representative of many other 2009 pandemic strains whose sequences were 
published in the database. This eleven amino acid truncation is due to a premature stop codon and 
not the deletion of a nucleotide sequence as has been known to occur in H5N1 NS segments (Li, 
Wang et al. 2010). Both types of truncations preserve the integrity of the NEP sequence at this locus 
which highlights the essential nature of this second segment-8-encoded gene. A summary of this 
data is included in the appendix.  
  
223 | P a g e  
 
Figure 39 Sequence alignment of A/PR/8/34, A/Victoria/3/75 and the pandemic H1N1 NS1 protein 
A/England/195/09 
Alignment of A/PR/8/34, A/Victoria/3/75 and A/England/195/09 using the CLUSTAL 2.0.12 tool 
available from www.ebi.ac.uk/clustalw reveals the extent to which these NS1 proteins share 
sequence homology. The N terminus, in common with the other NS1 proteins investigated, shows a 
high degree of homology. The N terminal RNA binding amino acids are absolutely conserved.  
The effector domains between the different NS1 proteins are more variable, both in length and 
composition. The A/England/195/09 NS1 protein is shorter, meaning it lacks the second NLS/NoLS, 
which is present in A/Victoria/3/75 and partially preserved in A/PR/8/34. Restoration of the full 
length NS1 sequence does not enhance virulence or replication (Hale, Steel et al. 2010). 
The consensus CPSF binding amino acids are present at amino acids 103 and 106, and additional 
amino acids highlighted in blue are distributed through the effector domain. 
Binding to TRIM25 requires amino acids present at 96/97 and 196, which straddles the PKR binding 
amino acids shown here in red, and the Nuclear Export Signal (NES) shown here in green.  
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The NS1 of 2009 H1N1 virus lacks the C terminus. This domain in full length NS1 proteins may 
contain PDZ and CRC domains, which have been reported to have a role in controlling apoptosis of 
an infected cell in the case of avian influenza viruses (Liu, Golebiewski et al. 2010), and also as a 
determinant of virulence (Jackson, Hossain et al. 2008) in a virus strain and host-dependent manner 
(Zielecki, Semmler et al. 2010). The PDZ and Crk/CrkL SH3 locus both overlap with the C terminal 
nuclear/nucleolar localisation signal and these features are all missing from the A/England/195/09 
sequence as shown in Figure 39. Restoration of a full-length NS1 protein by removal of the stop 
codon did not enhance replication or virulence (Hale, Steel et al. 2010). 
Furthermore, a recently-described mechanism that promotes the stabilisation of NS1 proteins is not 
present in the pandemic NS1 protein. SUMO modification of amino acids 219 and 221 in the C 
terminal NLS of NS1 proteins has been reported (Xu, Klenk et al. 2011). The C terminal truncation of 
NS1 from A/England/195/09 means that this modification will not occur, despite the presence of K at 
amino acid 219. Restoration of the sequence to restore the second K at the 221 locus in H1N1 2009 
NS1 protein did not restore sumoylation. Therefore it seems likely that this particular NS1 protein 
has an additional mechanism to protect it from degradation.  
The NS1 RNA binding domain and importin α binding site stretching from amino acid 35 and amino 
acid 41 is absolutely conserved between the three NS1 proteins aligned in Figure 39, therefore it is 
expected that the H1N1 2009 NS1 protein would enter the nucleus efficiently. Furthermore, the 
A/England/195/09 NS1 protein has the two consensus amino acids at 103 and 106 which have been 
experimentally proven to promote the ability of NS1 proteins to bind CPSF (Kochs, Garcia-Sastre et 
al. 2007). From this it is predicted that this NS1 protein would be able to limit host gene expression 
using this mechanism, and combining this with the intact NLS, the NS1 protein should efficiently 
accumulate in the nucleus in a manner similar to the A/Victoria/3/75 NS1. 
The sequence of the NS1 protein proposed to bind PKR is between amino acids 123 and 127, and the 
consensus amino acids responsible for this binding property have been highlighted in Figure  39.  
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RIG-I and Trim 25 
 
RIG-I is the major pattern recognition receptor in mammalian cells responsible for the detection of 
an influenza A infection. Up-regulation of RIG-I has been shown to be a successful strategy to 
counter the replication of the pandemic strain of influenza supporting the critical role of this antiviral 
host factor for the host to defend against this emergent strain, as well as other strains of influenza 
(Ranjan, Jayashankar et al. 2010). The effects of the RIG-I protein during an influenza infection are 
countered by the NS1 protein, because the influenza A NS1 protein specifically inhibits TRIM25-
mediated RIG-I CARD domain ubiquitination. This occurs through an interaction involving the amino 
acids 96 and 97 of influenza A NS1 proteins with the coiled coil domain of TRIM25, blocking TRIM25 
multimerisation, a necessary process for the activation of the ubiquitinylation function of this 
protein (Gack, Albrecht et al. 2009). These two amino acids are highly conserved in influenza A NS1 
proteins as a double EE amino acid motif at 96 and 97, and as shown in Figure  39 this is also the 
case for the NS1 of A/England/195/09. The interaction between TRIM25 and the NS1 protein is also 
abrogated if the conserved RNA binding abilities conveyed by amino acids R38 and K41 are 
disrupted. However it is unclear if it is the RNA binding by NS1 per se that is important, or the 
consensus amino acids at this locus which may interact with another partner, as the substitution of 
R38K which would preserve RNA binding (Wang, Riedel et al. 1999) but alter the amino acid 
composition of this binding site has not been investigated. 
 
A further amino acid which is important for the NS1 protein to prevent IRF-3 activation is located at 
amino acid 196. Alteration of this amino acid from a K to an E in an A/Udorn/72 NS1 protein restored 
TRIM25 binding to a virus whose NS1 was previously unable to effect this interaction (Kuo, Zhao et 
al. 2010). The location of the amino acid important to TRIM25 binding and inhibition of RIG-I 
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mediated IRF-3 activation is highlighted in Figure  39 and is also conserved in the A/England/195/09 
NS1 protein. 
The direct interaction of RIG-I and NS1 from influenza A has also been reported (Pichlmair, Schulz et 
al. 2006; Guo, Chen et al. 2007; Opitz, Rejaibi et al. 2007) and mapped to residue R38. The 
conservation of this amino acid and of those important to TRIM25 binding, implies that the NS1 from 
A/England/195/09 will be competent at controlling interferon induction in a manner reminiscent of 
the other viruses assayed thus far. 
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4.3 Database Evaluation of the Swine NS1 Population 
 
To eliminate the possibility that the A/England/195/09 NS1 protein chosen was atypical in its 
properties, a brief in silico analysis was done investigating the variation in sequences of NS genes of 
pandemic H1N1 2009 viruses available in the database. Using the Basic Local Alignment Search Tool 
or BLAST, over 100 identical sequences were retrieved from samples obtained globally, which 
supports the hypothesis that the protein selected represents a typical segment isolated during the 
H1N1 pandemic of 2009. This analysis did not investigate any subsequent evolution of the NS 
segment upon entry to the human population, but merely confirmed the homology of this sequence 
at the approximate start of the pandemic. The subsequent evolution of the viral NS gene is currently 
being documented in the ongoing Mechanisms of Severe Acute Influenza Consortium (MOSAIC) 
investigation, which is likely to present its findings within the next two years 
(http://clinicaltrials.gov/ct2/show/NCT00965354 retrieved 18 December 2010). 
Despite the large number of sequences returned by this BLAST search, it was unclear as to the extent 
to which the 219 amino acid length of the NS1 protein coded for by this segment reflects the 
distribution in length of NS1 proteins in human and swine hosts present in the NCBI database. 
Truncations of NS1 proteins have previously been described in both influenza A and B viruses which 
were competent at growing efficiently in the laboratory (Buonagurio, Krystal et al. 1984; Norton, 
Tanaka et al. 1987), and H7N7 viruses with an extensive passage in avian hosts were also found to 
accumulate truncations in this gene (Dundon, Milani et al. 2006) but these studies have not directly 
involved viruses of a human or swine origin. 
Using the database query tools at http://www.ncbi.nlm.nih.gov/genomes/FLU/Database/nph-
select.cgi?go=database accessed through the Los Alamos Influenza Virus resource, the variation in 
sequence length was explored further (data search conducted 18 December 2010). The results are 
presented in Figure 40. A search function including all the influenza virus subtypes and hosts, with 
no geographical or temporal exclusions retrieved 13,863 sequences. The default search parameter 
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which excluded laboratory strains was maintained, as some of these viruses had been altered 
genetically for the purposes of research, and identical sequences entered into the database were 
not excluded. The sequences were divided into two groups; NS1 proteins greater than 100 amino 
acids but less than or equal to 219 amino acids in length; and those NS1 proteins between 220 and 
237 amino acids in length. Approximately one third of the NS1 sequences which are available in the 
NCBI database are between 100 and 219 amino acids in length (Figure 40A). 
The dataset was then queried to establish how many of the entries available were of a swine or 
human origin which then carried forward 7,318 protein sequences as shown in Figure 40B, and this 
revealed that 10% of the NS1 proteins had been derived from a virus sequenced from a swine host 
compared to 90% from a human host. This large difference in entry numbers may represent a 
difference in the levels or type of surveillance occurring in these two influenza host populations, or 
the choice of the general database NCBI, over other influenza resources such as GSAID. 
The data was then sorted into human and swine host-derived populations, and of the 704 swine 
origin NS1 protein sequences available in NCBI, 68% were between 100 and 219  
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Figure 40 Analysis of NS1 protein length of sequences stored in NCBI database 
Figure A Frequency of truncated NS1 sequences in NCBI database 
Of 13,863 NS1 protein sequences annotated in the database, 32% were found to be in the region 
100-219 amino acids in length, suggesting that the NS1 protein of A/England/195/09 is not unique in 
being a short NS1 protein. 
Figure B Distribution of virus host data in the NCBI database 
Restricting the dataset to just human and swine host data, 10% of the sequences retrieved were of a 
swine origin, and 90% were from viruses which infected humans. Number of sequences evaluated 
was 7,318. 
Figure C Frequency of truncated NS1 proteins from all virus subtypes in swine host 
Of the 704 sequences retrieved as swine in origin, these were evaluated for their length distribution, 
and full length NS1 proteins were in the minority.  
Figure D Variation in the length of swine NS1 H1N1 protein sequences 
H1N1 viruses have persisted in swine since 1930 (Brockwell-Staats, Webster et al. 2009); the 
prevalence of the two groups of NS1 lengths in the available sequences was examined, and again the 
full length NS1 proteins were found to be in the minority. 
Figure E Variation in the length of swine NS1 H3N2 protein sequences  
The prevalence of full length sequences was much more abundant in the H3N2 subtype, and the 
distribution in swine was almost 50/50., although the sample size for this subtype was the smallest 
of the panel examined As a consequence of the increased level of entries of sequences into the 
database as a result of the emergence of the pandemic H1N1 there is a bias in the distribution of the 
protein lengths present  
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amino acids in length, compared to the 32% minority which were longer than 220 amino acid 
residues. 
The distribution of the NS1 protein lengths in the swine host was then evaluated for two of the 
subtypes known to infect swine, H1N1 and H3N2, which represent two of the predominant subtypes 
which are found in the human population. Figures 40E and 40F demonstrate that truncated NS1 
proteins are more common in H1N1 swine viruses than in H3N2 swine viruses; where 73% of H1N1 
swine influenza viruses have truncated NS1, only 48% of swine H3N2 strains do. The data derived 
from viruses isolated from a human host was then evaluated. Of the protein sequences annotated in 
NCBI as human, 43% were of the shorter form, and 57% were the longer form of NS1 protein (Figure 
41A). These data were then further sorted to produce an H3N2 population, and an H1N1 population, 
and evaluated for their relative abundance in these two virus subtypes. 
Interestingly, the human H1N1 virus population, which constituted 3,817 sequences retrieved, had a 
bias of 73% to 27% truncated to full-length, which was unexpected (Figure 41B). This suggests that 
the typical length distribution of NS1 in human H1N1 viruses may be similar to that of swine origin 
H1N1 viruses, and suggests that the truncated form of the NS1 protein is not unusual for a human 
infection, nor a feature unique to swine viruses. In contrast to this, only 1% of the NS1 proteins 
which are annotated in the database from a human H3N2 virus subtype were truncated, which 
corresponds to 16 truncated NS1 sequences, of the 2,342 retrieved (Figure 41C).  
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Figure 41 Analysis of NS1 protein length of sequences stored in NCBI database 
 
Figure A distribution of NS1 length in all subtypes isolated from a human host 
The distribution of NS1 lengths in the human host resembled the distribution shown in Figure 2 E, 
with an approximately 60/40 split in the full-length/truncated proteins. 
Figure B Distribution of NS1 length in H1N1  
The majority of the NS1 proteins coded for by H1N1 viruses isolated from a human host and present 
on the NCBI database were of the truncated form (73% of 3,817). 
Figure C Distribution of NS1 length in H3N2 viruses isolated from a human host The majority of the 
NS1 proteins isolated from a human host were full-length NS1 proteins. 1% or less of the sequences 
isolated (n=2,432) were of the truncated form. 
Figure D Variation in the length of human NS1 H1N1 protein sequences prior to 140209 
(compare B and D). Excluding the sequences entered into the database post 140209, results are in a 
distribution similar to that for human H3N2 viruses. The same constraint performed on H1N1 viruses 
from a swine source does not greatly alter the proportions of truncated to full-length NS1 proteins 
isolated from a swine host. 
Figure E Variation in the length of human H1N1 protein sequences from 150209 
Of the 2,778 human sequences entered into the database from 150209-181210, 96% of these 
sequences were truncated, which is something that was unusual prior to 2009 (compare D and F). 
The increase in frequency of occurrence or a sampling bias resulted in the new sequences masking 
the previously measured frequency of these truncated NS1 proteins (compare D and B). 
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The difference in relative abundance of truncated NS1 proteins could be due to a genuine 
differences in the functions of the NS1 proteins required between the two different virus subtypes, 
with truncated NS1 proteins providing an evolutionary advantage in one virus background compared 
to another, or this could be a bias introduced into the dataset by increased levels of surveillance as a 
result of the emergence of the pandemic strain. Indeed, limited or weighted sampling has been 
highlighted as a constraint on the data analysis to determine the origins of the H1N1 pandemic 
strain (Gibbs, Armstrong et al. 2009).  
 
Therefore, taking 15 February 2009 as the start of the epidemic (the date reported by Fraser et al, 
(2009) as being the first reported human case, and likely the start of the entry of a large amount of 
new information into the databases), 14 February 2009 was employed as filtering date to exclude 
newer data. After re-plotting the data to exclude this panel, the predominant length of NS1 proteins 
in the H1N1 viruses on NCBI was between 220 amino acids and 237 amino acids, as shown in Figure 
41D.  
However this adjustment did not significantly alter the distribution of H1N1 NS1 protein lengths in 
swine-origin influenza viruses (Figure 41E). The conclusion from this is that the shorter length of the 
A/England/195/09 NS1 protein is typical of the majority of swine-origin NS1 proteins, particularly of 
the H1N1 subtype. This conclusion is in agreement with a similar analysis published by  Dundon and 
Capua (2009), who also assigned NS1 protein length variation types to different influenza virus hosts. 
 
Since the newly-emerged H1N1 2009 strain has displaced the incumbent strains of seasonal H1N1 
influenza which were circulating in the human population (Tang, Lee et al. 2010), the proportion of 
full length NS1 proteins in H1N1 human isolates entered on the database since 15 February 2009 is 
very small, at only 4% (Figure 41F). Presumably these 114 sequences out of the 2,778 queried were 
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‘tail end’ sequences from previously circulating seasonal H1N1 strains that had been isolated prior to 
the pandemic but have since been displaced by the new virus. 
  
A limitation of this data analysis is that these levels include all the NS1 protein sequences in the 
database with no temporal exclusions. This was designed to allow the inclusion of the widest range 
of NS1 proteins possible and this data looks at these protein sequences in isolation of the other 
influenza virus genes and does not address the similarity of the gene populations investigated. In 
these searches identical sequences were not excluded, and this may result in the over 
representation of strains where a disease outbreak investigation has resulted in multiple data 
entries from effectively one source.  
While the predominant form of NS1 proteins in the swine host is the truncated form, in the human 
host prior to the entry of the pandemic strain this was not the case, although Figure 41E does 
indicate that there were truncated human H1N1 human viruses in the database before the 
pandemic. It is interesting to speculate whether the persistence of the pandemic-origin virus in the 
human population may also be accompanied by the restoration of the additional carboxy terminal 
amino acids presently missing from the NS1 protein, either by point mutation of the stop codon or 
by reassortment with another circulating virus. Supplementary data included in the Appendix 
suggests that the longer lengths of NS1 proteins predominate in virus subtypes isolated from other 
influenza virus hosts. 
4.4 Confirmation of the Lack of CPSF binding by NS1 protein of 
pandemic 2009 H1N1 influenza 
 
The NS1 protein of a much studied prototype H1N1 2009 pandemic strain, A/California/04/09, was 
cloned and evaluated by Hale et al. (2009). The protein did not repress luciferase gene expression 
when co-expressed in 293T cells, and was also unable to bind the F2F3 fragment of CPSF. The 
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rational mutation of amino acids at 108, 125 and 189 following predictions based on molecular 
modelling and conventional sequence analysis restored this interaction. The inability of the wild type 
NS1 protein from the A/California/04/09 virus to block the expression from a luciferase reporter 
gene, is a feature in common with the NS1 protein from the A/PR/8/34 virus used by Salvatore et al 
and work presented in an earlier chapter of this thesis using the NS1 proteins from A/Teal/317/97 
and A/Duck/Ukraine/63. 
The NS1 protein of the A/California/04/09 virus is identical in sequence to the NS1 of 
A/England/195/09. Furthermore the NS1 protein from A/PR/8/34 which is also unable to block host 
gene expression acts to enhance translation of proteins (Salvatore, Basler et al. 2002) and work 
presented in chapter 1 of this thesis demonstrated that A/Teal/317/97 and A/Duck/Ukraine/63 NS1 
proteins were also able to enhance translation.  
Therefore to evaluate if the A/England/195/09 NS1 protein was also able to enhance translation, the 
cDNA was cloned and the co-expressed protein was evaluated for its ability to enhance the 
translation of a luciferase reporter gene. As shown in Figure 42 the expression of A/England/195/09 
NS1 enhanced translation (p=0.02), at least as efficiently as that of A/PR/8/34 or A/Teal/317/97 NS1 
proteins. These effects are in support of data presented by Hale et al, (2009) showing that this NS1 
protein is unable to bind CPSF.  
Surprisingly the accumulation of A/England/195/09 NS1 protein itself was not as enhanced as for the 
other NS1 proteins that lacked CPSF binding. Western blot analysis showed that the slightly smaller 
Eng195 NS1 protein accumulated in the transfected cells to a lesser extent than the NS1 proteins of 
A/PR/8/34, A/Teal/317/97 or A/Duck/Ukraine/63 viruses. It may be that the truncation of the 
A/England/195/09 protein renders it unstable in the absence of other viral components. 
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Figure 42 the effect on luciferase activity from co-expression with range of NS1 proteins in 293T 
cells 
The effect on translation was evaluated in 293T cells as measured previously. Briefly, 293T cells were 
transfected with 0.25µg pCAGGS Luciferase, 1µg pCAGGS NS1 or Empty Vector and 2.75µg pcDNA 3A 
plasmid. After 48 hours the samples were lysed with reporter lysis buffer (Promega). The resultant 
supernatant was clarified by centrifugation and a proportion diluted 1 in 100. 10µl was then assayed 
for luciferase activity and the data presented relative to the empty vector sample. The NS1 protein 
of A/England/195/09 enhanced translation to levels equivalent to A/PR/8/34 (p=0.6). The levels of 
translational enhancement were significant for A/PR/8/34 (p=0.0001), A/Duck/Ukraine/63 (p=0.03) 
and A/Teal/317/97 (p=0.002) and A/England/195/09 (p=0.02). The data presented are 
representative of three separate experiments.  
 
The expression of the NS1 proteins in these lysates was evaluated using western blotting and anti-
sera against the V5 epitope (ABD Serotec) as described in the materials and methods. The expression 
of A/England/195/09 was difficult to establish in these experiments, and appeared to be equivalent 
to A/Victoria/3/75.  
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4.5 The localisation of A/England/195/09 NS1 Protein in Vero 
Cells 
 
Data presented in Chapter 1 established that different NS1 proteins expressed from the pCAGGS 
plasmid accumulated in difference cellular compartments. NS1 proteins which inhibited the 
expression of the reporter gene, likely though an interaction with the host CPSF, were seen to 
accumulate strongly in the nucleus. NS1 proteins which enhanced translation were also able to 
occupy the nucleus, but accumulated in the cytoplasm (Figure 7 Chapter 2). The intracellular 
distribution of the NS1 protein from the A/England/195/09 virus was investigated in Vero cells using 
indirect immunofluorescence. The results are shown in Figure 43 alongside those for A/PR/8/34 and 
A/Victoria/3/75 NS1 proteins and their mutants recapitulated from chapter 1 for ease of 
comparison. 
Surprisingly the localisation of A/England/195/09 NS1 was found to be strongly nuclear (Figure 43 
bottom left panel), and this may account for the apparently poor expression levels of this protein 
since the lysis procedure used to prepare samples for the luciferase assay may have extracted 
nuclear proteins less efficiently than those in the cytoplasm.  
In the A/Victoria/3/75 NS1 protein, the mutation G184R relocated the NS1 protein from the nucleus 
to the cytoplasm. This mutation was therefore engineered into the A/England/195/09 NS1 protein to 
establish if it would also cause the NS1 protein to redistribute in the cell. The G184R mutation did 
not affect the accumulation of the pandemic-origin NS1 protein in the nucleus (Figure 43 bottom left 
panel 2). 
 Interestingly, despite its nuclear accumulation, as shown above the A/England/195/09 NS1 protein 
was a strong enhancer of translation (Figure 44). Whereas G184R mutation in the  
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Figure 43 Indirect immunofluorescence showing localisation of NS1 proteins in Vero cells 
500ng of pCAGGS NS1 plasmids or Empty Vector was transfected into Vero cells growing on 
microscope cover slips using Lipofectamine 2000 (Invitrogen). 24 Hours post transfection, samples 
were prepared for indirect immunofluorescence as described in the Materials and Methods, using 
mouse anti-V5 sera, and a Texas Red conjugated anti-mouse secondary antibody. Cover slips were 
mounted in Molviol (Sigma) with DAPI. The images were obtained using fluorescence microscopy on 
a Carl Zeiss Axiovert 40 CFL, and manipulated using release 4.7 (Carl Zeiss GmbH). 
Wild type A/PR/8/34 was present in both the cytoplasm and the nucleus, while that of 
A/Victoria/3/75 and the NLS-tagged A/PR/8/34 was concentrated in the nucleus. The levels of the 
G184R mutant of A/Victoria/3/75 as established previously were increased in the cytoplasm. The 
A/England/195/09 was localised primarily in the nucleus of the transfected cells, with cells also 
having foci of accumulation present in the cytoplasm.  
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A/Victoria/3/75 NS1 relocated the protein to the cytoplasm and alleviated its block of reporter gene 
expression, this same mutation did not affect the translational enhancement capacity of either the 
cytoplasmic A/PR/8/34 NS1 protein nor of the nuclear A/England/195/09 NS1 protein (Figure 44). 
Thus far, to investigate the translational enhancement effects of NS1 proteins, 293T cells were used, 
because this cell line is highly permissive to transfection, making it likely that both plasmids are 
delivered to the same cell. On the other hand, for indirect immunofluorescence analysis, Vero cells 
were used because they are well-suited to this technique due to their flat morphology allowing a 
larger proportion of the cell to be presented in any given focal plane. Their robust adherence to 
cover slips also allows the multiple steps of processing required to probe for a given antigen without 
losing large numbers of cells. Vero cells are also permissive to transfection, though not to an 
equivalent degree that 293T cells are. However, 293T and Vero cells are from different animal 
sources, so an explanation for the nuclear localisation in Vero cells demonstrated in Figure 43 for the 
A/England/195/09 NS1 protein and its apparent ability to enhance reporter gene expression in 293T 
cells described in Figures 42 and 44 could be that the NS1 protein was localised differently in the two 
different cell types. Therefore using a subset of the NS1 proteins, including that of 
A/England/195/09, the reporter enhancement assay was conducted in Vero cells to establish if this 
NS1 protein was still able to enhance translation, despite poorly accumulating in the cytoplasm 
where the likely ligand PKR is typically localised.  
The A/England/195/09 NS1 protein was found to enhance translation in Vero cells despite its nuclear 
localisation (Figure 45). Both A/PR/8/34 and A/England/195/09 derived NS1 proteins enhanced 
luciferase activity in a statistically significant manner (p=0.016 and p=0.015 respectively). As had 
been established for expression in 293T cells, there was no statistically significant difference in the 
effects on expression between A/PR/8/34 and A/England/195/09 (p=0.167). 
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Figure 44 The Effect on luciferase Activity from the Co Expression with NS1 Proteins in 293T cells 
The effect on translation was evaluated in 293T cells as described previously. Briefly, 293T cells were 
transfected with 0.25µg pCAGGS Luciferase, 1µg pCAGGS NS1 or Empty Vector and 2.75µg pcDNA 3A 
plasmid. After 48 hours the samples were lysed with reporter lysis buffer (Promega). The resultant 
supernatant was clarified by centrifugation and a proportion diluted 1 in 100. 10µl was then assayed 
for luciferase activity and the data presented relative to the empty vector sample. 
All samples revealed a statistically significant variation in the expression of the reporter gene in 
comparison to the empty vector sample. The luciferase activity, and thus the expression of luciferase 
was enhanced in the presence of the 184 mutation for the NS1 proteins (p=0.002 for A/Victoria/3/75 
WT versus 0.05 for the remaining NS1 proteins). There was no significance to the differences 
between the 184 mutant proteins themselves however with p being in the region of 0.2-0.3 in a 
comparison of all three to each other. 
Data presented is representative of 3 separate experiments. 
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Figure 45 Effect on luciferase activity from co-expression with NS1 proteins in Vero cells 
To exclude the possibility that the NS1 proteins were having different effects in 293T cells and Vero 
cells, the A/England/195/09 was investigated for its ability to enhance translation in Vero cells using 
transient transfection. As before, 1µg of pCAGGS NS1 or control plasmid, 0.25µg pCAGGS Luciferase 
reporter, and 2.75µg of pcDNA 3A plasmid per well of cells was transfected using Lipofectamine. The 
Vero cells were transfected as a monolayer for this experiment. Data presented is representative of 
three separate experiments.  
The enhancement activities of A/PR/8/34 and A/England/195/09 were statistically significant 
(p=0.016 and p=0.015 respectively). The ability of the A/Victoria/3/75 to inhibit luciferase expression 
was also significant in this work (p=0.0036). There was no significance to the difference in effects on 
expression between the swine-derived NS1 and A/PR/8/34, which is comparable to those 
established for the 293T experiments (p=0.167). 
 
  




Effect on Luciferase Activity from Co 


























248 | P a g e  
 
4.6 The Localisation of the H1N1 NS1 protein during infection 
 
The nuclear localisation of the NS1 protein of A/England/195/09 was interesting in light of its 
inability to bind CPSF and it efficiency at enhancing exogenous gene translation. To assess whether 
the localisation of the protein when expressed from a plasmid represented the localisation of the 
protein during virus infection, attempts were made to visualise the protein in infected cells. 
However the NS1 anti-serum used was raised against A/PR/8/34 NS1 protein and cross-reacted 
poorly with the A/England/195/09 NS1 protein (data not shown). A recombinant virus based on 
A/England/195/09 was engineered in which a small tetra-cysteine tag with the sequence CCPGCC 
was inserted in the flexible inter-domain region of NS1 replacing the amino acids 79-84. During 
infection the NS1 protein of this virus accumulated in the nucleus, (unpublished work conducted by 
Chi Ma, an MSc student in our laboratory Figure 46). With the caveat that both NS1 proteins have 
been modified in some way, it can be assumed that the transient plasmid-directed expression 
system resulted in the same pattern of intracellular accumulation of the NS1 protein of 
A/England/195/09, and that this protein tends to accumulate in the nucleus. 
  




Figure 46 Intracellular distribution of FlAsH-tagged NS1 protein engineered into an 
A/England/195/09 virus  
Work conducted by MSc Student Chi Ma (Imperial College) established a virus containing the FlAsH 
tag in the sequence of the NS1 protein. Visualisation of the tag in infected cells confirmed that the 
NS1 protein was predominantly localised in the nucleus in infected MDCK cells, supporting the 
localisation established by the transient expression data. (Work presented here with thanks to Chi 
Ma). 
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4.7 Consequences of Impaired CPSF binding activities 
 
The NS1 protein of the A/England/195/09 virus accumulated in the nucleus but did not possess the 
capacity to inhibit host gene expression via CPSF binding. We therefore reasoned that it might be 
deficient in its ability to control interferon induction by an exogenous stimulus. 
The A/England/195/09 NS1 protein was evaluated for its ability to block expression from an 
interferonβ promoter in response to an NDV challenge. 
As shown in Figure 47, both wild type A/PR/8/34 NS1 and A/Victoria/3/75 NS1 proteins controlled 
interferon induction efficiently in this assay in response to an NDV challenge. Indeed even after the 
compromise in CPSF binding conferred by the G184R mutation in A/Victoria/3/75 NS1, the protein 
was still able to block interferon induction to some extent. In contrast an A/PR/8/34 NS1 protein re-
localised to the nucleus by addition of an exogenous SV40-derived NLS was unable to control the 
interferon response. 
The NS1 protein from A/England/195/09 was unable to block interferon induction in this assay. Hale 
et al. (2010) previously reported that the NS1 protein from A/California/04/09, which is identical in 
sequence to A/England/195/09, was competent at controlling interferon induction in response to 
Sendai virus stimulation. Although NDV and Sendai virus are different viral stimulators of interferon, 
they likely stimulate similar pathways involving RIG-I within the cytoplasm of the cell. Hale et al did 
not provide any localisation data in their work, nor was an epitope tag included in their pCAGGS NS1 
construct. Nonetheless this discrepancy between our data and theirs is puzzling. 
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Figure 47 Evaluation of the ability of the A/England/195/09 NS1 to block interferon signalling in 
293T cells 
293T cells were transfected in suspension using Lipofectamine 2000 with 250ng each of the reporter 
plasmids encoding β-galactosidase and the interferonβ luciferase plasmid described earlier, 
alongside 200ng pCAGGS NS1 expression plasmid per well of a twelve-well plate (CellStar, Greiner), 
as detailed in the Materials and Methods. 
24 hours post-transfection, wells were either infected with NDV diluted in serum-free media, or 
Mock treated for an hour, then the media was replaced with 2% foetal calf serum DMEM overnight. 
The resulting samples were washed once with ice cold phosphate-buffered saline, and lysed and 
assayed for both luciferase and β-galactosidase activity. The luciferase readings were normalised 
using the β-galactosidase to control for variance in transfection efficiency, number of cells and the 
effects of NS1 proteins on protein expression between the samples. Each data point represents the 
average of three identically treated samples, and the error bars are the standard deviation of each 
group.  
As shown in this figure, A/England/195/09 and A/England/195/09 G184R are both unable to block 
interferon stimulation. Surprisingly these samples also produced an increase in interferon driven 
luciferase over the control transfection, and that presented by the G184R variant was statistically 
significant.  
The inability of the A/PR/8/34 NLS protein to control interferon production is confirmed by the lack 
of statistical significance to the difference between this sample and the mock. Data is representative 
of three separate experiments.  
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4.8 Investigation into the Effect of Inclusion of the RNP 
 
It has been suggested that the viral RNP can help stabilise the NS1 complex with CPSF (Kuo and Krug 
2009). This is proposed to be an important part of the mechanism for controlling the expression of 
host genes, including interferon. One explanation for the apparent defect in the interferon control 
mediated by the A/England/195/09 NS1 protein was that it may require other viral components to 
complement its ability to counter interferon production. 
The polymerase complex has been recently shown to play a role in the control of interferon β (Iwai, 
Shiozaki et al. 2010). In addition, the cap snatching process utilised for the synthesis of viral mRNA 
may also act as an additional mechanism to limit host gene expression including induced interferon 
(Marcus, Rojek et al. 2005). It was therefore possible that either by the stabilisation of an NS1:CPSF 
interaction, or by the transfer of interferon control functions to the RNP, interferon control by the 
A/England/195/09 virus is achieved only in the presence of the polymerase components. This would 
account for the observations of Osterlund et al, (2010) who showed that the nvH1N1 did not induce 
high cytokine levels in human macrophage. To determine whether the cognate polymerase complex 
could complement the NS1 protein to control interferon production, the components for the RNP of 
A/England/195/09 and the A/PR/8/34 HA pol I plasmid to direct production of a viral-like RNA were 
co-expressed alongside the cloned NS1 protein. As a control NS1 protein which did not need the 
cognate polymerase to control interferon, but which is thought unable to bind CPSF, A/PR/8/34 was 
included. The transfected samples were mock treated, or stimulated with NDV and the levels of 
expression of luciferase were then normalised to β-galactosidase as described previously. The data is 
presented in Figure 48 and has been evaluated for statistical significance using a paired 2-tailed t-
test. 
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Figure 48 A/England/195/09 does not recover an ability to block interferon stimulation upon 
expression of its cognate polymerase complex  
To investigate if the NS1 protein could recover the ability to block interferon when expressed in the 
presence of the polymerase sub-units, 200ng of pCAGGS expression plasmids expressing PB1, PB2, 
PA and NP from A/England/195/09 was transfected into 293T cells, along with pPOLI HA to express 
the vRNA from A/PR/8/34 and 250ng each of the reporter plasmids encoding β-galactosidase and 
the interferonβ luciferase plasmid described earlier. After 24 hours, cells were stimulated by 
infection with NDV for a further 20 hours and then evaluated for luciferase activity, which was then 
normalised for the translational enhancement effects of the two NS1 proteins and variance in 
transfection efficiency using the β-galactosidase activity, as described in a previous figure. The data 
was also processed in an identical manner. 
The expression of A/PR/8/34 and A/England/195/09 did not significantly affect the expression of the 
interferon luciferase plasmid prior to stimulation (p=0.88 and p=0.29 respectively). As established 
previously, the A/PR/8/34 NS1 protein was able to block the interferon signalling modelled in this 
system and there was no statistically significant difference between stimulated and unstimulated 
A/PR/8/34 samples (p=0.15).  
There was a highly statistically significant difference between A/England/195/09 stimulated and 
unstimulated (p=0.00006). The p values shown on the graph are a characterisation of the statistical 
difference between the NDV-stimulated NS1 transfection and that of the empty vector, and in these 
experiments there was a statistical difference between both of the NS1 proteins and the control 
transfection. In the case of A/PR/8/34, this represents the NS1 protein efficiently blocking the 
interferon promoter expression of luciferase (p=0.034), and for this work a statistically significant 
increase in luciferase signal between the empty vector and the stimulated cells expressing 
A/England/195/09 (p=0.038). Therefore the elevated levels of luciferase activity in the 
A/England/195/09 samples are increased to a statistically significant level.  
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In this experiment the NS1 protein of A/PR/8/34 blocked the NDV stimulus effectively. In contrast 
the NS1 protein of A/England/195/09 was unable to block the interferon stimulus even in the 
presence of its cognate polymerase complex. The NS1 protein of A/PR/8/34 was able to block the 
NDV stimulus effectively as described previously, but there was no statistically significant difference 
between the stimulated and unstimulated A/PR/8/34 NS1 transfection samples (p=0.15). However 
the A/England/195/09 NS1 and polymerase complex did not block the interferon stimulus, in fact the 
luciferase signal was higher in the presence of NS1 and reconstituted polymerase than in the empty 
vector transfected wells (p= 0.04). It is possible that the A/England/195/09 NS1 was acting to 
enhance translation of the induced luciferase but this was not investigated further. 
The data presented in Figure 48, recapitulate the observations made previously in Figure 47, that the 
A/England/195/09 NS1 protein is deficient in its ability to control RIG-I mediated IFN induction even 
in the presence of its cognate polymerase. The challenge used in this experiment, although blocked 
effectively by A/PR/8/34, may not reflect the nature of the challenge which would be generated 
within a cell infected with pandemic H1N1 virus. Further work including a titration of the NDV 
stimulus, in the presence of the A/England/195/09 NS1 may reveal that this NS1 protein can indeed 
block a ‘mild’ IFN stimulus but is overcome by the stronger interferon trigger of NDV. Variation in the 
levels of stimulation may account for the discrepancy between the data generated by Hale et al and 
these data. 
Taken together, both datasets agree that the NS1 protein from the recent pandemic H1N1 do not 
bind CPSF. The localisation of the A/England/195/09 NS1 protein to the nucleus suggests it may 
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4.9 An Investigation of the Effects of the A/England/195/09 NS 
Segment on Viral Interferon Induction 
 
The experiments described above showed that in response to an NDV stimulus, the NS1 protein of 
the A/England/195/09 was unable to control interferon induction. The NDV stimulus used is a highly 
robust challenge, which is unrepresentative of the levels of stimulus which the influenza virus would 
normally induce during the course of infection.  
To investigate the ability of an A/England/195/09 NS1 to control interferon induction in the context 
of influenza virus infection, the virus was used to infect A549-IFN beta luciferase reporter cells at an 
MOI of 3, alongside a panel of other human influenza A viruses. At 20 hours post-infection the cells 
were evaluated for luciferase as a measure of the interferon induced and the data is presented in 
Figure 49. NDV challenge was included as a positive control, and generated a large interferon-
induced luciferase signal in comparison to the mock-infected cells. 
Infection with wild type A/PR/8/34 induced low levels of interferon. As shown previously a mutant 
A/PR/8/34 virus encoding an NS1 protein which is unable to bind RNA (A/PR/8/34 RKS) induced a 
high level of interferon of an order of magnitude over wild type, and in this experiment approaching 
the levels of stimulation of NDV. The remaining influenza viruses, including the two human H3N2 
viruses A/Victoria/3/75 and A/Sydney/97, and the H1N1 A/England/195/09 investigated in this 
experiment did not induce a high level of interferon.  
To ensure that equal virus challenge had been used for each virus strain, the efficiency of the 
infection was evaluated in Western blot analysis using an NP antibody, raised against an H7N7 NP 
(gift of the HPA, Colindale, UK). Although the other four viruses showed equal intensity of NP protein 
in cell lysates, probing the cell lysates infected with A/England/195/09 did not yield an NP band. 
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Figure 49 Variations in the interferon induction of a panel of influenza viruses 
Wild type influenza viruses were evaluated for their ability to induce the production of interferon in 
the A549 (human lung carcinoma) cell line, which had been stably transformed with the interferonβ 
construct driving the expression of luciferase in response to suitable stimulation. NDV infection is 
included here as a positive control for the stimulation of the reporter cells relative to the mock. 
Cells were infected at an MOI of 3 and evaluated for their luciferase expression after 20 hours. Equal 
volumes of the resulting lysate were evaluated using western blotting for the expression of the viral 
NP protein using an NP antibody raised against an H7N7 viral NP (gift from HPA, Colindale). Infection 
with NDV was used as a positive control for this work. With the exception of the A/England/195/09, 
the levels of luciferase induced by the infection of the virus were statistically significant over that of 
the mock infection which is the p value displayed on the graph. The level of luciferase activity 
induced by A/England/195/09 infection was not significantly different to that of mock (p=0.98), and 
subsequent analysis of the western blotting data suggested that the A/England/195/09 virus was not 
successfully infecting the A549 cells.  
This data is representative of 2 separate experiments.  
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The most likely explanation for this is that the NP protein of the full length A/England/195/09 is 
sufficiently different to that originally used to generate the antibody, that it was not detected by 
Western blot. Indeed there have been reported two different ‘subtypes’ of NP which are known to 
circulate in influenza A viruses, in addition to the sequence differences which exist between the 
various strains (Gammelin, Mandler et al. 1989). However another possibility is that the A549 cells 
were only inefficiently infected with the pandemic H1N1 virus.  
This might be because of an inefficient binding of the A/England/195/09 HA to the A549 cells, or to 
the zealous activity of the A/England/195/09 NA. A recent publication demonstrated the high 
enzymatic activity of the pandemic H1N1 neuraminidase protein, and adding NA inhibitors to a virus 
culture in order to limit this function, boosted viral yields (Lin, Zhou et al. 2009). Mechanistically the 
explanation for this was that the highly active NA protein desialylated the surface of the host cell, 
lowering the number of virus receptors presented on the surface, so viral entry was inefficient due 
to a shortage of suitable receptors. Utilising the reverse genetics system, it was possible to engineer 
a virus which contained the NA and HA proteins of A/PR/8/34 on the internal body of the 
A/England/195/09 virus, in order to ameliorate this problem. In this experimental genetic 
constellation the M segment for A/PR/8/34 was also included. The remaining components of the 
virus were the three polymerase complex proteins, the nucleoprotein, and the NS segment encoding 
the NS1 and NEP of A/England/195/09. 
Although such a viral reassortment is a highly artificial construct, this gene constellation allowed a 
fair comparison between different genetically-engineered viruses, which only differ in the machinery 
driving the production of PAMP (the viral RNP) and the protein designed to counter the host’s 
reaction to this PAMP (the viral NS1 protein), in an otherwise constant genetic environment. 
The previous experiment was then repeated in the A549-IFN beta luciferase reporter cell line, in 
parallel, with one half of the cells evaluated for viral antigen expression using immuno-histochemical 
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staining for M1 antigen, and the other half evaluated for luciferase production, driven by activation 
of the interferon beta promoter. 
After 20 hours, M1 antigen expression was evident (Figure 50A) following infection with the wild 
type viruses A/PR/8/34, A/Victoria/3/75 and A/Sydney/97. Infection with wild type 
A/England/195/09 however did not give a positive result, there was no visible antigen staining and 
the wells infected with this virus resembled those of the NDV and mock-infected controls. The M1 
protein is highly conserved between A/PR/8/34 and A/England/195/09 (see alignment in appendix) 
so it seemed unlikely that this negative result was also explained by incompatible anti-sera. 
Importantly, the virus containing the A/England/195/09 RNP components and NS, but with the 
external HA and NA genes of A/PR/8/34, A/England/195/09 3NP, was shown to efficiently infect the 
A549 cells (Figure 50A bottom right). 
In Figure 50B, the levels of interferon induced by this recombinant virus were evaluated in 
comparison with the other wild type viruses. As established previously, the levels of interferon 
induced by infection with A/PR/8/34, and A/Victoria/3/75 viruses were low. Although the levels of 
interferon induction following A/Sydney/97 virus infection were higher than the other wild type 
influenza viruses, these were not as high as the levels generated by either the NDV, or the 
recombinant A/England/195/09 3PNP virus. As seen previously, the levels of interferon induced by 
wild type A/England/195/09 were low and could not be statistically distinguished from that of the 
mock infected cells (p=0.68).  
Equal volumes of lysate from these infections were then evaluated for expression of the viral 
antigens for NP and M1 using Western blotting and the previously-described NP anti-sera from the 
HPA, and the broad-range influenza M1 anti-sera (ABD serotec). Prominent M1 bands were 
visualised for the four influenza viruses that had shown positive immuno-staining in Figure 50 part A. 
In contrast, the infection with wild type A/England/195/09 was very inefficient. Subsequent over-
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exposure revealed a faint M1 band corresponding to a low-level infection by the A/England/195/09 
virus. 
These data suggest that the H1N1 virus does not efficiently enter A549 cells. It seems possible that 
the conclusion made in the literature that suggest the pandemic H1N1 virus induces only low levels 
of interferon might be flawed by the inefficient entry of this virus to certain cell types or cultures. In 
light of this finding, the recombinant A/England/195/09 3PNP virus constellation within the PR8 HA 
and NA envelope was used in further experiments, as a model for the wild type virus to assess the 
effects of altering the balance between polymerase PAMP and viral antagonist NS1. 
  




Figure 50 Evaluating the Infection of A549 Cells 
 
A Evaluating the Infection of A549 Cells using Immuno Staining 
The A549 reporter cell line was again used to confirm that the chimeric virus generated between 
A/PR/8/34 and A/England/195/09 was able to successfully infect and replicate by using immuno-
staining of fixed cells after 20 hours’ infection. The parental virus, and 2 other human viruses were 
included in this work (A/Victoria/3/75 and A/Sydney/97). To process this data, the cells were fixed 
with ice cold methanol/acetone, and probed with a mouse anti-M1 serum (AbD Serotec). The bound 
primary antibody was detected with a secondary antibody with a β-galactosidase enzyme conjugate. 
The plates were developed using an XGal (bromo-chloro-indolyl-galactopyranoside) substrate in a 
suitable buffer which produces the blue colour. This data is representative of 2 independent 
experiments. 
B Interferon Induction at an MOI 3 in A549-luciferase reporter cell line 
The interferon induced in the A549 reporter cell line of a panel of human influenza viruses and the 
chimeric virus generated between A/PR/8/34 and A/England/195/09 was evaluated. Cells infected 
for 20 hours were washed once in ice cold phosphate-buffered saline, and lysed using 100µl freshly 
diluted 1X passive lysis buffer per sample (Promega). 20µl of the resulting lysate was analysed for 
luciferase activity. NDV infection is included here as a positive control for the stimulation of the 
reporter cells relative to the mock. 
The expression of the NP and M1 gene of the panel of viruses was also analysed by western blotting, 
and the resulting data is displayed below the chart to aid comparison. To generate this data, 10µl of 
the lysate was then mixed 1:1 with 2X Laemmli sample buffer and 5µl was resolved on a 15% SDS-
PAGE and analysed by western blotting for expression of the NP (mouse anti NP, HPA) and M1 
(mouse anti NP, ABD Serotec)antigens. (As described in the Materials and Methods)  
This blot confirms the low level of cross-reactivity of the NP antibody for the NP encoded by 
A/England/195/09, and validates the use of the M1 gene in the recombinant experimental virus as a 
potential viral epitope target for this work. This A/England/195/09 A/PR/8/34 virus will form the 
basis for further work as the model A/England/195/09 model virus. 
This data is representative of 2 independent experiments. 
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4.10 The Effect of Reassortment on the ability of A/England/195/09 
Virus to induce and control interferon 
 
The data in the literature suggest that the current genetic constellation of pandemic H1N1 2009 
virus does not give rise to a highly pathogenic virus. Most of the infections in humans result in mild 
illness (Hayden, Wick et al. 2010). However influenza viruses are notorious for their rapid evolution. 
In particular, the segmented genome of influenza virus frequently undergoes reassortment, forming 
novel gene constellations. The properties of the resultant virus may be difficult to predict, even using 
the previous knowledge about the viruses from which it was formed. Reassortment of the pandemic 
H1N1 2009 virus in pigs was modelled in Vietnam and found to be “highly likely” due to the multiple 
opportunities for swine to engage with endemic highly-pathogenic strains which are present in the 
domestic animal population (Boni, Manh et al. 2009).  
The wide distribution of pandemic H1N1 virus in humans also represents an opportunity for a 
reassortment event between the pandemic virus and a human-adapted seasonal strain. Indeed, 
H3N2 human influenza strains are currently co-circulating in the winter of 2010/2011 with swine-
origin H1N1 virus in humans. The pairing of novel gene constellations, for example of a TRIG 
polymerase from pandemic virus, and a full-length human NS1 protein, deriving from a seasonal 
human strain, may result. This could create a new virus that can circulate in humans but with 
different properties regarding the control of interferon than the existing H1N1 strain.  
 
To assess the compatibility between A/England/195/09 polymerase genes and NS genes from 
circulating human H3N2 viruses, artificial reassortment viruses were constructed. These once again 
contained the surface glycoproteins HA and NA and matrix protein of A/PR/8/34 coupled with the 
RNP components of A/England/195/09, with either the wild type A/England/195/09 NS segment, or 
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that from A/England/612/03, or A/Scotland/50/03. These H3N2 strains were isolated by the HPA 
during the emergence of A/Fujian/411/02-like human H3N2 strains in the UK population in 2003/4. 
A/England/612/03 was a virus isolated from a fatal geriatric case. A/Scotland/50/03 was isolated 
from a fatal infant case. These two full length NS genes are typical of those in contemporary human 
H3N2 viruses. 
The resulting viruses were inoculated at an MOI of 3 on the A549-Interferonβ luciferase reporter cell 
line, and the data has been presented in figure 51.  As before, NDV and the A/PR/8/34 recombinant 
virus encoding an NS1 protein mutated at the RNA binding site, RKS, induced high levels of 
interferon in comparison to the wild type A/PR/8/34 virus. The level of interferon induced by the 
model virus representing the wild type A/England/195/09 virus (A/England/195/09 WT) was also 
elevated above that of the A/PR/8/34 virus, and this was statistically significant (p=0.003).  
However when the NS segment for A/PR/8/34 was substituted in this genetic constellation in place 
of the A/England/195/09 NS segment, the resulting virus induced less interferon, suggesting that the 
A/PR/8/34 NS1 protein was better able to control the interferon induction than that of 
A/England/195/09 (p=0.003). Furthermore, the model viruses that had acquired H3N2 NS gene 
segments both also showed a statistically significant decrease in the level of interferon compared 
with the virus with A/England/195/09 NS, with p values of 0.002 and 0.001 for the 612 and Sc50 NS 
segment reassortant viruses. Thus in the context of the model A/England/195/09 viruses which 
contain the 3PNP of the new pandemic strain, reassortment with circulating H3N2 viruses may result 
in viruses that are better able to control interferon induction.  
A Western blot was conducted on equal volumes of the infected cell lysates, and probed with the 
anti-sera to the M1 protein used previously, to investigate the amount of matrix protein expressed 
as a consequence of viral infection. The M segment coded for by this panel of viruses had been kept 
constant in the construction of these viruses to allow this, and the results are shown in Figure 52.  
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Figure 51 Interferon Induction of a Panel of Recombinant Influenza Viruses Evaluated using A549-
Luciferase Reporter Cell Line 
The interferon induced in the A549 reporter cell line of a panel chimeric virus generated between 
A/PR/8/34 and A/England/195/09 was evaluated. Cells infected for 20 hours were washed once in 
ice cold phosphate-buffered saline, and lysed using 100µl freshly diluted 1X passive lysis buffer per 
sample (Promega). 20µl of the resulting lysate was analysed for luciferase activity. NDV infection is 
included here as a positive control for the stimulation of the reporter cells relative to the mock. 
All viruses showed a statistically significant increase in interferon induction over the mock infected 
sample (p value not shown). Increases in interferon driven luciferase production were observed for 
the RNA binding mutant of A/PR/8/34, over that of the wild type virus. The model wild type 
A/England/195/09 virus demonstrated an increase in the interferon induced over A/PR/8/34 wild 
type virus. The A/England/195/09 chimeric viruses modelling reassortment with A/PR/8/34, 
A/England/612/03 and A/Scotland/5/03 showed decreases in the levels of interferon induced to 
values below that of A/PR/8/34. These were statistically significant with p values of 0.04, 0.001 and 
0.002 respectively.  
The increase in interferon induction of the RNA binding mutant of A/PR/8/34 was significant with a p 
value of 0.013. The decreases in interferon induction measured for the chimeric viruses relative to 
the model A/England/195/09 wild type virus were also significant with p values in the range of 
0.001-0.003 as shown.  
This data is representative of 2 separate experiments. 
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Figure 52 Evaluation of the Matrix Protein Expression in A549 Cells Infected with Recombinant 
A/PR/8/34 and A/England/195/09 Viruses 
Lysates from the A549 luciferase reporter cell line infected with the panel of recombinant viruses 
was evaluated by western blotting. An aliquot of the samples evaluated for luciferase activity was 
mixed 1:1 with 2 x Laemmli loading buffer as detailed in the Materials and Methods. 5ul was loaded 
on a 15% SDS PAGE and the gel run to ensure an adequate separation of the proteins. The proteins 
in the SDS PAGE were then transferred to hybond C nitrocellulose using the semi dry technique, and 
probed with mouse monoclonal anti sera raised against the viral M1 protein which is present in all 
the viruses (mouse monoclonal M1, ABD Serotec). The pattern of the levels of M1 protein expression 
mirrors the pattern of the interferon signal generated.. 
 













































































Expression of the Matrix Protein in A549 Cells 
Infected with Recombinant A/PR/8/34 and 
A/England/195/09 Viruses
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As described in chapter 3, the higher induction of interferon shown by a recombinant virus such as 
the A/England/195/09 3PNP virus could be either due to a deficiency in the NS1 protein’s ability to 
control interferon induction, or because the polymerase activity of such a virus is altered in a way 
that generates more PAMP, or both. To investigate the effect of segment 8 exchange in the context 
of the H1N1 2009 polymerase, 293T cells were transfected with the viral RNA-like luciferase reporter 
system described earlier. After 24 hours the cells were infected at an MOI of 3 with the panel of 
viruses and further incubated for another 20 hours. The samples were then lysed and evaluated for 
luciferase activity as a measure of the level of viral polymerase activity which had taken place within 
the cells.  
The results are shown in Figure 53. The first thing of note for these experiments was the increased 
level of activity in the samples containing the pandemic influenza polymerase. In this assay, the 
A/England/195/09 drove the production of reporter protein, to generate approximately 50 times 
more luciferase activity than the A/PR/8/34, and this difference was statistically significant 
(p=0.001). 
Pairing the H1N1 2009 polymerase with segment 8 from any of the other viruses lowered the 
luciferase signal by a statistically significant extent. (p=0.001 A/PR/8/34, p=0.002 for 
A/England/612/03 and p=0.001 A/Scotland/5/03). 
When the M protein levels were measured in the A549 cell line, which had demonstrated 
differences in interferon levels, the profound difference observed of the viruses with 
A/England/195/09 polymerase versus A/PR/8/34 polymerase was less marked. However it was still 
the case that the M protein production was highest for the model wild type A/England/195/09 virus 
and this was decreased when different segment 8s were introduced. 
Taken together, these observations would fit with a hypothesis that the NS segment reassortment is 
causing a polymerase dysregulation. Dysregulation of polymerase activity has previously been 
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reported in H7N7 recombinant viruses (Ma, Brenner et al. 2010; Wang, Robb et al. 2010) and viruses 
encoding NS segments with large portions of the NS1 protein coding sequence deleted (Falcon, 
Marion et al. 2004), and earlier work in this thesis also confirmed this precedent.  
  





Figure 53 Evaluation of Influenza Viral Polymerase Activity Using 3-5-8 Luciferase Reporter 
293T cells were transfected for 24 hours with a reporter construct which generates a viral genome 
like RNA coding for a luciferase reporter gene flanked by the influenza NS segment non coding 
region, altered at nucleotides 3,5 and 8 in the promoter. Subsequent protein expression was then 
driven by viral infection at an MOI of 3 for 20 hours. The A/PR/8/34 and the panel of recombinant 
model A/England/195/09 wild type and NS segment recombinants were investigated. As luciferase 
expression was driven by the actions of the viral polymerase in the infection, this assay is a measure 
of the polymerase activity encoded by these viruses, and the increases in activity were established as 
significantly above those of A/PR/8/34 wild type. 
The decreases in expression of luciferase in the model A/England/195/09 NS recombinant viruses 
relative to the model wild type virus were significant and correlate with the effects seen in the 
interferon reporter assay between this group. However the pattern of differences in polymerase 
activity of these chimeric viruses relative to A/PR/8/34 does not correlate with the decrease in 
interferonβ luciferase signal seen.  
This data is representative of 2 separate experiments. 
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4.11 Analysis of the RNA Species Generated by the Recombinant 
Viruses Containing the A/England/195/09 RNP Complex 
 
All the viruses investigated here contained the HA segment from A/PR/8/34, and this allowed some 
RNA analysis to be conducted on a genuine viral gene product. The transcription and replication of 
the HA segment was investigated using primer extension analysis and the results of a typical gel are 
shown in Figure 55.  
The signal detected with the 5S RNA primer, revealed that the number of cells from which RNA was 
extracted was approximately equivalent for all the samples. The viral RNA levels detected in cells 
infected by wild type A/PR/8/34 virus was lower than for A/England/195/09 model wild type virus, 
though the differences were not the same as the fifty-fold variance seen in the luciferase reporter 
assay. Four individual primer extension analyses representing two individual experiments were 
quantitated using phosphoimage analysis and the data is presented in Figures 56 and 57. 
Briefly, the gels from each experiment were dried down on Whatman paper, and exposed to a pre-
blanked storage phosphor screen for 2-3 days. The exposed plate was then read using a Storm 860 
phosphoimager, and the image collected. Using ImageQuant version 5, boxes enclosing the largest 
band per RNA species was then used to allocate the signal size, and the raw data was collected. Data 
was expressed relative to the A/PR/8/34 wild type for each species of RNA. 
It was originally intended that the 5S RNA signal be used for normalising the data, but the effect of 
this normalising affected the data such that the differences easily visible by eye were lost. This is 
likely due to the order of magnitude difference between the labelling efficiency of the 5S RNA probe 
and the other RNA probes, and is something to be addressed in future repeats of this assay. 
The cRNA and mRNA levels were not very different from each other for any of the viruses analysed. 
However both A/England/195/09 model wild type virus and the A/England/195/09 virus with 
A/PR/8/34 NS segment produced higher levels of vRNA than did wild type PR8. In contrast, coupling 
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the A/England/195/09 polymerase constellation with the NS segment from the H3N2 viruses 
regulated the amount of vRNA produced. 
The key finding for this section of the investigation have been summarised in a table in Figure 17. 
The levels of a given assay for A/PR/8/34 have been set at 1, and then everything has been 
evaluated relative to A/PR/8/34, to allow an easy point of reference. 
As was found for A/PR/8/34 based viruses, the substitution of the NS segment for another, resulted 
in a decrease in activity from the starting activity. But the quantitations of the bands generated for 
primer extension (55-56) do not support the observation that there was a significant gulf of 
difference between A/PR/8/34 and A/England/195/09 in the first place for a reduction to occur. 
 
The aim of this section was to establish if the recombination of the swine-origin influenza would 
result in an increase in virulence. To evaluate this, a reporter gene driven by virus infection, the 
stimulation of the interferonβ promoter in a stable cell line by virus infection and the three RNA 
species made by an infecting virus were all analysed.  
The results show that recombination of H3N2-derived NS gene segment into a pandemic H1N1 
genetic backbone resulted in regulation of polymerase activity that results in a decrease in viral gene 
products and less interferon induction. While these in vitro experiments do not constitute an 
entirely rigorous assessment of virulence or pathological outcome, it is implied that these reductions 
should they occur in the field would reduce the viral pathogenicity in agreement with current 
literature (Ilyushina, Ducatez et al. 2010). 
  




Figure 54 Primer Extension Analysis of RNA Transcripts Derived from the HA Segment of a Panel of 
Recombinant A/PR/8/34 and A/England/195/09 Viruses Isolated from 293T Cells 
293T cells were infected for 20 hours to mirror the conditions used for both the polymerase assay 
and those of the polymerase reporter assay. Subsequently the RNA was isolated using Trizol 
(Invitrogen) and the levels of 3 different RNA levels associated with the virus were investigated. An 
additional host transcript for the 5S RNA was also investigated and validates that the number of cells 
per sample was approximately equivalent. 
Slight increases in cRNA and vRNA are observed for the A/England/195/09 and the A/PR/8/34 NS 
recombinant relative to the A/PR/8/34 wild type. The levels of mRNA may be elevated for the 
A/England/195/09 derived viruses but this is does not appear to be significant by eye. 











































































Primer Extension Analysis of RNA Transcripts Derived 
from the HA Segment of a Panel of Recombinant and 
A/England/195/09 Viruses isolated from 293T cells 
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Figure 55 Primer Extension Evaluation of the m and cRNA Levels Inside 293T Cells Infected at an 
MOI of 3 for 20 Hours 
A - Quantitation of the Relative Levels of cRNA Expression derived from Primer Extension Analysis 
of HA Transcripts 
Primer extension analysis was conducted on RNA extracted from 293T cells, infected at an MOI of 3 
for 20 hours to mirror the conditions used for the polymerase driven expression system. The data 
from 3 separate RNA panels was evaluated relative to that generated by the A/PR/8/34 infection for 
the cRNA levels. There was no significant difference in cRNA levels between the model wild type 
A/England/195/09, or the two A/England/195/09 withH3N2 NS reassortant viruses and A/PR/8/34. 
However a statistically significant increase was measured between A/PR/8/34 and the 
A/England/195/09 with a A/PR/8/34 NS (p=0.045). 
 
B - Quantitation of the Relative Levels of mRNA Expression derived from Primer Extension Analysis 
of HA Transcripts  
Primer extension analysis was conducted on RNA extracted from 293T cells, infected at an MOI of 3 
for 20 hours to mirror the conditions used for the polymerase driven expression system. The data 
from 3 separate RNA panels was evaluated relative to that generated by the A/PR/8/34 infection for 
the mRNA levels. 
Relative to A/PR/8/34, the levels of increased activity are significant only for the A/England/195/09 
wild type and A/PR/8/34 NS recombinant. 
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Quantitation of the Relative Levels of cRNA Expression 
derived from Primer Extension Analysis of HA Transcripts
Quantitation of the Relative Levels of mRNA Expression 






















p=0.035 p=0.057 p=0.26 p=0.14
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B
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Figure 56 Primer Extension Evaluation of the vRNA Levels Inside 293T Cells Infected at an MOI of 3 
for 20 Hours 
As described earlier, the data from a series of primer extension analyses was expressed relative to 
that generated by one of the samples the A/PR/8/34. The samples were then evaluated for the 
expression of the different RNA species generated by the virus and the quantitation of the different 
levels was evaluated for statistical significance.  
As for the mRNA and cRNA, the relative levels of vRNA are elevated for the A/England/195/09 and 
the A/PR/8/34 NS recombinant of this virus, and these are statistically significant.  
There is no statistically significant alteration in the levels of expression of vRNA for the 
A/England/612/03 and A/Scotland/5/03 recombinant viruses in this assay. 
  




Quantitation of the Relative Levels of vRNA Expression 
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Figure 57 Summary Table of Findings Using A/PR/8/34 and A/England/195/09 recombinant viruses  
The key data from the 4 assays conducted on the recombinant model A/England/195/09 viruses has 
been expressed relative to the effects seen by A/PR/8/34. The consistent finding highlighted by this 
work is the elevated level of polymerase activity seen by the wild type model A/England/195/09, 
which shows a high degree of activity in the polymerase driven luciferase activity, and has elevated 
levels of RNA transcripts present when in the Primer Extension Analyses, however this has proved to 
be insignificant in a T test. 
This high activity also corresponds to a high level of interferon induced luciferase expression. 
Conversely the elevated polymerase activity of the A/PR/8/34 and H3N2 recombinants does not 
seem to translate to an elevated interferon driven luciferase level, or elevated RNA transcripts as 
measured in primer extension.  
As the pattern of expression of the M1 protein was not quantitatively evaluated this data has been 
omitted, however the pattern is reminiscent of the pattern of the polymerase assay. 
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The aim of the work in this chapter was to use some of the techniques and experiences derived from 
the characterisation of the influenza virus NS1 gene, and apply them to the dissection of the NS1 
protein of the new pandemic H1N1 strain. Initial analysis of the protein sequence using web tools 
identified that the NS1 protein of the pandemic H1N1 virus protein was of equivalent length to NS1 
proteins which predominate amongst swine viruses. The sequence of the NS segment was also 
found to be identical to a large number of sequences which have been entered into the database.  
A key finding was that the new H1N1 NS1 protein tended to localise predominantly to the nucleus 
and yet it did not appear to bind CPSF nor inhibit host gene expression. This was in agreement with 
data published by Hale et al. (2010). Moreover the expression of the A/England/195/09 NS1 protein 
enhanced translation of the luciferase reporter gene to an even greater extent than other NS1 
protein analysed thus far even though the protein was located in the nucleus. This might be 
explained if the nuclear NS1 protein is able to bind to dsRNAs as they are transcribed by polymerase 
II in the nucleus and therefore prevent them from reaching PKR to activate it in the cytoplasm. This 
hypothesis would fit with the idea put forward in chapter 1 that translational enhancement by NS1 
expression relies on RNA binding rather than on direct PKR interaction. 
However the nuclear localisation of the NS1 protein of pandemic virus coupled with its inability to 
inhibit host gene expression via CPSF binding would suggest that it would only poorly control 
interferon induction since the TRIM/RIG-I targets reside in the cytoplasm. Osterlund et al. (2010) had 
already suggested that pandemic H1N1 virus did not induce high levels of interferon and other 
cytokines in human macrophage and dendritic cells. In preliminary experiments we also found this 
result in studies in A549 cells, but on closer examination the low interferon induction was accounted 
for by an inefficient entry of the H1N1 virus to the target cell. Indeed when the A/England/195/09 
internal genes were encapsidated in an A/PR/8/34 laboratory-adapted envelope, a recombinant 
virus was created that directed high levels of polymerase activity and high levels of interferon 
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induction. Ultimately the fitness of such a virus may be determined by its relative sensitivity to the 
interferon it induces. Some preliminary efforts were made to measure the sensitivity of the 
pandemic virus to interferon treatment (Appendix 5). The experiments were conducted in human 
airway epithelial cells in which the H1N1 2009 virus grows to high titres (Brookes, Miah et al. 2011). 
Treatment of the cells with recombinant interferon protein did indeed reduce the viral titres but the 
levels of reduction were modest. It would be interesting to pursue these experiments in the future 
making comparison between the sensitivity of the pandemic virus and of other circulating human 
influenza strains to interferon treatment. These results might have important implications for 
therapeutic strategies against the new virus. It is unlikely that the newly-emerged virus will remain 
evolutionarily static in its new host. Already in the second and third waves, mutations are 
accumulating that may affect the balance between polymerase activity and interferon control. 
Mutation in NS1 at residue 123 has been noted but the effects of this are not yet clear (Galliano et 
al. submitted). A drastic way in which the new virus could change phenotype is via reassortment 
with another subtype such as the co circulating H3N2 viruses whose NS1 genes are very different to 
the current H1N1 NS1. To test for some of the expected features of such a recombination event, 
viruses containing A/England/195/09 polymerase coupled with H3N2 NS gene segment were 
generated. In general these viruses were able to control the levels of interferon they induced much 
better than viruses with the A/England/195/09 NS gene. This could be a worry since viruses that 
control interferon might be expected to spread faster than those which do not. However the viruses 
with H3N2 NS segments also showed a degree of regulation of the polymerase activity that meant 
that less PAMP was likely produced in the first place. This was particularly evident for the production 
of vRNA, thought to be the major PAMP the influenza generates (Rehwinkel, Tan et al. 2010). Thus 
the overall replication capacity of these reassortant viruses might be compromised by the additional 
regulation imposed on the polymerase by a CPSF binding NS1 protein. Future studies to determine 
the relative fitness of these viruses in relevant models including human airway epithelial cells and 
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animal models might help elucidate the relative importance of these viral features for the outcome 
of infection. 
The construction of the 3PNP recombinant virus gene constellation allowed the safe assessment of 
the effect of a number of different RNP:NS segment pairings, against a well-characterised laboratory 
strain. With the caveat that these viruses might not behave entirely like the parental virus in term of 
cells targeted in a whole animal, the strategy has provided preliminary insight into what will be a 








A panel of interferon antagonists derived from various mammalian viruses have been shown  to be 
able to block RNA silencing (de Vries, Haasnoot et al. 2009). This useful finding allows the 
maintenance and even enhancement of exogenous gene expression in a variety of systems including 
transgenic plants under conditions whereby expression would typically gradually be ablated by the 
RNAi system. Included within this panel was the influenza A virus NS1 protein. The NS1 protein had 
been previously been shown to enhance translation of a reporter gene in a mammalian culture 
system (Salvatore, Basler et al. 2002). Taken together, these publications would suggest a useful role 
for the NS1 protein in enhancement of protein production which has an obvious biotechnological 
application.  
Syngenta UK ltd, an agrochemical company with a base of operations at Jealots Hill in Berkshire work 
to develop novel compounds active against important fungal pathogens of arable crops which have 
the potential to cause millions of pounds in damage to food crops every year. Research in this area 
requires the over expression of target proteins within the organism for proof of principle and mode 
of action studies. The target fungi Mychosphaerella graminicola is of particular note with many 
millions of dollars spent in its control every year. Transformation of this fungi has been achieved 
using a modification of the Agrobacterium infiltration method used for the construction of 
transgenic leaf explants. 
Briefly a binary construct, which is a modified or disarmed T1 plasmid is transformed into a culture 
of Agrobacterium, which is then incubated along with M graminiola, and these are then cultured 
overnight in non selective conditions. During this initial culture stage, the Agrobacterium, in 
response to an artificial plant stress pheromone (mimicking damage to the plant and thus an entry 
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point) exports a cDNA sequence, with suitable flanking regions to direct incorporation into the host 
genome and transform the fungi.  
The cultures are then selected for using a suitable agent, and surviving colonies are then expanded 
into culture for analysis. One problem is that overall yield of exogenous protein expression are low. 
It is not at all clear why this is but bearing in mind experience from generation of transgenic plants, 
one possibility is that an indigenous RNAi system, or a PKR analogue, is triggered in the fungus that 
limits protein expression. 
Initially it was hoped that a dissection of the modes of action of NS1 proteins in enhancing 
translation would enable a model optimized NS1 protein to be offered, which upon introduction into 
the T1 plasmid would then enable a greater degree of over expression of a transgenic protein.  
The first NS1 protein that was reported to enhance translation was cloned from the laboratory 
adapted and mouse adapted influenza virus, A/PR/8/34. Salvatore et al previously showed that PR8 
NS1 enhanced translation of a transfected gene in mammalian cells. In the studies described here 
we confirmed that this PR8 NS1 protein did indeed act in this way and further NS1 proteins cloned 
from other strain of influenza A and B virus were identified as also being able to enhance translation. 
The degree of enhancement of expression achieved however was not to the same degree as that 
published in this first paper. 
Dissection of this assay confirmed a requirement for dsRNA binding activities of the NS1 protein 
used, suggesting that unregulated levels of dsRNA produced as a consequence of transcription from 
transfected plasmids may be a contributing factor which limits the levels of protein produced in a 
variety of experimental scenarios. It is likely that translational enhancement is due to basally 
expressed anti pathogen factors present in the animal cells used such as PKR. This work does not 
exclude other eukaryotic cells as having functionally homologous factors which would be compatible 
with this enhancement phenotype. However, such systems have only been identified in animal cells 
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so far. Future work to engineer these proteins into the model filamentous fungal platform used at 
Syngenta alongside a reporter such as Luciferase or GFP would enable validation of the protein for 
this purpose. 
RNA binding by NS1 was a requirement for the protein to support translational enhancement. 
Surprisingly NS1 proteins engineered to lack RNA binding capacity, whilst unable to support 
translational enhancement, retained the ability to block interferon production stimulated by either 
dsRNA or NDV stimuli. Viruses which carry RNA binding defects have been reported as being highly 
attenuated (Garcia-Sastre, Egorov et al. 1998; Ferko, Stasakova et al. 2004) but other published 
papers have found them to replicate efficiently (Li, Min et al. 2006; Min and Krug 2006). These 
seemingly contradictory viewpoints might be reconciled by the acknowledgement that they are 
derived from work conducted with 2 different strains of influenza viruses whose NS1 proteins might 
behave quite differently. Work conducted by Georg Kochs (Kochs, Garcia-Sastre et al. 2007) and also 
by our laboratory (Hayman, Comely et al. 2006; Hayman, Comely et al. 2007) suggests that NS1 
proteins from different viral sources have different modes of action. The divergent modes of actions 
demonstrated in this thesis between 2 contrasting NS1 proteins derived from influenza viruses 
A/PR/8/34 and A/Victoria/3/75 are likely accounted for by inability or ability to bind CPSF, and other 
host 3’ mRNA maturation components. Although the ability to modulate host gene expression is 
theoretically advantageous for the virus, exchange of whole segments between viruses, or 
engineering point mutations resulted in unforeseen effects on viral replication and viral growth 
kinetics. Ultimately the greater understanding of these effects might be utilized to generate vaccine 
seeds that produce higher yields of virus. This is increasingly important in an era when vaccine 
manufacture might switch from egg production toward production in mammalian cells. For many 
mammalian cell substrates that might be suitable for such purpose, such as Vero cells, influenza 
yields are low. It has already been shown that switching the NS gene segment can increase virus 
yields in these cells (Ozaki and Kida 2007), although the mechanisms for this were not previously 
elucidated. 
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Here we suggested based on viruses generated by reverse genetics that NS1 is a regulator of 
polymerase gene function and that the capacity to bind CPSF might contribute to a quenching of 
virus replication. In data not shown that utilized MDCK cells that expressed the BVDV NPro protein 
and thus did not mount an interferon response, the growth characteristic of the panel of mutated 
viruses tested was similar to that in wild type MDCK cells. This suggested that the changes in the 
virus replication brought about by mutation or exchange of NS were not solely due to effect on the 
amount of interferon induced, but were due to a change in polymerase function. 
The findings described herein that link NS1, CPSF and virus polymerase activity might explain why 
some naturally occurring viruses have lost CPSF binding ability in an attempt to deregulate their 
polymerase and enhance their replication in certain new hosts.  
The emergence of a novel pandemic strain provided a new NS1 protein for study. The majority of 
swine viruses have NS1 proteins that are truncated in comparison to the A/PR/8/34 or Victoria/3/75 
NS1 proteins. The new H1N1 2009 NS1 protein was in our hands unable to function to block 
interferon induction stimulated by an exogenous virus, and this is likely due to its inability to bind 
CPSF, a feature which also rendered it a strong translational enhancer 
Although NS1 has traditionally been assigned as a nuclear protein in the literature, the notion that 
its localization can control its function is becoming increasingly popular (Keiner, Maenz et al. 2010). 
In the work presented here localisation of NS1 proteins was key to determining their function. 
Specifically NS1 proteins that were ‘locked’ in the nucleus were poor enhancers of translation and 
this was presumed to be because the target for this phenotype, perhaps PKR, was a cytoplasmic 
protein. Although the finding that the new H1N1 2009 virus NS1 protein is a good enhancer appears 
to cofound this rule, we propose that this NS1 protein is able to catch the dsRNA as it is produced de 
novo from polymerase II transcription in the nucleus. It should be borne in mind with all of these 
studies though that the cell and virus replication within it are dynamic and that the 
immunofluorescence that has been used in this study capture only static snapshot of the infected or 
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transfected cell. In the future, live cell imaging with protein partners that bear tags which fluoresce 
when brought into close proximity may allow for a more dynamic description of the many roles of 
NS1 during the complex replication cycle of influenza virus.  
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Appendix 
Appendix 1 Analysis of NS1 Protein Length of Sequences in NCBI Database – Supplemental data not 
included in Chapter 4. 
Appendix 2 Alignment of M1 gene from A/PR/8/34 and A/England/195/09 
Appendix 3 Analysis of the coding strategy of NS1 from A/England/195/09 and the resulting effects 
on NEP ORF 
Appendix 4 Phylogenetic tree of the NS1 proteins used in this study showing relatedness using 
Neighbour joining analysis.  
Appendix 5 Test of Efficacy for use of Interferon as a treatment for combating H1N1 infection. 
Appendix 6 List of Primers Used 
Appendix 7 Interferon Induction of Recombinant influenza Viruses Evaluated Using A549-Luciferase 
Reporter Cell Line (re evaluation of Figure 32 used in viva) 
Appendix 8 Evaluation of Influenza Viral Polymerase Activity Using a Transiently Tranfected Viral 
Genome like Luciferase Reporter in 293T cells (re evaluation of Figure 33 used in viva) 
Appendix 9 Yield of Virus Obtained After 24 Hours from an Initial infection of MDCK Cells at an MOI 
of 0.01 (re evaluation of Figure 34 used in viva) 
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CLUSTAL 2.0.12 multiple sequence alignment
A/England/195/2009 MSLLTEVETYVLSIIPSGPLKAEIAQRLESVFAGKNTDLEALMEWLKTRP 50
A/Puerto Rico/8/1934 MSLLTEVETYVLSIIPSGPLKAEIAQRLEDVFAGKNTDLEVLMEWLKTRP 50
*****************************.**********.*********
A/England/195/2009 ILSPLTKGILGFVFTLTVPSERGLQRRRFVQNALNGNGDPNNMDRAVKLY 100
A/Puerto Rico/8/1934 ILSPLTKGILGFVFTLTVPSERGLQRRRFVQNALNGNGDPNNMDKAVKLY 100
********************************************:*****
A/England/195/2009 KKLKREITFHGAKEVSLSYSTGALASCMGLIYNRMGTVTTEAAFGLVCAT 150
A/Puerto Rico/8/1934 RKLKREITFHGAKEISLSYSAGALASCMGLIYNRMGAVTTEVAFGLVCAT 150
:*************:*****:***************:****.********
A/England/195/2009 CEQIADSQHRSHRQMATTTNPLIRHENRMVLASTTAKAMEQMAGSSEQAA 200
A/Puerto Rico/8/1934 CEQIADSQHRSHRQMVTTTNPLIRHENRMVLASTTAKAMEQMAGSSEQAA 200
***************.**********************************
A/England/195/2009 EAMEVANQTRQMVHAMRTIGTHPSSSAGLKDDLLENLQAYQKRMGVQMQR 250
A/Puerto Rico/8/1934 EAMEVASQARQMVQAMRTIGTHPSSSAGLKNDLLENLQAYQKRMGVQMQR 250
******.*:****:****************:*******************
A/England/195/2009 FK 252
A/Puerto Rico/8/1934 FK 252
**
Alignment of M1 from 
A/PR/8/34 and 
A/England/195/09
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CLUSTAL 2.0.12 multiple sequence alignment













P  K  Q  K  R  E  M  A  G  T  I  R  S  E  V  - R  N  K  M  V  D  - R  S
A/PR/8/34
ccaaaacagaaacggaaaatggcgagaacagctaggtcaaaagttcgaagagataagatggctgattgaagaagt
P  K  Q  K  R  K  M  A  R  T  A  R  S  K  V  R  R D  K  M  A  D  - R  S
A/Victoria/3/75
ccagagcagaaatgaaaagtggcgagagcaattgggacagaaatttgaggaaataaggtggttaattgaagaaat









* * ********* *
NS1 Stop Codon and the Effect on NEP Protein Sequence
ccaaaacagaaacgagaaatggcgggaacaattaggtcagaagtttgaagaaataagatggttgattgaagaagt
Q  N  R  N  E  K  W  R  E  Q  L  G  Q  K  F  E  E I  R  W  L  I  E  E
A/PR/8/34
ccaaaacagaaacggaaaatggcgagaacagctaggtcaaaagttcgaagagataagatggctgattgaagaagt
Q  N  R  N  G  K  W  R  E  Q  L  G  Q  K  F  E  E I  R  W  L  I  E  E
A/Victoria/3/75
ccagagcagaaatgaaaagtggcgagagcaattgggacagaaatttgaggaaataaggtggttaattgaagaaat
Q  S  R  N  E  K  W  R  E  Q  L  G  Q  K  F  E  E I  R  W  L  I  E  E
A/England/195/2009




































































































Evaluating the Efficacy of Interferon 
Treatment for an A/England/195/2009 
Infection
p=0.014 p=0.6 p=0.3
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Primer Sequence Primer Name  Primer Function 
GGGCCCAAATTTgcggcggcgaccatggactccaac Eng195 Not I For 5' Cloning Primer for NS1 
A/England/195/09 
GGGCCCAAATTTACGCGTtttctgctctggagg Eng195 Mlu I Rev  3' Cloning Primer for NS1 
A/England/195/09 
ttaccttctcttcccgggcatacttatgaggatgtc SpliceFor Removal of Splice Acceptor 
Site in NS1 from 
A/England/195/09 
gacatcctcataagtatgcccgggaagagaaggtaa SpliceRev Removal of Splice Acceptor 




R38A K41A For  
CTGCCCCTTCCTCTTAGGGAAGCCTGGTCTGCG
CGAAGCCGATCAAGGAATG  
R38A K41A Rev  
CATTCCTTGATCGGCTTCGCGCAGACCAAGCAG
GACTAAGAGGAAGGGGCAGTAC 
R38A K41 S42G For  
GTACTGCCCCTTCCTCTTAGTCCTGCTTGGTCTG
CGCGAAGCCGATCAAGGAATG 
R38A K41 S42G Rev  
GAA CTA TAC AAA GAA TTC ACC ATG GCT 
GGT GAT CTT TCA GCA 
pkr gfp with kozak 5 prime EcoRI 
AAATTTGGGCCCggcggccgcatatttaacacgtttaa pkr gfp 3 prime NotI   
GTATCAGAATGGACCAGGCGGCAGCGGATAA
GAACATCATACTG 
PR8 PKR I123A M124A 
For 
Primers to remove reported 




PR8 PKR I123A M124A 
Rev 
Primers to remove reported 




PR8 PKR K126A N127A 
For 
Primers to remove reported 




PR8 PKR K126A N127A 
Rev 
Primers to remove reported 




VIC PKR I123A M124A 
For 
Primers to remove reported 




VIC PKR I123A M124A 
Rev 
Primers to remove reported 




VIC PKR K126A N127A 
For 
Primers to remove reported 




VIC PKR K126A N127A 
Rev 
Primers to remove reported 





PR8 NES Primers to re clone PR8 with 
HIV NES at the N Terminus 
GGGCCCAAATTTgcggcggcgACCatgctgcagctgcc
gccgctggaacgcctgaccctgGCAGCAGCAatggattc
Vic NES Primers to re clone Vic with 
HIV NES at the N Terminus 






PR8 NLS Primers to re Clone PR8 with 
SV40 NLS at the N Terminus 
GGGCCCAAATTT gcggcggcg ACC 
atgggcccgaaaaaaaaacgcaaagtggaaagcggc GCA 
GCA GCA atggattccaacact 
Vic NLS Primers to re Clone Vic with 
SV40 NLS at the N Terminus 
ggtatttgtgagccagggcattg 85rev pCAGGS Cloning and 
sequencing Primer 
gctaaccatgttcatgccttc 4715 pCAGGS Cloning and 
sequencing Primer 
TGTGTCTGCATCTGCAGCTGC  PR8 HA PLUS Primer Extension Primer for 
PR8 HA Template 
TTCTGGCGATCTACTCAACTGTC  PR8 HA NEGAT Primer Extension Primer for 
PR8 HA Template 
ACCCTGCTTAGCTTCCGAGA  5SRNA 62 Loading Control for Primer 
Extension using 5SRNA 
GGGTCCTCATCGGAAGACTTGAATGGAATG vic and Swine G184R 
for 
Published CPSF mutant 
CATTCCATTCAAGTCTTCCGATGAGGACCC vic and swine G184R 
Rev 
Published CPSF mutant 
GAG TCC TCA TCG GAA GAC TTG AAT GGA 
ATG 
pr8 G184R For Published CPSF mutant 
CATTCCATTCAAGTCTTCCGATGAGGACTC PR8 G184 Rev Published CPSF mutant 
 ATA TCG TCT CGTATT AGT AGA AACAAG 
GGT GTT TT 
NS1-BsmBI-R NS Segment Primer for 
cloning and Sequencing 
TAT TCG TCT CACCCA GCA AAA GCAGGG TG NS1-BsmBI-F NS Segment Primer for 
cloning and Sequencing 
aaggaaatgcggccgcaaatggaggacaac BbeiNS1For Flu B Primer for cloning NS1 
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Yield of Virus Obtained After 24 Hours from an Initial 















































(p= 0.0006) (p= 0.0135)
(p= 0.0434) (p= 0.001)
























































Interferon Induction of Recombinant influenza 








Evaluation of Influenza Viral Polymerase Activity 
Using a Transiently Tranfected Viral Genome like 








































(p= 0.03) (p= 0.003)
